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This thesis presents the results of structure-activity relationship (SAR) studies 
on inhibitors of two important enzymes: alpha-amylase and steroid Sa-reductase. 
Ascorbic acid, a reported inhibitor of alpha-amylase, has been 
investigated to determine which of its structural features are necessary for its 
inhibitory action. These studies have involved the synthesis of thirteen derivatives 
of L-ascorbic acid and "three derivatives of D-isoascorbic acid, incorporating 
systematic modifications of the functional groups present in both molecules. We 
have found that the ene-diol moiety in ascorbic acid is crucial for its inhibitory 
action. Modification of this functionality significantly reduces inhibitory activity. 
Ascorbic acid, and some of its derivatives, are shown to be potent inhibitors 
of barley-malt, porcine-pancreas, human-saliva, bacterial- and fungal alpha-
amylases. 
Kinetic studies to determine the mode of inhibition of ascorbic acid 
demonstrate that it has characteristics of a competitive inhibitor of alpha-
amylase. 
SAR studies on inhibitors of steroid Sa-reductase were focused on three 
main areas; modification of known inhibitors to improve potency and isozyme 
selectivity, synthesis and investigation of a potential new class of inhibitor and 
investigation into the utility of a novel pharmacophore. 
A 4-methyl-octahydrobenzoquinolinone derivative, incorporating a 
photoisomerisable phenylazo group at the C9 position was synthesised, as was a 
dihydrophenanthrene-2-carboxylic acid derivative containing a styryl substituent 
at C7. 
A series of piperidone derivatives was synthesised to investigate their 
potential as steroid Sa-reductase inhibitors. 
Four lactam-based inhibitors of steroid Sa-reductase were modified to 
incorporate a thiolactam, a previously uninvestigated pharmacophore. 
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RELATIONSHIP 
Structure-activity relationship (SAR) studies are a powerful tool for 
investigating chemical properties "that influence interactions and reactions 
between molecules. These studies determine the change in adivity, reac·tivity or 
binding of a molecule, due to the systematic introduction of chemically induced 
structural modifications.1-3 Examples include simple alterations such as the 
lengthening, shortening or branching of chains, the introduction of new 
subs1ituents or altering the position of attachment of existing substituents, and the 
introduction of chemical isosteres. . As well as providing information regarding 
optimal structural properties, such as size and shape, SAR studies enable the 
determination of electronic and lipophilic properties that are important for the 
biological activity of the molecule. 
SAR studies are generally utilised in two ways. Firstly, they give insight into 
the specific functionality of a molecule that is essential to its activity. This 
'pharmacophore' encompasses properties such as structure (geometry, 
conformation, size), electronic properties and the lipophilic nature of the group 
under consideration. Once a pharmacophore has been identified, further 
development may include the preparation of structural analogues of a 'lead'· 
molecule in an attempt to improve its properties.1.2 Secondly, SAR studies are 
used to develop highly active compounds for the elucidation of information 
about the molecule with which the lead compound binds and interacts. An 
example of an area in which both of these aspects of SAR studies are very 
applicable is that of medicinal chemistry; in parl"icular drug Q~i; 
The development of a new medicine is often based around the discovery 
of novel active compounds by general screening procedures.1.2 Natural products 
isolated from various plant, marine, and microbial origins, are a rich source of 
• A 'lead' molecule is an initial active compound on which the SAR studies are 
undertaken. 
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undiscovered, structurally-diverse and potentially-active molecules. As these 
compounds often have complex structures, SAR studies are useful for identifying 
the active pharmacophore, which can then be isolated and developed further. 
An example of this was the discovery of the natural product asperlicin, 
which is an antagonist of cholecystokinin. Determination of the core 
pharmacophore present in asperlicin lead to the development of a highly potent 
and specific, orally-active compound L-364,718 (Figure 1.1).4 
(A) 
Asperlicin Core Pharmacophore 
(8) 
L-364,718 
Figure 1.1: (A) The structure of asperlicin and its core pharmacophore (shown in bold). (B) The 
structure of L-364,71B. 
Common targets for drug design are enzymes. The biological pathways 
responsible for many disease states often involve enzyme-catalysed reactions. An 
obvious medical intervention is to block these pathways by inhibition of the 
appropriate enzyme.3 This can result in a decrease in the amount of the reaction 
product formed, or an accumulation of the enzyme substrate, either (or both) of 
which may be desirable in treating an ailment. 
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1 . 1 . 1 SYNTHETIC TEC H N 
Once an enzyme has been targeted for inhibition, initial drug development 
begins with the identification of a lead compound. Often this compound will 
resemble the structure of the natural substrate of the enzyme; however, lead 
compounds may also be obtained by screening procedures in which numerous 
libraries of known compounds are evaluated for the desired activity. 
A recent advance in the synthesis of structurally diverse libraries of 
compounds is combinatorial chemistry. This technique relies on the availability of 
synthetic 'building blocks' with which all possible permutations of the desired 
molecules are constructed.5-7 Until recently, -this technology has been mostly 
utilised in the synthesis of diverse peptide libraries using amino acids as the 
'building blocks'; however, this technique has now found application in the area 
of general organic synthesis. Combinatorial synthesis can also be used for 
optimising the properties of a lead molecule. 
1 . 1 .2 COMPUTER-AIDE D TECHNIQUES 
If the target enzyme has been isolated and characterised, a computer-
generated selection of possible inhibitors can be investigated. There are many 
computer programs available that can be employed to generate and visualise 
the three-dimensiona structure of an enzyme.1.2,8 These programs use information 
gained from techniques such as X-ray crystallography, NMR spectroscopy, 
molecular modelling and computational chemistry. The affinity and specificity of 
a potential inhibitor for an enzyme may then be determined using a combination 
of complementary surface topographies, electronic properties, and hydrophobic 
sites, in both molecules.8 
Computer programs employed to find pharmacophore properties of a 
potential inhibitor (complementary to the enzyme) look for properties such as 
hydrogen bonding, charged groups, and hydrophobic areas of the inhibitor. They 
can also relate minimum energy conformations of possible inhibitors to the known 
characteristics of the enzyme active site. 
If the target enzyme is uncharacterised, computer-based analysis of 
chemically and structurally distinct inhibitors for similar properties can provide 
information about the spatial arrangement of -the enzyme's adive site and 
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electronic and hydrophobic binding properties of the enzyme. This information 
can then be used in the design of more potent and selective drugs. 
Further development of novel medicines usually includes quantitative 
structure-activity relationship studies {QSAR).8 These provide models in which the 
biological activity of a compound is related to its physicochemical properties in a 
numerical fashion. Particular focus is given to the structural features of a 
compound that influence in vivo transportation and distribution to the target site. 
Measurable biological data (such as KI and leso values - section 4.2) that indicate 
the activity of a molecule, are related to pharmacokinetic parameters such as 
lipophilicity, polarisability, electronic parameters, steric parameters and molecular 
weight. 
QSAR results are mostly used in conjunction with SAR studies, to find the 
optimum compromise between drug adivity and in vivo delivery to the target site. 
1 .2 WORK PRESEN D IN THIS THESIS 
The work presented in this thesis involves SAR studies of inhibitors of two 
enzyme systems. 
1. alpha-amylase 
2. steroid 5a-reductase 
Alpha-amylases are a well-stUdied class of enzymes in which the amino-
acid sequences have been determined and, more recently, crystal structures of 
various species of enzyme have been solved.9-14 X-ray-crystallographic analysis 
has also been carried out on various alpha-amylase enzymes with inhibitors bound 
in the active site. These studies have provided insight into the enzyme-ligand 
interactions that occur during binding and have allowed a mechanism by which 
these enzymes function to be postulated. 
Given that inhibition of alpha-amylase is beneficial in various medical and 
industrial circumstances (section 2.3) we have inves'~igated ascorbic acid - a 
reported inhibitor of alpha-amylase. Our SAR studies have been aimed at 
determining the pharmacophore of this molecule using systematic chemical 
modifications of the structure. We have also used kinetic studies to investigate the 
mode of inhibii'ion for ascorbic acid and one of its derivatives. 
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The inhibition of steroid Sa-reductase (SR) has been postulated to be of 
importance in treating various urological and skin ailments. 15-17 Unlike alpha-
amylase, the structure of SR has yet to be well characterised, so the design of 
inhibitors of this enzyme has involved numerous SAR studies to develop potent 
inhibitors and provide information about the structure of SR and its mechanisms of 
action. 
Our SAR studies, with respect to SR, have involved three separate areas of 
investigation. 
1. The chemical modification of two known SR inhibitors to improve their 
potency and selectivity; 
2. The synthesis and investigation of a new class of inhibitor that is 
structurally analogous to known potent inhibitors: 
3. The chemical modification of various known inhibitors to incorporate a 
novel pharmacophore mimic. 
The activity of the prepared compounds has been measured against 
human type 1 SR. 
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ALPHA-AMY LAS 
One of the beneficial aspects of ea'I'ing copious amounts of cakes, biscuits 
and pastries is the plentiful supply of carbohydrates that they provide to one's 
body. The process of digestion, to enable utilisation of this energy source, involves 
many biological processes and the action of many enzymes. One of the most 
important is the hydrolytic enzyme alpha-amylase. 
Alpha-amylases (1,4-a-D-glucanohydrolases, EC 3.2.1 .1*) are members of a 
class of enzymes called glucosidases, which catalyse the breakdown of 
carbohydrates. 1-5 Their main function is to catalyse the hydrolysis of a-1,4-
glucosidic linkages in various oligo or polysaccharides, to produce maltose units, 
with retention of the a configuration at the C1 anomeric carbon (Figure 2.1). 
OH RO~~'l ·OH (A) Reducing 
end ~O~~ 
a-1 A-Glucosidic Linkage -- 0 0 OH 
HO OH ~
(8) ~HO 
HO~~l 
HO 3 OH OH 
o 0 
""'l!-- Anomeric Carbon 
HO OH OH 
Maltose unit 
a 
CI. and j3 configurations 
Figure 2.1 : (A) Alpha-amylase hydrolyses the glucosidic linkage between C 1 and C4 of two adjacent 
glucose molecules. (8) The terms a and p refer to the stereochemical configuration of the hydroxyl 
group at the anomeric carbon Cl. 
Alpha-amylases are found in most organisms that require the conversion of 
stored or ingested carbohydrate to energy. They are, therefore, readily found in 
bacteria, fungi, plants and animals. l In animals, the main sources of the enzyme 
* This number is the classification number for alpha-amylases assigned by the 
Enzyme Commision. 
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are from the salivary glands and the pancreas, whereas in plants, alpha-amylase 
production is most often associated with seed germination.6 The enzymes from 
these varying sources have different pH and temperature requirements for optimal 
activity (Table 2.1).7 
erature re uirements for various aloha-am lases. 
Enzyme pH range Optimal Optimal 
H tem 
Pancreatic Porcine 5.5 - 8.5 6.0 - 7.0 40 - 45 
pancreas 
Bacillus subtilis 4,5 -9.0 6.5- 7.5 70 -85 
5.8-8.0 7.0 90 - 105 
4.0- 7.0 5.0 6.0 55 - 60 
3.5 7.5 4.5- 7.0 60 -
2.1 A LPHA-AMYLASE 
Inactivation 
tem 
75 
95 
120 
80 
85 
Alpha-amylase is an important enzyme due to its necessity in the 
metabolism of carbohydrates, but is also an industrially- and medicinally-useful 
enzyme. 
2.1.1 INDUSTRIAL App LICATIONS OF ALPHA-AMYLASE 
The main industries to utilise alpha-amylases are those in which the 
manufacturing processes involve the use of starch - the natural substrate of the 
enzyme.6-8 For example, in the baking industry, the level of alpha-amylase activity 
in flour can affect the quality of baked goods. For breads, alpha-amylase activity 
is directly related to the taste, crust colour, toasting qualities, and volume of the 
loaf. Thus, the ability to determine and control the amount of enzyme activity in 
this process is important. The same is true for the brewing industry where a/pha-
amylases contribute to the breakdown and fermentation processes of grain 
mashes,8 
The differences in alpha-amylase enzymes from different species have 
been utilised by industry to great advantage for their specific starch-processing 
requirements. In the modified-starch industry, the high-temperature stability of 
certain bacterial alpha-amylases has made their use popular for the conversion of 
starches into syrups for use in confectionery and fruit processing. Previous 
methods of saccharification involved the use of acid to hydrolyse the starches, 
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which lead to many by-products. The use of enzymes for this process has 
provided greater control and specificity over end products.? 
1 MEDICINAL App LI OF ALPHA-AMYLASE 
The medical interest in alpha-amylase stems from its involvement in the 
metabolism of carbohydrates. Alpha-amylase is secreted from the pancreas and 
salivary glands into the digestive tract where it acts on ingested carbohydrates.3•9 
From there, it is "transferred into the blood stream before eventually being 
excreted in the urine. In most animals, the serum [blood or urine) levels of a/pha-
amylase are quite low. However, in disease states such as acute pancreatitis or 
salivary lesions, these levels can increase. Therefore, diagnosis of these conditions, 
routinely includes analysis of a serum sample to determine the levels of a/pha-
amylase activity in "the patient.3•9-13 
The inhibition of alpha-amylase activity also has many medicinal 
applications. The breakdown of carbohydrates ultimately leads to the formation 
of glucose, the main energy source in the body. The level of glucose circulating in 
the blood is regulated by the release of insulin and is maintained at approximately 
100 mg/dl.3 In disease states such as non-insulin-dependent diabetes mellitus, 
hyperglycaemia, and hyperinsulinaemia, glucose and insulin levels are 
unregulated and can lead to further disease such as cataracts. 14 The use of 
alpha-amylase inhibitors to slow the breakdown of carbohydrates is currently 
being investigated as a possible aid in the treatment of these ailments.3 
The importance of alpha-amylase in these areas of industry and medicine 
has lead to much research on how alpha-amylases function and how their activity 
can be controlled to improve their usefulness. The following section outlines the 
current knowledge of the general structure and mechanisms of action of a/pha-
amylases. In section 2.3 the use of inhibitors as tools for learning more about the 
structure and function of alpha-amylases, and for controlling their activity, is 
discussed. 
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2.2 STRUCTURE A N 
OF ALPHA-AMYLASE 
MECHANISMS OF ACTION 
2.2.1 SUBSTRATE 
Alpha-amylases are classified as en do enzymes. As such, they hydrolyse 
their substrate at random sites within the molecule rather than from the ends.1-3 
(A) 
OH Amylose 
RO~O, OH HO~~ 
OH 0 
OH oHO 0 ~OH 
o OH 
. ,HO OHO~ 
HO 
OH 
OH 
OH Amylopectin 
(B) HO~ OH 
0:0 OHO~\, 
RO~ O~v- 6H l a-1,6-glucosidic IInkoges 
HO OH 0H~q ~06 01( ~O~ 0 
°HO OHO~OH 0 
HO 
OH 
OH 
Figure 2.2: (A) Amylose. (8) Amylopectin. The a-l ,6 linkages in this molecule are resistant to hydrolysis 
by alpha-amylase. 
The natural substrates of alpha-amylase are oligosaccharides and 
polysaccharides.1-3.5,7,g These carbohydrates are mainly sourced from plants in the 
form of starch, a major source of dietary carbon for animals. Starch is made up of 
two main polysaccharides: amylose (15 - 25%) and amylopectin (75 - 85%) (Figure 
2.2). 
Amylose is a mostly unbranched, chain-like molecule consisting of up to 
1000 glucose residues connected via a-1 A-glucosidic linkages. These chains twist 
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and coil to give helical three-dimensional structures, which help hold the 
molecules of the starch grains together.8 Upon hydrolysis by alpha-amylase, 
amylose is converted, almost completely, into maltose.3 
Amylopectin is a highly-branched polysaccharide with an average 
molecular weight of 107 g/mol. The longest chain lengths in the molecule contain 
approximately 25 glucose units. These chains are connected to each other via 0,-
l,6-glucosidic linkages. Alpha-amylase is unable to hydrolyse 0,-1 A linkages 
adjacent to these branch points, so the products of the enzyme action on 
amylopectin are maltose (90%) and small a-dextrins containing the 1,6-bonds.3 
The branching in amylopectin molecules also prevents fhemfrom folding into 
helical-type structures. 
2.2.2 STRUCTURE 
The average molecular weight of alpha-amylases is approximately 50 kD,L2 
thus the enzyme is small relative to its natural substrate. It is a metalloenzyme; 
binding a calcium ion and also a chloride ion, which are both necessary for the 
structural integrity and activity of the enzyme. 
The amino-acid sequence for several different alpha-amylases, including 
plant, animal and bacterial species has been established.2,15-19 All exhibit a high 
degree of homology showing three well-conserved regions. The tertiary structures 
of porcine-pancreatic, aspergillus oryzae and barley-alpha-amylase have been 
determined by X-ray crystallography,2,15-19 All show similar structural motifs that 
relate to the homologous regions of amino-acid sequence and their active site, 
calcium binding site and chloride binding site are in similar locations (Table 2.2). 
The most prominent feature of the alpha-amylase tertiary structures is an 
(0,/13)8 barrel which forms domain A in all three enzymes (Figure 2.3).1,2 Another 
common feature is an extended loop which joins the a-helix 3 and 13-strand 3 in 
the (alf3)8 barrel. This structure forms domain B in porcine pancreas and barley 
alpha-amylases, and is also present in the aspergillus oryzae enzyme (al"rhough it 
doesn't constitute a separate domain). A third structural feature is a section of 
anti-parallel 13-sheet of between five and ten f3-strands located at the C-terminal 
end of the enzyme. This structure makes up domain B in aspergillus oryzae and 
domain C in porcine pancreas and barley alpha-amylase. 
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Table 2.2: A comparison of the structural features of porcine pancreatic, aspergillus oryzae and 
barley a/pha-amylases. 
PORCINE PANCREAS ASPERGIl.LUS ORYZAE BARLEY 
(PPA) 
COMPOSITION 496 amino-acid 478 amino-acid 403 amino-acid 
residues, Ix Ca2+, Ix residues, 2x Ca2+, 1 x residues, 3x Ca2+, 1x 
CI- C!- C!-
DOMAIN A Comprised of residues Comprised of residues Comprised of 
1-99 and 170-404. 1-380. Folds as an residues 1-88 and 
Folds as an (a./~)8 (a./~)8 barrel. Loop 153-350. Folds as 
barrel. between Aa3 and A~3 an (al(3)8 barrel. 
is extended chain 
containing 3 B-strands. 
DOMAIN B Comprised of residues Comprised of residues Comprised of 
100-169. Located 381-478. Folds as 1,8 residues 89-152. 
between Aa3 and A(33 stranded antiparallel Located between 
of domain A. Folds as ~-sheet. Is linked to Aa3 and A~3 of 
2 antiparallel (3-sheets domain A via a single domain A Has an 
(3 & 4 strands) plus 1 poly-peptide chain. irregular folding 
parallel ~-sheet of 2 pattern stabilised 
strands. by Ca2+ ions. 
DOMAIN C Comprised of residues NA Comprised of 
405-496. Folds as 2 residues 305-403. 
facing anti parallel ~- Folds as a 5 
sheets (4 strands stranded 
each), piUS 1 antiparallel ~-sheet. 
antiparallel (3-sheet of 
2 strands. 
ACTIVE SITE Located between the Located between the Located between 
C-terminal end of the C-terminal end of the the C-terminal end 
(3-barrel and domain (3-barrel and domain of the (3-barrel and 
B. Proposed catalytic B. Proposed catalytic domain B. 
residues are Asp300, residues are Asp297 
Asp 197 and Glu 233. and Glu 230. 
CALCIUM BINDING Located between Maps exactly onto the Similar location to 
SITE domains A and B. Ca2+ binding site in PPA The calcium 
Coordinated by 8 PPA The coordinating near the active site 
ligands. Asn 1 00, residues are Asn121, is coordinated by 7 
Arg158, Glu162, Asp175 and ligands in a 
Asp 167(bidentate), His His 210. They are distorted 
201 plus 3 H2O. located on the pentagonal 
Geometry is that of a extended loop in bipyramid 
distorted pentagonal domain A geometry. 
bipvramid. 
CHLORIDE BINDING Located close to the 
SITE active site CI- is 
coordinated by 5 
ligands. Arg195, 
Asn298, 
Arg337 (bidentate) 
and 1 H2O. 
SUBSTRATE BINDING Is comprised of 5 Is comprised of 7 Is comprised of 10 
SITE subsites. The active subsites. The active subsites. The active 
site is between sites 3 site is between site 4 site is between site 
and 4. and 5. 6 and 7. 
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Figure 2.3: A schematic diagram of porcine pancreatic alpha-amylase. The circles represent Ct-
helices and the squares represent ~-strands. The colourless squares are directed into the page, and 
the shaded squares, out of the page; The hashed lines show hydrogen bonding. The labels indicate 
to which domain the structure belongs. 
2.2.2.1 ACTIVE SITE 
The active site of the enzyme is located in a V-shaped cleft at the C-
terminal end of the p-barrel in domain A. Amino-acid residues involved in the 
activity of the enzyme are located either on the loops of the barrel at the C-
terminal ends, or on p-strands adjacent to the loops. The location of the active 
residues in these regions is thought to allow flexibility in the amino-acid sequence 
of different alpha-amylases without disrupting the (a/~)8 barrel structure. 
2.2.2.2 ION BINDING SITES 
The presence of a calcium ion is important for the tertiary structure of the 
enzyme as well as its activity.1.2 In porcine-pancreas alpha-amylase, the calcium 
ion, located between domains A and B, is coordinated by eight ligands to form a 
distorted pentagonal bipyramid. The ion is thought to stabilise and maintain the 
activity in the active site by the correct positioning of cataly"I'ic residues. The 
relative position of the calcium ion in aspergillus oryzae and barley a/pha-
amylases has been shown to overlap with that of the porcine pancreatic enzyme. 
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Acarbose 
Figure 2.4: Ribbon cartoon of aspergillus oryzae a/pha-amylase. The left figure shows the domains of 
the enzyme. The right figure shows the inhibitor acarbose bound in the active site and the binding 
site of the primary calcium ion. 
However, aspergillus oryzae has an additional calcium binding site that may be 
involved in the catalytic step of the enzyme, and barley alpha-amylase has a 
total of three calcium binding sites, which are thought to be involved in stabilising 
the folding of domain B in this enzyme. 
The chloride ion is also located close to the active site and is coordinated 
by five ligands. The binding of this ion in mammalian alpha-amylases, has been 
shown to shift the pH of optimum activity to neutrality and to increase their 
activity.2,lB 
2.2.3 MECHANISM ACTION 
The hydrolysis of a-1 A-glucosidic bonds catalysed by alpha-amylase, in 
most instances, involves the transfer of a glucosyl residue (donor) to a water 
molecule (acceptor). This reaction is achieved with retention of configuration at 
C 1, suggesting that solvolysis occurs before the product is released from the 
enzyme. Two mechanisms for the hydrolysis reaction have been postulated.1.2 
One involves a double nucleophilic displacement while the other proposes the 
presence of an oxocarbonium ion intermediate. 
2.2.3.1 THE NUCLEOPHILIC 0 I SPLACEMENT MECHANISM 
A nucleophilic-displacement mechanism for the hydrolysis reaction 
catalysed by amylolytic enzymes was first proposed by Koshland.1.2 For the 
reaction due to alpha-amylase where there is retention of configuration at C 1, a 
double displacement is envisioned (Figure 2.5). A concerted protonation of the 
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glucosidic oxygen by an acidic residue, and the attack of the anomeric carbon 
by a carboxyl anion, gives a covalently-bound glucosyl-enzyme intermediate with 
a ~ configuration. A second displacement catalysed by a basic residue, 
hydrolyses the covalent glucosyl-enzyme bond, to yield the product with an a 
configuration. 
OH 
H91~ 
~ OR 
• 
ENZyO 
OH 9-
R~~ 
OR 
H 
0/ 
1st displacement 2nd displacement OAENZ 
ASP or GLU amino acid residues 
Figure 2.5: Nucleophilic double displacemen~ mechanism. 
2.2.3.2 THE OXOCARBONIUM ION MECHANISM 
In this mechanism, protonation of the glucosidic oxygen by an acidic 
residue, together with an enzyme-induced ring distortion to a half-chair 
configuration, leads to an enzyme-stabilised glycosyl oxocarbonium-ion 
intermediate. The half-chair configuration is assumed to relieve steric strain at the 
anomeric carbon and allow front-side attack by water to give an a product 
(Figure 2.6). 
OH 
HO~ 
HO OR 
ENZyO 
OH HO 
~~ 
OR 
H 
d 
OAENZ 
Oxocarbonium ion intermediate 
Figure 2.6: Oxocarbonium ion mechanism. 
If complete formation of the oxocarbonium ion is achieved, i.e. bond 
breaking occurs before nucleophilic attack by the acceptor molecule, then an 
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SN 1 type mechanism is envisioned. However, if the nucleophile reacts before 
complete ion formation, then an SN2 type displacement mechanism with an 
oxocarbonium-ion-Iike transition state would probably occur. 
2.2.3.3 THE CATAL YTle RESID U ES 
The catalytic residues in the active site are thought to be glutamic acid 
(Glu) and aspartic acid (Asp), which both contain carboxylate moieties. 15-2o These 
residues act as both acid and base in the proposed hydrolysis mechanisms. The 
tertiary structures of porcine pancreatic-, aspergiffus oryzae- and barley alpha-
amylase show that both residues lie within close proximity of each other in the 
active site and are suitably located for protonation of the glucosidic oxygen in the 
substrate. 
ENZyO 
OH + 0 Ro~9/ HO~ 
HO O-R 
/ 
"H 
-0 
OAENZ 
Oxocarbonium-ion transition-state 
ENZyO 
OH 0-
R<Fo~q -. 
o~ 
OH 
H 
cI 
oAENZ 
Glycosyl-enzyme intermediate 
ENZyO :j: 
OH 0 
R9,c±:)/ 
HO O-H 
I 
H 
o 
OAENZ 
Oxocarbonium-ion transition-state 
Figure 2.7: Current proposed mechanism of hydrolysis by alpha-amylases. 
Tao et aI.2,18,19 detected the formation of a glycosyl-enzyme intermediate in 
porcine-pancreatic alpha-amylase in cryogenic experiments with 13C-labelled C 1 
maltotetraose as substrate. However, a crystal structure by Qian et a1.18,19 of the 
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same enzyme soaked with acarbose a transition-state-analogue inhibitor -
suggested that the Glu233 and Asp300 catalytic residues were positioned too far 
from the glucosidic linkage to allow formation of a covalent bond. Their study 
proposed that the substrate-enzyme intermediate is unlikely and hydrolysis is more 
likely by general acid catalysis. 
Recently, McCarter and Whithers reported the isolation and identification 
of a covalently-bound inhibitor-enzyme intermediate.21 Their study involved the 
use of a mechanism-based inhibitor, 2-deoxy-2,2-difluoroglycoside, which has 
been shown to bind irreversibly in the active site of porcine-pancreatic alpha-
amylase. Based on this evidence, the mechanism of hydrolysis is currently 
proposed to proceed via the original double-displacement mechanism proposed 
by Koshland. The enzyme-glycoside intermediate is formed and subsequently 
hydrolysed via transition states with substantial oxocarbonium ion character as 
shown in Figure 2.7. 
2.2.4 ACTION PArrER N 
The action pattern of an enzyme is a description of the way in which an 
enzyme interacts with its substrate. L2 Alpha-amylase, as a polymer-degrading 
enzyme, has a variety of oligosaccharide and polysaccharide substrates and 
each interacts with the enzyme in a specific fashion. For example, different 
substrates may exhibit different modes of binding that influence the way in which 
the enzyme hydrolyses them to products: however, the mechanism by which the 
enzyme works can also be influenced by environmental factors such as pH, 
temperature, or substrate concentrations. The combina'I'ion of all these 
environmental factors, and any other influences on how the enzyme functions, are 
characteristics of the action pattern of the enzyme. 
2.2.4.1 SUBSITE MODEL 
A proposed model that accounts for the different actions of different 
alpha-amylase enzymes is the subsite model.L2 This model assumes that the active 
site is comprised of separate subsites which each bind a glucose residue of the 
substrate. The subsite in which the hydrolysis reaction occurs is the catalytic site. 
As the residues in the substrate are essentially identical, they have equal 
probability of binding in any site and, therefore, can form a variety of complexes 
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with the enzyme (Figure 2.8). Each subsite has a certain substrate affinity or 
binding energy, which influences the binding mode of the polymer. According to 
Thoma et a/. 1 the concentrations of each complex will be proportional to the sum 
of the binding energies for each occupied subsite. Thus the sUbstrate-enzyme 
complex can be either productive or non-productive, depending on the binding 
energies and whether the catalytic subsite is bound in the complex. 
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Figure 2.8: (Aj A schematic representation of the different binding modes of a substrate molecule in 
the subsites of an enzyme, The circles represent glucose residues the pale coloured circles indicate 
the reducing end of the molecule. (8) Different binding energies of each subsite will influence the 
binding modes of the substrate, 
Use of the subsite model requires knowledge of the approximate number of 
subsites, the location of the catalytic subsite, the substrate affinity for a particular 
subsite and the rate of hydrolysis. Many workers have established the subsite 
model for various a/pha-amylases1.2 using a variety of techniques including 
product analysis, labelling experiments and kine'lk studies. 
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Porcine-pancreatic, aspergillus oryzae and barley alpha-amylases contain 
5, 7 and 10 subsites respectively. In the former two, the catalytic site is between 
subsites 3 and 4, whereas for the latter, it is between sites 6 and 7. 
MUL TIMOLECUL A REACTIONS 
Although hydrolysis is the main reaction catalysed by alpha-amylase, it is 
not the only one. Since the hydrolysis reaction is reversible, alpha-amylase must 
also catalyse stereospecific substrate synthesis. Hehre et 0/.1 have demonstrated 
this point by showing that alpha-amylases only have specificity for glycosyl donors 
in the catalysed reaction, not acceptors. Thus the assumed acceptor, water, can 
in fact be replaced by another substrate molecule. Under certain reaction 
conditions the action pattern of alpha-amylase is known to include catalysis of 
reactions such as transglycosylation, condensation, or shift-binding (Figure 2.9).2 
Transglycosylation occurs when a glycosyl group from another substrate 
molecule acts as the acceptor instead of a water molecule. Condensation, the 
reverse of hydrolysis, is where two small substrates are polymerised to form a new 
glucosidic bond. The enzyme then rapidly cleaves the newly formed substrate 
molecule. Shift-binding is thought to occur when there is a high concentration of 
small substrate molecules and two molecules each bind half of the same adive 
site. The binding affinities of one molecule pushes the other into a new binding 
position, allowing cleavage of a new bond. 
The catalysis of these multimolecular-type reactions is mostly dependent on 
the substrate concentra"l"ion and chain length. The smaller the chain length, the 
less likely the substrate is to bind to all the enzyme's subsites, and the smaller the 
chance of productive binding with the enzyme. When the concentration of these 
small substrates is high, the probability of multimolecular reactions occurring is 
increased. 
Porcine-pancreatic alpha-amylase catalyses condensation readions in the 
presence of high concentrations of maltotriose, and performs condensation and 
transglycosylation reactions with high concentrations of maltotetraose.L2 For 
substrates containing five or more glucose residUes the catalysed reaction 
involves unimolecular hydrolysis. 
For aspergillus oryzae alpha-amylase the main multimolecular reaction is 
transglycosylation.2 
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Figure 2.9: Alternative reactions catalysed by alpha-amylase. (A) transglycosylation, (8) 
condensation, (C) shift-binding. Dark circles are glucose units, pale circles are the reducing end of 
the molecule, the block is the active site of the enzyme. 
2.3 INHIBITORS OF ALPHA .. AMYLASE 
AI'though the adion of alpha-amylase is important for 'the breakdown and 
metabolism of carbohydrates for the majority of species, there is also a demand in 
certain circumstances for inhibition of the enzyme's activity. An inhibitor is defined 
as any substance that reduces the rate of an enzyme-catalysed reaction when 
present in the reaction mixture. The inhibition is generally due to an interaction 
between ei'~her 'the enzyme or subs'trate and inhibitor, that slows or prevents the 
productive binding of the enzyme and substrate.22,23 
The study of enzyme inhibitors provides useful information about how an 
enzyme works. Structural, chemical, and electronic properties of an inhibitor can 
provide insight into how a substrate binds, how the catalysed reaction proceeds, 
or what functionalities present in the enzyme govern and maintain the optimal 
activity of the enzyme. This information, in turn, can be used to develop enzymes 
with more desirable properties or better enzyme inhibitors. 
Inhibition stUdies of alpha-amylase have been used to ascertain the 
number of binding sites in '~he adive sites of different enzymes and 'the relative 
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affinity of each site for the substrate.2 Studies have also provided much of the 
information that is known about the action pattern of a/pha-amylases.l 
Inhibitors of alpha-amylase are also applicable in the areas of medicine 
and agriculture. 
1 MEDICINAL USE 
INHIBITORS 
ALPHA-AMYLASE 
The control of disease states related to carbohydrate metabolism, such as 
diabetes, hyperglycaemia, or hyperinsulinaemia, is usually achieved through 
control of diet. This involves a reduction in carbohydrate intake and the regular 
intake of small meals.3 Reducing the rate at which carbohydrates are 
metabolised through the inhibition of alpha-amylase has an application in "rhe 
treatment of such medical conditions. Reducing the production of secondary 
metabolites, thus, ultimately reducing the amount of glucose produced, may 
allow for more control of blood sugar levels. 
2.3.2 AGRICULTURAL USES OF ALPHA-AMYLASE 
INHIBITORS 
Alpha-amylases present in stored wheat have very low activities in the 
absence of moisture. In the presence of moisture, however, germination occurs 
and the activity of the alpha-amylase increases to facilitate plant growth. This 
sprouting leads to the breakdown of stored starch and proteins in the wheat 
grains, making any flour produced unsuitable for baking and therefore of little 
value.6 The cjevelopment of an alpha-amylase inhibitor for use on wheat 
harvested in wet conditions would provide commercial benefit for both the 
agricultural sector and industries reliant on quality wheat products. 
2.3.3 SUBSTRATE ANA LOGUE INHIBITORS 
There are many naturally occurring inhibitors of alpha-amylases, from 
various plant, bacterial, and microbial sources, described in the 
Iiterature.3,5,16,l7,24,25 They are usually proteins, or oligosaccharide and 
polysaccharide compounds with structures similar to that of "rhe natural substrate 
of the enzyme. Examples include compounds like nojirimycin and lucomycin A, 
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(Figure 2.10) and the end products of alpha-amylase action on starch, e.g. 
maltose, maltotriose and maltotetraose . 
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Figure 2.10: Inhibitors of alpha-amylases. 
Many inhibitors have also been synthesised based on the structure of the 
natural substrate (section 2.2.1). The similarities between the structure of the 
natural substrate and the inhibitors effectively 'trick' the enzyme into binding the 
inhibitor. 
The most effective of these inhibitors are often more structurally similar to a 
transition-state intermediate in the catalysed reaction (section 2.2.3) than either 
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the enzyme substrate or products. This is due to the fact that the enzyme binds 
the transition state more tightly than the substrate as a method of reducing the 
activation energy for the reaction. 26 
2.3.3.1 TRANSITION-STATE MIMIC 
An example of an inhibitor that binds a/pha-amylase as a transition state 
mimic is a compound given the generic name acarbose. Acarbose is a pseudo-
oligosaccharide inhibitor that was first isolated from culture broths of Actinop/anes 
strain SE 50.3 It belongs to a family of pseudo-oligosaccharide inhibitors all 
containing a characteristic core unit (acarvosine) essential for their inhibitory 
action. Acarvosine consists of a cyclitol unit (hydroxyme'thylconduritol residue) 
and an amino sugar (4-amino-4,6-dideoxy-D-glucopyranose), which is linked to a 
variable number of glucose residues via 0,-1 A-glucosidic linkages. In the case of 
acarbose, the number of attached sugars is two (Figure 2.11 J. It has been shown 
that the double bond in the cyclitol unit is important for the inhibitory activity, and 
that neither the cyclitol unit nor the amino sugar alone is capable of inhibiting 
a/pha-amylase. 
OH 
acarvosine 
~ cyclitolunit 
HO~ ) amino sugar 
HO OHHNS~) 
~ OH 
HO OH 0,,-- c.~' . 
~ OH HOOH~ 
HO OH OH 
glucose residues 
Figure 2.11: Acarbase. 
The crystal structures of porcine-pancreas, aspergillus oryzae and barley-
malt a/pha-amylases, containing acarbose bound in the active site of the 
enzyme, have been solved by various workers. 15,17-19 These structures have 
provided information regarding the probable binding of substrate molecules in 
the active site, and the identification of catalytic residues through their location 
and binding of acarbose. As discussed in section 2.2.3 these findings have given 
insight into the possible hydrolysis mechanism of the enzymes. In each crystal 
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structure, the bound inhibitor contains additional glucose residues that extend 
from the original four-unit acarbose filling all the available subsites. Given that 
alpha-amylase is able to cleave only '~he reducing end glucose residue from 
acarbose,15,17,18 it has been postulated that the altered molecules found 
occupying the active site in these studies were due to transglycosylation reactions 
catalysed by the enzyme (section 2.2.5). 
Acarbose is thought to be a transition-state analogue of the natural 
substrate; the half-chair conformation of the cyclitol unit resembles that of the 
proposed oxocarbonium-ion transition-state intermediate in the hydrolysis reaction 
(section 2.2.3). This cyclitol unit has been located in all instances in the catalytic 
subsite of the enzymes. 
Acarbose is currently being prescribed for the treatment of diabetes,14 
however, an'l'isocial side effects (e.g. flatulence) associated wi'~h '~his "treatment 
have piqued medical interest in the deyelopment of alternative inhibitors. 
The majority of substrate-analogue inhibitors bind their target enzyme 
reversibly, effectively hindering the catalysed reaction rather than preventing it. 
However, some inhibitors are irreversible and their binding can result in covalent 
linkages that prevent the enzyme catalysed reaction occurring. One type of 
inhibitor that produces these covalent linkages is a mechanism-based inhibitor. 
2.3.3.2 MECHANISM-BASED IN HIBITORS 
Mechanism-based inhibitors are initially bound by the enzyme as a 
substrate analogue; however, subsequent enzyme adion results in an adivated 
molecule that inhibits the enzyme. The first reported mechanism-based irreversible 
inhibitor of alpha-amylase was a 2-deoxy-2,2-difluoroglycoside (McCarter and 
Withers),21 which forms a stable enzyme-glycosyl intermediate that hydrolyses to 
product only very slowly (Figure 2.12). The presence of fluorine atoms at the C2 
position of the glucose analogue destabilises the oxocarbonium-ion transi'I'ion-
state and prevents crucial hydrogen bonding to the enzyme, which results in a 
slowing down of the catalysed reaction. Incorporation of a reactive leaving 
group helps accelerate the formation of the enzyme-glycosyl intermediate, but 
the rate of the subsequent reaction is reduced, effectively inactivaj'ing the 
enzyme. 
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Figure 2.12: The mechanism-based inhibitor trinitrophenyl-2-deoxy-2,2-difluoroglycoside. 
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The development of this inhibitor has provided valuable insight into the 
mechanism of hydrolysis by alpha-amylases [Section 2.2.3). 
2.3.4 PROTEIN .. BASED INHIBITORS 
There have been many proteinaceous inhibitors discovered from plants 
and microbial origins and their activity against varieties of alpha-amylases from 
exogenous and endogenous sources investigated.24 
Protein inhibitors of alpha-amylase generally exhibit time-dependent 
reversible inhibition of their target enzyme, in most cases by a non-competitive 
mechanism (section 4.3.2.1). A crystal structure of the inhibitor Tendamistat 
complexed with porcine-pancreatic alpha-amylase,16 has revealed that this 
inhibitor binds the enzyme such that the active site of the enzyme is blocked, 
preventing substrate binding. Some protein inhibitors, however, have been 
postulated to bind the enzyme's natural substrate as a method of reaction 
inhibition. 
Optimal pH is also important for protein inhibitory activity. In general the 
greatest activity is observed when the protein is operating at its isoelectric point or 
at a pH where the net electric charge on the protein inhibitor is opposite to that of 
the alpha-amylase. 
2.3 OTHER INHIBITO RS 
Some reported inhibitors of alpha-amylase are not of the typical 
oligosaccharide structure. Examples include papaverine, chlorpromazine and 
prochlorperazine (Figure 2.10). These molecules are reasonably large with a lot of 
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functionality. However, simple compounds have also been reported to inhibit 
alpha-amylase. One such molecule is ascorbic acid.27 
2.3.5.1 ASCORBIC ACID 
Figure 2.13: Ascorbic acid. 
HO 
HO~O 
HO OH 
Ascorbic acid, or vitamin C (Figure 2.13), is a simple, water-soluble molecule 
that is probably most well known for its antiscorbutic effects and thus its necessity 
in the human diet.28.29 The main biological function of ascorbic acid is as an anti-
oxidant or reducing agent and during reaction is converted to dehydroascorbic 
acid (DHA) (Figure 2.14). This oxidation is thought to occur by two, one-electron 
steps via an ascorbyl free radical. DHA is a potentially toxic and unstable 
compound, which is normally rapidly converted back to ascorbic acid by enzyme 
catalysed processes. Thus ascorbic acid and DHA are two halves of a redox 
couple which functions by cycling between their reduced and oxidised states. 
HO 
HO~O 
HO OH 
HO 
HO~O + 
o 0 
Figure 2.14: The redox couple of ascorbic acid and dehydroascorbic acid. 
Our attention was drawn to an obscure report by Palla and Verrier,27 
suggesting that ascorbic acid is a powerful inhibitor of alpha-amylase. This report 
appears to have been overlooked, as no references to this work could be found in 
subsequent literature. Because of its ready availability, low cost, and relatively 
uncomplicated structure, ascorbic acid is an ideal compound to study with 
respect to its inhibitory actions. We decided, therefore, to thoroughly investigate 
the inhibitory adion of ascorbic acid wi'~h regard to alpha-amylases. We chose to 
focus our studies on determining the structural features of ascorbic acid that were 
necessary for its action and to undertake kinetic studies to elucidate its mode of 
Alpha-Amylases 31 
inhibition. With this information, the development of potent ascorbic-acid-based 
alpha-amylase inhibitors may be possible. 
The following part of this thesis presents the results of our structure-activity 
investigations into ascorbic acid as an inhibitor of alpha-amylases. 
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ASCORBIC .. Acl INHIBITORS 
SAR studies on ascorbic acid required the preparation of derivatives 
incorporating systematic changes in its structure, to enable the determination of 
those features that were necessary for its inhibitory action against alpha-amylase. 
Although ascorbic acid is a simple molecule, it is highly functionalised. It contains 
four hydroxyl groups, and a double bond, organised into an ene-diol moiety and 
a diol chain (Figure 3.1). The ene-diol forms pali of a five-membered lactone ring 
with the diol chain attached at C4. 
HQ 
HO 
dialchainJ 
Figure 3.1: The structure of L-Ascorbic acid. 
OH 
ene-dial 
The natural form of ascorbic acid has an L configuration at CS.l However, 
the epimer D-isoascorbic acid is also commercially available, so we were able to 
investigate the importance of this stereochemistry on its inhibitory action . 
. 1 DERIVATIVES 0 ASCORBIC ACID 
Most of the ascorbic-acid derivatives investigated were known 
compounds, prepared using literature methods. Chemical modification centred 
mainly on the hydroxyl groups and included protection with acetal, acyl or alkyl 
groups. The effect of reducing the C2 - C3 double bond was also investigated. 
Table 3.1 gives a complete list of the derivatives prepared. 
Characterisation of the synthesised products u'rilised proton and 13C NMR 
spectroscopy, mass spectrometry, and IR spectroscopy. These data were 
compared to literature values where appropriate. In some instances the 
observed proton-NMR data is described relative to the resonances observed for 
ascorbic acid. These are as follows: lH NMR (D20) 04.88 (1 H, H4), 3.98 (1 H, HS), 
3.67 (2H, H6). 
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NMR studies have shown that the preferred conformations about the C4-C5 
and C5 - C6 bonds of ascorbic acid in solution are the same as those observed in 
the crystal la1'"I"ice. 1 Thus, we were interested in analysing the crystal shuctures of 
the prepared ascorbic-acid derivatives for the purpose of modelling optimal 
structural conformations. However, suitable crystals were only obtained for two of 
the prepared derivatives. 
Table 3.1 : L-ascor IC aCI an -Isoascor b' 'd dO' Ic-aci enva Ives prepare b' 'd d ' f d 
No. Name structure 
3.1 5,6-isopropylidene-L-ascorbic acid Me+q 0 
0j{0 
H - OH 
3.2 3-0-methyl-5,6-isopropylidene-L-ascorbic acid Me+q" 0 
o~o 
Mea OH 
3.3 2-acetyl-3-0-methyl-5,6-isopropylidene-L-ascorbic acid ~f~ 
~o oco~ 
3.4 3-0-methyl-L -ascorbic acid HO H~O 
/leO OH 
3.5 2,3-di-O-methyl-5,6-isopropylidene-l-ascorbic acid "" ~~o 
/leO 0"" 
3.6 2,3-di-O-methyl-L-ascorbic acid H~ 
/leO 0"., 
3.7 2,3-di-O-methyl-6-acetyl-L-ascorbic acid Ho f.leOCO~ 
~o O~ 
3.8 2,3-di-O-methyl-5,6-diacetyl-L-ascorbic acid f.leOCO MeOCO~O 
Mea 0'''' 
3.9 5,6-di-acetyl-L-ascorbic acid MeOCQ MeOCO~O 
H OH 
3.10 2,3-di-O-methyl-6-propionyl-L-ascorbic acid HO E1DCO~O 
,,"0 0,," 
3.11 2,3-di-O-methyl-6-butyryl-L-ascorbic acid HO A"OCO~O 
,,"0 0,," 
3.12 6-palmitate-L-ascorbic acid Hg 0 ,,"ICH21140CO~0 
H oH 
3.13 L-gulono-1 A-lactone HO H~O 
HO OH 
3.14 5,6-isopropylidene-D-isoascorbic acid "" ~+o o~ 
3.15 2,3-di-O-methyl-5,6-isopropylidene-D-isoascorbic acid ~f~ 
Mea 
""" 3.16 2,3-di-O-methyl-D-isoascorbic acid H~ 
/leO O~ 
Synthesis of 5,6-lsopropylidene-L-Ascorbic Acid (3.1) 
Compound 3.1 was prepared using the method of Jung et 01.2 A solution of 
L-ascorbic acid, acetone, and acetyl chloride was stirred together at room 
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temperature for three hours and then refrigerated. Product 3.1 precipitated out of 
solution and was recrystallised from acetone/petroleum ether in a 84% yield. 
Analysis by proton-NMR spectroscopy revealed an additional six-proton singlet 
resonance, relative to ascorbic acid, at 0 1.30, corresponding to the methyl 
groups of the isopropylidene moiety. 
Me 
Me+CJ;. 0 
__ .... ~ O~O 
HO 
-:: 0 HO~O 
HO OH HO OH 
L-.ASCORBIC ACID 3.1 
Scheme 3.1: (il acetone, acetyl chloride, stirred 3 hours. 
3. 1 . 1 PROTECTION OF 
GROUPS 
C2 OR C3 HYDROXYL 
HO 
-:: 0 HO~O 
/ HO OH ~ 
f Ascorbic acid \ 
Me 
Me+~ 0 
O~O 
HO OH 
3.2 R1 = Me, R2 = H 
3.5 R1 = Me, R2 = Me 
3.4 R1 = Me, R2 = H 
3.6 R1 = Me, R2 = Me 
Figure 3.2: Potential routes to methylated derivatives of ascorbic acid and compound 3.1. 
The available Iiterature2,6 suggests that derivatives of ascorbic acid and 
compound 3.1 in which the C2 and/or C3 hydroxyl groups are protected by 
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methylation, can be prepared by either of two routes as shown in Figure 3.2. 
Route A involves the methylation of ascorbic acid followed by protection of the 
diol chain with an acetonide group, while route B involves methylation of 
compound 3.1 followed by hydrolysis of the acetonide group. 
Given the reported success of direct methylation of ascorbic acid, 
preparation of these compounds was initially attempted by route A using a 
procedure reported by Jung et al. 2 However, this procedure, and subsequent 
alternative protocols utilising diazomethane as the methylating agent,3-6 resulted 
in either unreacted starting material or complex mixtures of products (as 
determined by proton-NMR spectroscopy). We therefore prepared the target 
derivatives using route B. 
Me Me Me 
Me+~ 0 Me + Cf;. 0 
.O~O_~.O~O 
Me+Cf; 0 
o~-yo 
+ n 
HO OH MeO OH MeO OCOMe 
a1 a2 3.3 
HO 
-:: 0 HO~O 
MeO OH 
3.4 
Scheme 3.2: (i) NaHC03, DMSO, Mel, stirred at 50°C overnight; (ii) methanol, 2M HCI, stirred 
overnight. 
Three compounds synthesised in this way are shown in Scheme 3.2. 
Preparation of the singly protected C3 methoxy derivative 3.4 allowed us to 
establish the necessity of this functional group for inhibitory activity (see Chapter 
4). Preparation of compound 3.2 incorporating protection of the C3, C5 and C6 
hydroxyl groups allowed a comparison to be made between the activity of 
compounds 3.1 and 3.4 and thus the importance of these functional groups could 
also be ascertained. 
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Synthesis of 3-0-Methyl-5,b Isopropylidene-L-Ascorbic Acid (3.2) and 2-Acetyl-3-
O-Methyl-5,b-lsopropylidene-L-Ascorbic Acid (3.3) 
3-0-Methyl-5,6-isopropylidene-L-ascorbic acid [3.2) was prepared using the 
procedure of Nihro et 01.7 as shown in Scheme 3.2. Compound 3.1, NaHC03 and 
DMSO were stirred together, followed by addition of iodomethane. Reaction 
overnight followed by work-up and purification gave 3.2 in a 19% yield. Analysis 
by proton-NMR spectroscopy revealed an additional three-proton singlet 
resonance at (5 4.18 corresponding to the methoxy group. 
Compound 3.3 was isolated in a 8% yield during the purification of product 
3.2 [Scheme 3.2). The proton-NMR spectrum for 3.3 included an additional three-
proton singlet resonance at (52.29 relative to compound 3.2, which was assigned 
to the acetate group. Proton resonances at (5 lAO and 1.36 indicated that the 
acetonide group was still intact thus acylation had not occurred at C5 or C6 in 
product 3.3. Additional NMR experiments revealed a nOe between the C4 proton 
at (5 4.67 and the methoxy group at (5 4.08, indicating that methylation had 
probably occurred on the C3 hydroxyl group. Thus the acetate was assigned as 
being attached at the C2 position. 
Synthesis of 3-0-Methyl-L-Ascorbic Acid (3.4) 
The singly protected compound 3.4 was synthesised by hydrolysis of the 
acetonide of compound 3.2 (Scheme 3.2). Removal of the solvent and 
purification gave 3.4 as an 011 in a 56% yield. Characterisation by proton-NMR 
spectroscopy revealed an absence of the singlet resonances of the acetonide 
group, previously present in compound 3.2. 
Attempted Synthesis of 2-0-methyl-L-Ascorbic Acid 
Attempts were made to prepare 2-0-methyl-5,6-isopropylidene-L-ascorbic 
acid using a procedure described by Seib et 0/. 3 To a stirred solution of 3.1 in an 
aqueous NaOH solution (pH> 1 0, determined using pH paper) at 60°C was added 
dimethyl sulfate, and the mixture was reacted for 1 hour. Analysis of the products 
by proton-NMR spectroscopy revealed a mixture of compounds that were not 
characterised. Alternative methods described by Nihro et aU and Kato et 0/.8 
gave similar results. 
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3. 1 .2 PROTECTION OF 
GROUPS 
AND C3 HYDROXYL 
Modification at all four hydroxyl groups, and subsequent hydrolysis to give 
the C2-C3 protected derivative allowed the significance of the C2 hydroxyl group 
for inhibitory activity to be investigated and the importance of the C5 and C6 
groups relative to the C2 and C3 groups to be established. 
Me 
Me+G:.. 0 
O~O 
HO OH 
3.1 
MeOeo 
-:: 0 HO~O 
MeO OMe 
3.7 
Me 
Me+G:., 0 
O~O 
MeO OMe 
3.5 
ii/ 
~ 
HO 
-:: 0 HO~O 
MeO OMe 
3.6 
Scheme 3.3: (i) dimethyl sulfate, K2C03, acetone, refluxed overnight; (ii) methanol, 2M HC!' 50°C 4 
hours; (iii) W, ethyl acetate. 
Synthesis of 2,3-Di-O-Methyl-5,6-lsopropylidene-L-Ascorbic Acid (3.5) 
Compound 3.5 was prepared using a general procedure reported by Le 
Merrer et al. 9 (Scheme 3.3). Compound 3.1 was refluxed overnight in a mixture 
containing K2C03, acetone, and dimethyl sulfate to give 3.S in a 29% yield after 
crystallisation. The proton-NMR spectrum showed two three-proton singlets at 0 
4.15 and 3.86, due to the methoxy groups on C3 and C2 respectively. 
Synthesis of 2,3-Di-O-Methyl-L-Ascorbic Acid (3.6) 
Compound 3.6 was prepared by the hydrolysis of the acetonide of 
compound 3.5 as shown in Scheme 3.3. Evaporation of the solvent gave 3.6 in a 
70% yield after recrystallisation. A proton-NMR spectrum of 3.6 revealed the 
absence of the methyl resonances at 0 1.39 and 1 .36 associated with the 
isopropylidene group in 3.S. 
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. 1 PROTECTION OF AND C6 HYDROXYL 
GROUPS 
Synthesis of 2,3-Di-O-Methyl-6-Acetyl-L-Ascorbic Add (3.7) 
Compound 3.7 was fortuitously obtained when attempting to workup the 
hydrolysed product 3.6 by extraction with ethyl acetate. 
Compound 3.5 was stirred in a mixture of methanol and aqueous HCI at 
50°C for 4 hours. Extraction of the mixture with ethyl acetate followed by removal 
of the solvent gave a solid residue, which was recrystallised from ether to give 3.7 
as colourless prisms in a 74% yield (Scheme 3.3). Proton-NMR spectroscopy 
revealed a three-proton singlet at 0 2.11. The C6 protons of 3.7 were also shifted 
downfield relative to compound 3.6, from 0 3.80 to 4.34 and 4.22. 
The 13C-NMR spectrum of 3.7 contained additional resonances, relative to 
3.6, at 0 20.81 and 171.01, due to the presence of the acetyl group. Given that 
ethyl acetate was the only source of acylating agent in the reaction, we propose 
that residual acid present in the reaction mixture, after evaporation of the solvent, 
catalysed a transesterification reaction between the free primary alcohol of 3.6 
and ethyl acetate to give compound 3.7. Due to the quality of the crystals 
prepared, an X-ray crystal structure analysis was performed to confirm the 
structure of compound 3.7* (Figure 3.3). A search of the Cambridge 
Crystallographic Database revealed no previous reports of this compound. 
In the crystalline state 3.7 has two main intermolecular hydrogen-bonding 
interactions (Figure 3.4). The first is between the carbonyl oxygen of the acetyl 
moiety and the C4 hydrogen of the lactone ring of an adjacent molecule, and 
the second is between the C 1 carbonyl oxygen and 'rhe C5 hydroxyl group of 
another adjacent molecule. The second interaction is easily seen in the lower part 
of Figure 3.4, labelled D. This figure also shows the screw axis of the P(2) 1 space 
group in which this molecule crystallises, seen by inspection of the molecules 
labelled A, Band C . 
• For complete crystallographic data the reader is referred to appendix C. 
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0111 
Figure 3.3: The crystal structure of 2,3-di-O-methYI-6-acetyl-L-ascorbic acid. 
Figure 3.4: Packing arrangement of compound 3.7 looking down the a axis. 
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Synthesis of 2,3-Di-O-Methyl-5,6-Diccetyl-l-Ascorbic Acid (3.B) 
HO 
-:: 0 HO~O 
MeOCO 
-:: 0 
___ ~ Meoco~O 
MeO OMe MeO OMe 
3.6 3.8 
Scheme 3.4: (i) acetic anhydride, pyridine, stirred two hours. 
Attempts to optimise the synthesis of compound 3.7 lead to the diacetyl 
compound 3.B. This derivative was expected to have similar activity to 
compound 3.5 as all four hydroxyl groups are protected in both compounds. 
Preparation of 3.B also enabled the effect of different choices of C5 and C6 
protection on inhibitory activity to be investigated. 
Compound 3.6 was dissolved in pyridine and stirred with acetic anhydride 
at room temperature for 2 hours. The solvent was removed and the resulting solid 
recrystallised from ether to give crystals of 3.B as -transparent plates in a 24% yield. 
proton-NMR spectroscopy (CDCI3) revealed a six-proton singlet at 8 2.07 
corresponding to acetate groups at C5 and C6. As expected, the resonances for 
the C6 and C5 protons were significantly downfield (at 8 4.36, 4.26 and 5.35 
respectively) relative to the chemical shifts of the same protons in 3.6 (Figure 3.5). 
The 13C-NMR spectrum contained additional resonances relative to 3.6 (at 0 20.36, 
20.55,169.38 and 170.22), corresponding to the two acetyl moieties. 
Synthesis of 5,6-Di-Acetyl-L-Ascorbic Acid (3.9) 
To ensure that the activity observed for compound 3.1 was not as a result of 
hydrolysis under the assay conditions, and therefore due to ascorbic acid, a 
derivative containing acetyl protecting groups at C5 and C6 was prepared. 
Synthesis of this compound (3.9) also enabled comparison with the activity of 3.B. 
The 5,6-diacetyl ascorbic-acid derivative 3.9, was prepared based on a 
procedure by Creighton et al. 10 (Scheme 3.5). 
HO 
~ 0 HO~O 
HO OH 
L-ASCORBIC ACID 3.9 
Scheme 3.5: (i) acetic anhydride, H2S04, stirred 40°C 2 hours. 
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Figure 3.5: proton NMR spectra of compounds 3.6 and 3.B. 
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A drop of concentrated aqueous H2S04 was added to a mixture of 
ascorbic acid and acetic anhydride and the mixture was stirred with gentle 
heating for 2 hours. Evaporation of the solvent and seeding of the resultant syrup, 
produced 3.9 as crystalline needles. A proton-NMR spectrum revealed the 
expected downfield shift, relative to ascorbic acid, of the resonances 
corresponding to the C5 and C6 protons of 3.9 (8 5.43, 4.37 and 4.23 respectively). 
The acetyl methyl groups appeared as two three-proton singlets at 8 2.00 and 
1.97. 
3. 1 .4 EXTENDEO .. Acy L .. GROUP PROTECTION OF THE 
C6 HYDROXYL GROUP 
The reactivity of the C6 primary alcohol of ascorbic acid in the presence of 
the C2- and C3-protected ene-diol of compound 3.6, is demonstrated by the 
simplicity with which 3.7 was prepared (Scheme 3.3). Due to the ease with which 
this reaction occurred, it was decided to investigate the possible synthesis of 
similar derivatives, containing extended carbon chains at C6, using a similar 
methodology (Figure 3.6). Compounds were prepared incorporating a propionyl 
and a butyryl group: compounds 3.10 and 3.11 respectively (Figure 3.6). As part of 
this series, we attempted to prepare a compound containing a benzoate moiety. 
However, reaction of compound 3.6, p-TSA and ethyl benzoate at 50°C overnight 
and subsequent workup, returned only starting material as determined by proton-
NMR analysis. 
HO 
-:: 0 HO~O 
MeO OMe 
3.6 
HO 
-:: 0 0 Me~O~ 
o MeO OMe 
HQ 
-; 0 0 Me/-(O~ 
o MeO OMe 
HO 
-:: 0 0 Me-/'{O~ 
o MeO OMe 
3.7 3.10 3.11 
Figure 3.6: Derivatives 3.6, 3.7, 3.10 and 3.11. 
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This series of syntheses gave lower yields for the longer acyl-group 
substitutions, (3.7 = 74%, 3.10 = 12%,3.11 = 7%, see Figure 3.6 for structures). These 
results led us to conclude that the success of transesterification reactions at C6 of 
compound 3.6, using these simple procedures, had some dependency on the size 
of the introduced ester group. 
Synthesis of 2,3-Di-O-Methyl-6-Propionyl-L-Ascorbic Acid (3.10) 
HO HO 
-:: 0 HO~O 
-:: 0 
___ " EtOCO~O 
MeO OMe MeO OMe 
3.6 3.10 
Scheme 3.6: (i) ethyl propionate, pTSA, 700 e overnight. 
Compound 3.6, pTSA and ethyl' propionate were stirred at 70°C overnight 
(Scheme 3.6). Workup and purification by radial chromatography gave 3.10 in a 
12% yield. The proton-NMR spectrum was consistent with acylation at C6, as 
characterised by a downfield shift of the C6-proton resonances relative to those 
seen in the spectrum of compound 3.6. The presence of a two-proton quartet at 
o 2.38 and a three-proton triplet at 0 1.15 was consistent with a propionyl group. 
The 13C-NMR spectrum of 3.10 showed additional resonances at 0 8.97, 27.38 and 
174.45, relative to the starting material 3.6, consistent with the presence of a 
propionyl group. 
The appearance of a molecular ion with a mass of 260 in the mass 
spectrum of this compound confirmed the incorporation of the propionyl group. 
Synthesis of 2,3-Di-O-Methyl-6-Butyryl-L-Ascorbic Acid (3.11) 
HO HO 
-:: 0 HO~O -:: 0 PrOco~O 
MeO OMe MeO OMe 
3.6 3.11 
Scheme 3.7: (i) ethyl butyrate, pTSA, 700 e overnight. 
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Compound 3.6 was stirred with ethyl butyrate in the presence of pTSA. 
Workup and purification by radial chromatography gave 3.11 as a yellow oil in a 
7% yield. Analysis by proton-NMR spectroscopy revealed a downfield shift of the 
C6 proton resonances to 0 4.35 and 4.23, relative to 3.6, characteristic of C6 
acylation. The appearance of an additional two-proton triplet at 0 2.34, a two-
proton quartet at 0 1.67, and a three-proton triplet at 0 0.96 was consistent with 
acylation by a butyryl moiety. The 13C-NMR spectrum contained the appropriate 
additional resonances for a butyryl group: 0 13.61, 18.32, 35.93 and 173.64. 
The appearance of a molecular ion with a mass of 274 in the mass 
spectrum of 3.11 confirmed the incorporation of a butyryl group. 
Synthesis of 6-Palmitate-L-Ascorbic Acid (3.12) 
This compound was synthesised to establish if a large steric group attached 
to ascorbic acid affected its inhibitol)' properties [Scheme 3.8). It also provided a 
means of determining whether the inhibitory activity of compounds 3.9 and 3.10 
were dominated by (a) the length of the chain at C6, or (b) the protection of the 
secondary alcohols at C2 and C3. Preparation of 3.12 further tested the necessity 
of the C6 hydroxyl group for activity. 
HO HO 
-:: 0 HO~O 
HO OH 
-:: 0 Me(CH.2)1~OCO~O 
I HO OH 
L-ASCORBIC ACID 3.12 
Scheme 3.8: (iJ palmitic acid. H2S04. 
Compound 3.12 was prepared as described by Seib et 0/. 11 Ascorbic acid 
and palmitic acid were stirred together in concentrated aqueous H2S04. Workup 
gave 3.12 as a white solid in a 42% yield. proton-NMR data on this compound 
(CDCb/DMSO) was in agreement with the literature. As expected for acylation, 
the chemical shifts of the C6 protons of 3.12 were downfield, relative to ascorbic 
acid, at 84.28 and 4.20. The following resonances defined the palmitate chain: a 
two-proton triplet at 8 2.33; a two-proton multiplet at 1.61; a 26-proton multiplet at 
1.25 and a three-proton triplet at 0.87 for the terminal methyl group. 
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3. 1 .5 REDUCTION OF THE DOUBLE BOND 
Synthesis of L-Gulono-1 A-Lactone (3.13) 
This compound tested the necessity of the double bond for the inhibitory 
action of ascorbic acid. It was prepared using literature methods 12,13 (Scheme 
3.9). An aqueous solution of ascorbic acid was hydrogenated over Pd/C for three 
days. Workup gave 3.13 as colourless prisms, which were suitable for X-ray 
crystallographic analysis [Figure 3.7). proton-NMR showed the expected 
appearance of an additional two-proton resonance at 0 4,43 due to reduction of 
the double bond. 
HO HO 
-:: 0 HO~O -:: 0 _____ • HO~O 
HO OH HO OH 
L-ASCORBIC ACID 3.13 
Scheme 3.9: (i) 10% Pd/C, water, H2, 40 psi, 3 days. 
The crystal structure of 3.13 shows that hydrogenation of the ascorbic-acid 
ene-diol moiety has occurred from the less-hindered face of the lactone ring 
resulting in two new stereocentres in which the hydroxyl groups extend out from 
the plane of the ring (Figure 3.7). 
0(1) 
Figure 3.7: Crystal structure of 3.13. 
Ascorbic-Acid Inhibitors 47 
Unlike compound 3.7, compound 3.13 crystallised in an orthorhombic 
crystal system with the space group P(2) 1 (2) 1 (2) 1. It can be seen from Figure 3.8, 
that compound 3.13 has two major intermolecular hydrogen bonding interactions 
to two separate, adjacent molecules: one between 04 and the C3 hydrogen, 
and another between the carbonyl oxygen atom and the C2 hydrogen. 
Figure 3.8: Hydrogen bonding between molecules of 3.13. 
3. 1.6 D"lsOASCORBIC .. ACID DERIVATIVES 
The synthesis of D-isoascorbic acid derivatives allowed the effects on the 
inhibitory activity of ascorbic acid due to epimerisation at C5 to be evaluated. 
Synthesis of 5,6-lsopropylidene-D-Isoascorbic Acid (3.14) 
Initial attempts to prepare 3.14 using the method of Jung,2 returned only 
starting material. Therefore, it was prepared by a method described by Godefroi 
et 01.13 (Scheme 3.10). D-Isoascorbic acid and dimethoxypropane were stirred in 
boiling acetone with SnCI3 for 15 minutes at which time the reaction was 
quenched by the addition of pyridine. Workup gave compound 3.14 as white 
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solid in a 64% yield. Characterisation by proton-NMR revealed two three-proton 
resonances at 8 1.34 and 1.27 corresponding to the acetonide group. 
Me 
__ Met~o 
D-ISOASCORBIC ACID 
HO 
HO~O 
MeO OMe 
3.16 
iii 
.... --
HO OH 
3.14 
Me 
o 0 Me+~O0 
MeO OMe 
3.15 
Scheme 3.10: (i) acetone, SnCI2, dimethoxypropane, pyridine; [iiI acetone, K2C03, dimethyl sulfate; 
(iii) slow hydrolysis. 
Synthesis of 2,3-Di-O-Methyl-5,6-lsopropylidene-D-lso-Ascorbic Acid (3.15) and 
2,3-Di-O-Methyl-D-lso-Ascorbic Acid (3.16) 
Preparation of 3.15 was achieved using the same method previously 
described to prepare derivative 3.5. Workup and purification by radial 
chromatography gave 3.15 as an oil in a 68% yield. A proton-NMR spectrum of 
this product contained two additional three-proton resonances, relative to 
compound 3.14, at 8 4.15 and 3.85, due to the methoxy groups on C3 and C2 
respectively. 
A forgotten sample of 3.15, left to stand open to the atmosphere for a few 
weeks and subsequently analysed by proton-NMR spectroscopy, revealed loss of 
the acetonide resonances at 8 1.45 and 1.37 to give compound 3.16. 
3.1. ADDITIONAL Co MPOUNDS 
Along with the ascorbic-acid derivatives prepared, we were interested to 
test compounds that structurally resembled possible reaction products of ascorbic 
acid, in particular a ring opened analogue and the oxidised dehydroascorbic 
acid. 
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3.1.7.1 DIHYDROXYFUMARIC ACID 
Dihydroxyfumaric acid (DHFA) was purchased to determine if it was 
necessary to have the ring system for inhibitory action. As can be seen in Figure 
3.9, dihydroxyfumaric acid is a straight-chain molecule containing an ene-diol and 
carboxylate functionalities. As the ene-diol predominantly exists as the 
thermodynamically-stable trans isomer (95%),14 the requirement for a cis ene-diol 
conformation could also be tested. 
:tZ:
HO 0 HO 
o OH 
OH 
Figure 3.9: Dihydroxyfumaric acid. 
3.1.7.2 DEHYDROASCORBIC ACID 
Since ascorbic acid is readily oxidised, (section 2.3.5.1), the possibility exists 
that inhibition of alpha-amylase by ascorbic acid is due to the first stable oxidation 
product: dehydroascorbic acid (Figure 3.10). To test this possibility, 
dehydroascorbic acid (kindly supplied by Sian Fayle) was also tested for inhibitory 
activity against alpha-amylase. 
HO 
-;: 0 HO~O 
o 0 
Figure 3.10: Dehydroascorbic acid. 
3.2 SUMMARY 
Sixteen ascorbic-acid derivatives were prepared, incorporating a range of 
functional-group modifications. In most instances the modification was achieved 
by protection of the hydroxyl groups with methyl, acyl. or acetyl groups. D-
isoascorbic-acid derivatives were also prepared, as was a reduced compound. 
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Two unexpected acylated molecules were isolated: 3.3 and 3.7. A crystal 
structure analysis of compound 3.7 confirmed its structure. 
A simple procedure for the acylation of the C6 hydroxyl group in a C2 and 
C3 hydroxyl-protected derivative was also investigated. 
The inhibition activity of these derivatives, which has lead to the 
identification of the pharmacophore of this molecule, and the possible mode of 
inhibition of ascorbic acid is discussed in the following chapter. 
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4 INHIBITORY 
ACID AND 
OF ASCORBIC 
ERIVATIVES 
The effects that structural modification of ascorbic acid has on its inhibitory 
action against alpha-amylase, were determined by measuring the uninhibited 
activity of the enzyme and comparing this to its activity in the presence of each 
ascorbic-acid derivative prepared. 
The activity of an enzyme is a measure of the rate of the reaction that it 
catalyses; the higher the activity, the faster the initial rate of the reaction. (For 
alpha-amylases, this reaction is the hydrolysis of a-l A-glucosidic linkages.) The 
international standard for expressing enzyme activity is in katal (kat), one unit of 
which is equal to the enzyme activity sufficient to catalyse the transformation of 
one mole of substrate in one second under standard conditions. 1 However, these 
units are excessively large; for example, normal cellular enzyme activity is typically 
20 !lkat/L.1 Therefore, the more traditional units of the amount of enzyme that can 
catalyse the transformation of one micromole of substrate in one minute are 
commonly employed. One unit (U) of alpha-amylase is often defined as the 
amount of protein that produces 1.0 ),.lmole of maltose in 1 minute at pH 6.9 and 
20°C.2 
The activity of an enzyme is determined with an enzyme assay, which is an 
experimental method for quantifying the conversion of substrates into products. 
This is most easily achieved by directly monitoring either a loss in enzyme substrate 
or a gain in products. However, this is not always possible, and indirect methods 
must then be employed. 
Apart from the determination of an enzyme's activity, appropriate assays 
also provide information about mechanistic processes and the optimal catalytic 
environment for the enzyme. This information has many practical applications. 
For alpha-amylase, which catalyses the hydrolysis of many different 
oligosaccharides and polysaccharides, the activity of the enzyme is highly 
dependent on the substrate. 
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4. 1 ALPHA-AMYLA S E ASSAYS 
The action of alpha-amylase produces a variety of characteristic changes 
to its substrate.3 These include a decrease in substrate viscosity and turbidity, an 
increase in the number of molecules bearing reducing ends: a reduction in the 
degree of iodine staining of the substrate, and changes in the optical rotation of 
the substrate. These characteristics can be easily monitored, and most have 
been used to develop assays for the determination of alpha-amylase activity. For 
well-defined substrates the amount of a defined product can also be measured. 
In order to accurately measure the inhibitory effectiveness of the ascorbic-
acid deriva1'ives against alpha-amylase, we required an assay 'that was simple to 
set up and use, was reliable, and specifically measured the activity of alpha-
amylase. The following section provides a brief overview of the different types of 
alpha-amylase assays available. Due to the enzyme selectivity, improved kinetics 
and ease of use reported for the Megazyme assay, it was selected for the analysis 
of the inhibitory activity of 'the ascorbic-acid deriva'l'ives studied in this work. 
4.1.1 SACCHAROGEN IC AND AMYLOCLASTIC ASSAYS 
Early alpha-amylase assays were based on an increase in the number of 
reducing ends (saccharogenic), and/or changes in the turbidity, viscosity and 
iodine-staining ability (amyloclastic) of the substrate following hydrolysis. 
4.1 . 1 . 1 SACCHAROGENIC Ass A YS 
If it is assumed that every action-event of alpha-amylase on its substrate will 
produce a molecule with a reducing end, then the number of reducing ends 
present after hydrolysis gives an estimate of the enzyme's activity. Assays based 
on this principle utilise the redox chemistry of sugars and were developed from 
techniques used to determine blood glucose levels. Typical assay procedures 
include the reduction of copper, ferricyanide, picric acid or 3,5-dinitrosalicylic 
acid.4 The methods of Nelson and SomogyiS are well-known examples; a sample 
containing reducing ends is reacted wi'th an alkaline cuprous-oxide reagent and 
• The reducing end of a carbohydrate molecule is the terminal in which the Cl 
anomeric carbon is not bonded to another molecule. Each hydrolysis event produces a 
new reducing end such that the resulting two fragments each have one. 
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then visualised by the addition of a chromogenic compound such as 
arsenophosphate. The colour intensity of the solution is related to its 
concentration (via the Beer-Lambert law), and is compared to a series of known-
concentration standards. 
If precautions are taken to ensure purity of reagents and care in 
experimental techniques, this type of assay can give reliable, reproducible results. 
However, there are many disadvantages to this assay. It is quite laborious and 
time consuming, and it requires the daily preparation of standard solutions, 
making it inconvenient for rapid screening. The assays are based on the presence 
of reducing compounds but do not distinguish between different types; therefore, 
the presence of glucose or other reducing agents can cause false positive results. 
Finally, as any glucosidase enzyme is able to produce reducing ends, 
saccharogenic type assays are not specific for a/pha-amylase. 
4.1.1.2 AMYLOCLASTIC ASSAYS' 
Whereas the saccharogenic assays described above are based on the 
accumulation of product, amylociastic assays monitor the destruction of 
substrate. The turbidity and viscosity of starch solutions are related to the swelling 
of the starch granules (when introduced into the solution) and subsequent 
interaction between these swollen grains. Hydrolysis results in a loss of turbidity due 
to a reduction in grain size, and a decrease in viscosity due to disruptions in the 
intermolecular interactions and structure of the starch.4 The activity of aJpha-
amylase is related to the amount of enzyme required to reduce viscosity by 20%: 
however, the results are dependent on the type and purity of the substrate. These 
assays are useful for rapid screening of activity, but are severely limited in regard 
to the kinetic information they provide. They are most useful when used in 
conjunction with another assay. 
The most useful amylociastic assay is based on the starch-iodine test.4.6.7 
The intensity of the characteristic blue-coloured complex formed when iodine is 
added to starch is reduced upon hydrolysis of the starch.3 The colour of iodine in 
starch is due to the helical arrangement of the amylose chain in the starch grains. 
Each helical tum consists of six glucose residues that surround a single iodine atom. 
Longer helices, therefore, result in the formation of linear chains of iodine atoms. 
The colour is dependent on the length of the iodine chain, and is therefore, a 
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function of the number of helical turns; a blue complex is only observed in chains 
of more than 45 glucose units. . Hydrolysis results in a change in colour until the 
achromatic point is reached (i.e. the point at which all colour is dispersed Table 
4.1) ,4 
The change in 'staining ability' of carbohydrate chains less than 25 units in 
length is not notable, so although this assay is able to measure the initial attack of 
the enzyme on starch substrates, it is insensitive to multiple attacks.3 The degree of 
enzyme activity is estimated by colour comparisons with standard solutions. 
Table 4.1: Colour of the amylose-iodine complex as a function of the number of helical turns in 
amylose. 
NO. OF HELICAL TURNS COLOUR 
<2 None 
2 Brown 
3 5 Red 
6 8 Purple 
>9· Blue 
Because this assay measures the hydrolysis of the substrate, when the 
achromatic point is reached the enzyme is no longer operating under substrate 
saturation conditions. Consequently, this type of assay doesn't provide an 
accurate es"l"imate of the enzyme's activity. Interference by proteins in the starch-
iodine assay can also give false positive results. Iodine-based assays are unable to 
measure abnormally high or low amylase levels, they require a set of standard 
solutions and, as with the saccharogenic assays they are not specific for alpha-
amylases. 
A review of up to 50 different saccharogenic and amyloclastic type assays 
by Searcy et al. 4 concluded that the saccharogenic methods are superior to 
amyloclastic assays due to the increased information they provided. However, 
routine use of either of these types of assay has diminished due to the 
development of highly defined enzyme substrates. 
4. 1 .2 CHROMOGENIC"S U BSTRATE ASSAYS 
An improvement in alpha-amylase assays came with the introduction of 
chromogenic substrates. The idea was based on the use of certain dyes to colour 
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cellulose-type fabrics.8 These water-soluble dyes are covalently bound to the 
starch polymer via ether or ester linkages to give an insoluble, coloured product. 
The first reported use of a dyed substrate was by Rinderknecht and Wilding 
who described the preparation of insoluble, dyed starch grains using Remazol 
brlliiant-blue dye under alkaline conditions.9 Hydrolysis of the starch leads to 
soluble, coloured fragments, which can be separated from the unreacted, 
insoluble material and measured photometrically. 
The development of these substrates has included a variety of different 
dyes and starches from various sources (Table 4.2L 10 the most effective being 
those prepared from well-defined starches, which give meaningful results over a 
wide range of amylase activities. 
T bl 42 C a e .. ompanson 0 I eren lye su s ra es or amYlase assays f d'ff t d d b t t f 
SUBSTRATE DYE 
Amylopectin Reactone red 2B 
Amylopectin Prodon brilliant red M-2 BS 
Dyed starch Cibachron blue F 3 GA 
Dyed starch Remazol brilliant blue R 
Dyed amylose Cibachron blue F 3 GA 
The use of dyed substrates allows quantitation of hydrolysis events provided 
the ratio of dye to substrate molecules is known, However, care must be taken 
not to incubate the reactions for too long. This causes the apparent reaction rate 
to increase as smaller chains formed during hydrolysis are cleaved more rapidly 
than longer chains.3 Careful removal of the unreacted substrate is also important 
for an accurate measurement of the activity. 
Advantages of this type of assay include its ease of use, and the accuracy 
of the information obtained regarding the enzyme's activity. However, this 
method once again requires a set of standard solutions against which the activity 
is measured, and a 'blank' for each set of measurements. 
Assays using dyed substrates are also non-specific for alpha-amylases. 
4.1.3 DEFINED"SUBST ATE ASSAYS 
The most recent advance in assays for alpha-amylase has been the use of 
highly-defined simple substrates. These allow for high purity of the substrate as well 
as the monitoring of specific hydrolysis products. Often the substrate will contain a 
chromophore that is released in the assay and detected photometrically. 
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Alternatively, the assay can incorporate a coupled reaction, where the hydrolysis 
products of alpha-amylase action are substrates for a second reaction, the 
products of which can be monitored. In many cases, the assay also includes 
coupling enzymes that either assist in the substrate cleavage to release the 
chromophore, or are necessary for the coupled reaction. 
Examples of assays using the defined substrates maltotetraose and 4-
nitrophenyl maltoheptaoside are described below,lO along with the Megazyme 
assay used in this work. 
4. 1 .3. 1 MALTOTETRAOSE 
This assay involves four coupled reactions (Figure 4.1). Maltotetraose is 
cleaved by alpha-amylase to give two maltose molecules. Maltose and 
phosphate (Pi) react in the presence of maltose phosphorylase (MP) to produce 
glucose and l)-glucose-1-phosphate. The I)-glucose-phosphate, in the presence 
of I)-phosphoglucomutase (I)-PGM), is converted to glucose-6-phosphate, which, 
in the presence of glucose-6-phosphate dehydrogenase (G6P-DH), is oxidised to 
gluconate-6-phosphate by NAD+, producing NADH. 
The assay is followed photometrically by measuring the increase in NADH 
production via its absorption at 339 nm. In this way a direct measure of the alpha-
amylase activity is obtained. 
HO 0 HO 0 HO 0 HO 0 ~~o~~\~~~\~OH 
maltotetraose + H20 
HO oHO 0 HO~O~OH 
maltose + Pi 
HO 0 OPOi2 HO~ 
MP 
f)-glucose-l-P --;::-I1--:-P-;-G~M:::-,)Ir"" 
G-l,6-P2 
a-amylase 
100 
HO 0 HO 0 HO*"O~OH 
2 maltose 
glucose + f)-glucose-l-P 
glucose-6-P 
~~~ 
HO~OH 
JPO~~O 
HO~ 
glucose-6-P + NAD+ G6P-DHI>' gluconate-6-P + NADH + H+ 
Figure 4.1: Maltotetraose coupled assay. 
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Errors mainly occur in this assay when analysing samples with high levels of 
maltose. However, the assay of samples from cereal, food, or fermentation 
industries is complicated by the presence of interfering enzymes such as ~­
amylase, amyloglucosidase, a-glucosidase, and various debranching enzymes, all 
of which are capable of cleaving the substrate. 
4.1.3.24-NITROPHENYL-MALTOHEPTAOSIDE 
~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 ~ 0 HO~O~O~O~%~O~O~OVN02 
3 4-nitrophenyl maltoheptaoside 
j a-_hso 
HO 0 HO 0 HO 0 ~~o~~i~\~OH HO OHO OHO OHO 0 ,Ho~o~~~s::i~\~O~OH 
2 maltotriose + maltotetraose 
HO 0 HO 0 HO 0 HO 0 HO~%'~~~&\~O~O-oN02 
+ 2 4-nitrophenyl maltotetraoside + 
HO 0 HO~OH 
3 glucose + 
HOVN02 
4-nitrophenol 
Figure 4.2: 4-nitrophenylheptaoside colorimetric assay. 
This assay involves a co-enzyme a-glucosidase that has high specificity for 
small substrates (2-3 residues). It is monitored by the release of a coloured 
chromophore. 4-Nitrophenyl maltoheptaoside is hydrolysed by alpha-amylase 
into mostly maltotriose, maltotetraose, 4-nitrophenyl maltotetraoside and 4-
nitrophenyl-maltotrioside. The 4-nitrophenyl maltotrioside is then cleaved by 0.-
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glucosidase to give glucose and 4-nitrophenol (Figure 4.2). The enzyme activity is 
directly related to the release of 4-nitrophenol, which is measured photometrically 
via its absorbance at 405 nm. 
This assay is specific for alpha-amylase and gives generally reliable 
measures of activity. However, it is possible that the substrate is hydrolysed by 
alpha-amylase to give 4-nitrophenyl maltopentaoside, which may be further 
cleaved by the enzyme. This creates the potential for inaccuracy in the 
measurement of activity. In addition, the use of this type of assay is limited for 
samples containing interfering enzymes. 
One assay utilising a defined substrate, which has overcome the problem 
of interfering enzymes is the 'Megazyme' Assay. 
4.1.3.3 MEGAZYMEAsSAY 
The Megazyme assay by McCleary and Sheehan 11 uses a non-reducing-
end-blocked p-ni"~rophenyl maltoheptaoside (BPNPG7) previously developed by 
Blair12 (Figure 4.3). The presence of the blocking group, in addition to the p-
nitrophenol chromophore, provides the substrate with resistance to attack by f3-
amylase, a-glucosidase and glucoamylase, all of which function as exo enzymes; 
hydrolysing their substrates from the ends. Only alpha-amylase, an endo enzyme, 
which cleaves its substrate at internal linkages, is able to hydrolyse the substrate. 
The assay includes a-glucosidase and glucoamylase, in excess levels, as 
coupling enzymes. Unlike alpha-amylase, these glucosidases are specific for small 
substrates (2-3 units) and act rapidly on the alpha-amylase-hydrolysed substrate to 
release the nitrophenol molecule. This improves the kinetics of the assay, as each 
molecule of the chromophore released corresponds to a single action-event by 
alpha-amylase. The production of nitrophenol is measured photometrically via 
the absorption of the phenolate ion at 410 nm. 
The Megazyme assay is specific for alpha-amylase, and, as well as its ease 
of use, it is reported to provide accurate and reliable kinetic data on the activity 
of the enzyme, providing the necessary precau"l"ions, (wnh regard to experimental 
technique and purity of reagents), are taken. 
In spite of investigations to ascertain the suitability of the Megazyme assay 
for analysis of our compounds, we did experience some difficulties obtaining 
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reproducible results for our inhibition and kinetic analyses. This is reflected in the 
errors associated with our reported values in sections 4.2 and 4.3. Whilst the 
Megazyme assay gives excellent results when used as a fixed-time assay, there 
remains scope for further development to produce an assay that reliably gives 
initial rate data for alpha-amylase activity. 
Blocked p-nitrophenyl maltoheptaoside BPI\IPG7 
GROUP 0 BWCKING~O H~O 
'0 HO OH HO OH nOH 
J a-Am~ase 
+ "O~Oio-NO' 
:Lo, 
HO~~OH 
j glucoamyiase a-glucosidase 
+ HO-Q-NOZ 
j Trizma base 
Reaction stopped and yellow colour developed 
Figure 4.3: Megazyme ~say: alpha-amylase hydrolyses the substrate to remove the blocking group. 
This allows rapid attack by a-glucosidase and glucoamylase, which releases the p-nitrophenol 
molecule. The addition of Trizma base inactivates the enzymes and deprotonates the phenol to 
give the more highly-coloured phenolate ion, which is detected photometrically. 
4.2 INHIBITORY ANALYSIS OF ASCORBIC-ACID 
DERIVATIVES 
The inhibitory effectiveness of the ascorbic-acid derivatives was analysed 
by comparing "rhe activity of the enzyme in the presence of each inhibitor, with 
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the activity of the uninhibited enzyme. The activity in all instances was 
determined using the Megazyme alpha-amylase assay' (section 4.1.3.3). 
The assay protocol involved mixing the inhibitor and enzyme together, then 
initiai"ing "~he reaction by the addition of substrate.t The reaction was terminated 
after 10 minutes by the addition of excess base, which inactivates the enzymes 
and deprotonates the released nitrophenol chromophore. 
The initial rate of the alpha-amylase action on the substrate was 
determined by measuring the absorbance of p-nitrophenolate at 410 nm after a 
set time. The absorbance of the chromophore reflects its concentration in solution 
and may be directly related to the number of action events due to a/pha-
amylase. A high level of absorbance is indicative of a high initial-rate of enzyme 
activity, a low absorbance indicating a low initial-rate. 
The initial rates in this study are calculated in terms of 'Megazyme" units as 
defined by McClearyet a/. 11 One unit.is equal to the amount of enzyme required 
to produce one micromole of p-nitrophenol in one minute. These units are simply 
converted to other standards units. 
The reduction in alpha-amylase activity due to inhibition was calculated as 
a percentage of the uninhibited activity. For example, a value of 25% indicates 
the normal enzyme activity was reduced by one quarter in the presence of the 
inhibitor. Initial assays were performed using barley-malt alpha-amylase, as this 
enzyme is inexpensive, readily available and stable at 4°C. However, derivatives 
that showed good inhibitory action, were further assayed against fungal, 
bacterial, pancreas, and saliva alpha-amylases. The results of these assays are 
shown in Table 4.3 
• The assumption was made that the reduced activity of the enzyme in the 
presence of the inhibitor was due to inhibition of alpha-amylase, and that the coupling 
enzymes were unaffected. This is reasonable, given that the coupling enzymes are in 
large excess. 
t This method was chosen for experimental convenience. No significant differences 
were observed in the results when pre-incubating the inhibitors with alpha-amylase, 
relative to pre-incubating the inhibitors with the substrate (see chapter 7). 
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Table 4.3: The percentage inhibition oLq/pha-amvlases bv 5 mM of inhibitor 
Derivative Alpha-amvlases 
Malt funaal bacterial pancreas saliva HQ 95% - -H~°"P"o -
F\ 
Ho OH 
l-ASCORBIC ACBJ 
"'" 
90% 94% 98% 99% 88% ~-r~ o 0 
HO OH 
3.1 
w.+j.y 29% 17% 8% - 0% o oro 
H 
MeO OH 
3.2 
... 9% 
-
. 
- · MB-ro o~ 
M;Q oecem 
3.3 
H05-~r 
Me{) OH 
9% 
· 
. 
- · 
3.4 
"" 2% -~+~ - - -o 0 
~ 0Me 
3.5 HO 4% HoJ-.J>k · - · · 
.... 0 0 .... 
3.6 HO 3% MeOCO~O - - · · 
WoO """ 3.7 
~CO MeOCO~O 
MeO 0,," 
7% 
· 
- . 
· · 
3.8 
"""'0 89% 91% 92% 99% MeOCO~ -
HO OK 
3.9 
acco~ 10% - - - -
3.10 
~oco~~ 0% -
3.11 
,~ 90% 70% 84% 88% 69% 
3.12 
Ho5;;y;: 
4% - - - -
3.13 
H~ti:0 96% 98% 99% 100% 100% i 
O-lOClASCORBK; ACD 
'~f~o 90% 91% 93% 99% 98% 
3.14 
~t~~ 0% · - - -
3.15 
62 Inhibitory Activity of Ascorbic Acid and Derivatives 
HO 11% 
· · · 
. 
• H~ 
MoO OM< 
3.16 H0-'-H 53% · · · -
o " 
DBiYDROA5CORBIC ACIl) 
:SOH 92% · · · -
HO OH 
DHYDROllYFUMARIC ACD 
A summary of the results from these studies is presented in Figure 4.4. The 
most obvious result from this SAR study, as seen in Table 4.3, is that all the potent 
inhibitors of barley-malt-a/pha-amylase show similar activity against fungal, 
bacterial, pancreas, and saliva alpha-amylases. This result is not unexpected 
given the high structural and functional homology of alpha-amylases (Section 
2.2.2). 
The poor activity displayed by dehydroascorbic acid, relative to ascorbic 
acid, suggests that this form of ascorbate is unlikely to be largely involved in 
a/pha~amylase inhibition. However, the ring-open analogue of ascorbic acid -
dihydroxyfumaric acid - shows significant inhibitory activity, suggesting that the 
ring structure of ascorbic acid is not important. 
Further inspection of Table 4.3 reveals more interesting trends: All of the 
most potent inhibitors, 3. L 3.11, 3.12, and 3.14 possess unprotected hydroxyl 
groups at the C2 and C3 positions of ascorbic acid (Figure 3.1). Protection of the 
C5 and C6 hydroxyl moieties by acetal and acyl groups in these derivatives 
appears to be well tolerated, including the presence of an extended carbon 
chain on C6 as found in derivative 3.12. 
The stereochemistry at C5 appears to be unimportant for inhibitory activity 
as displayed by the results for L-ascorbic acid, D-isoascorbic acid and their 
acetonide protected derivatives 3.1 and 3.14. This is in keeping with the original 
results of Palla et al. who reported powerful inhibition of wheat alpha-amylase by 
ascorbic acid and its D isomer.13 
In contrast, all derivatives with protecting groups on both the C2 and C3 
hydroxyl groups results in a marked decrease in activity. The same is true for 
deriva"l"ives 3.3 and 3.4 where only the C3 hydroxyl group is methylated. 
Reduction of the double bond between C2 and C3 also results in a marked 
reduction in inhibitory activity. 
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These combined results strongly suggest that the ene-diol moiety in 
ascorbic acid is essential for the inhibition of alpha-amylase (Figure 4.4). 
Dehydroascorbic acid has 
poor inhibitory activity 
Modification of 
the diol chain is 
well tolerated 
CS stereochemistry 
unimportant for 
inhibitory action 
DIOLCHAIN / 
~H~ 4 0 o 
The ring-open ascorbic acid 
analogue shows good 
inhibitory activity 
HO 5 
6 
Modification of the C3 
hydroxyl group and both 
the C2 and C3 hydroxyl - HO 
groups significantly 
reduces inhibitory activiy ENE·DIOl 
-- Reduction of the double 
bond reduces inhibitory 
activity 
The ene-dial functionality is 
essent ial for t he inhibit ory 
activity of ascorbic acid 
against alpha amylase 
Figure 4.4: The core ene-diol pharmacophore of ascorbic acid. 
Two possible reasons for the enhanced activity of the ene-diol-containing 
inhibitors, revealed by this study, are steric and electronic interactions, between 
the inhibitor and alpha-amylase. 
The two main structural features of ascorbic acid are the lactone ring and 
the diol chain that extends out of the plane of the ring from the C4 position. In 
ascorbic acid, 02 and 03 lie in the plane of 'the lactone ring; however, upon 
reduction of the C2-C3 double bond, the hybridisation at these centres becomes 
Sp3 and the hydroxyl groups subsequently protrude out of the plane of the ring. 
This is clearly seen in the crystal structure of the reduced ascorbic acid derivative 
3.13 (Figure 3.7). Given that inhibitory action is significantly reduced after 
reduction of "rhe double bond, maintenance of planarity across the ene-diol 
system may be important for the binding interactions of ascorbic acid with a/pha-
amylase. 
A modification of ascorbic acid's shape may also explain the reduced 
activity of the derivatives containing methoxy groups at C2 and C3. The 
increased size of the introduced methyl groups, relative to the original hydrogen 
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atoms, may provide enough steric interference to prevent successful binding 
interactions. 
Alternatively, the presence of the methoxy group may interfere with 
important electronic properties of the molecule. The C3 hydroxyl group is the 
most acidic in ascorbic acid with pka = 4.2.14 Deprotonation to give the ascorbate 
anion results in a delocalisation of the charge over the n system to the Cl 
carbonyl group. The ability of ascorbic acid to form this resonance structure may 
be important for binding interactions to the enzyme since methylation at the C3 
hydroxyl group prevents this resonance structure from forming. 
The interference role of the methyl group - be it structural or electronic -
might be determined by analysis of the singly-protected C2 hydroxyl group. If the 
electronic properties of ascorbic acid are important for its inhibitory action, 
protection at C2 should have no deleterious effect on inhibitory activity. However, 
if the methyl group interferes sterically,. pr by hindering hydrogen bonding, the C2-
protected derivative may result in a similar loss of activity. 
4.2. 1 STABILITY OF OTECTING GROUPS 
Given the similarity of inhibition activity between ascorbic acid and the 
potent derivatives protected only at C5 and C6 (3.1, 3.11, 3.12 and 3.14), it was 
postulated that the protecting functionality might be hydrolysed under the 
conditions of the assay, and results for these compounds in fact represented 
inhibition by underivatised ascorbic acid. To investigate this possibility, NMR 
spectra were collected for the acyl and acetyl protected derivatives 3.1 and 3.12 
both before and after subjecting them to similar temperature conditions, and for 
the same time, as occurs in the assay. Neither sample displayed resonances 
corresponding to ascorbic acid. Based on these observations we have assumed 
that under the reaction conditions of the assay no solvent mediated hydrolysis 
occurred. 
4.2.2 INHIBITOR NCY 
On average, the derivatives 3.1, 3.11, 3.12, 3.14, both epimers of ascorbic 
acid, and DHFA showed greater than 90% inhibition of alpha-amylase activity at 5-
mM concentrations of inhibitor. We were interested in determining the potency of 
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The results clearly show that the production of p-nitrophenol is linear over 
the time frame of the assay; therefore, the absorbances recorded ten minutes 
after the initiation of the reaction are proportional to the initial rate of reaction. 
This result is consistent with data reported by McCleary et 01.11 
Figure 4.6: Graphs showing the linearity of the Megazyme assay over a 10 minute period. 
Similar experiments were carried out with inhibitors in the assay to ensure 
that it remained linear over a lO-minute period in their presence. Figure 4.7 shows 
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the results for the inhibitors ascorbic acid and compound 3.1. As with the 
uninhibited case, the results of "the assay vary linearly over a 10-minute period. 
0.25 
0.2 
Absorbance 
at 410 nm 
0.15 
0.1 
0.05 
Ascorbic acid 
Product 3.1 
O~--~--~------~------~--------L-----~ 
o 2 4 6 8 10 
Time (minutes) 
Figure 4.7: Linearity of the Megazyme assay in the presence of inhibitors. 
4.3.1.2 THE MICHAELIS-MENT EN MODEL 
The most widely-used model for assessing the kinetic parameters of an 
enzyme system is the Michaelis-Menten (M-M) model. This model is based on the 
following reaction scheme and has been shown to be useful for the analysis of a 
wide range of enzyme systems. 16.17 
E + S " ES E + P 
(4.1 ) 
The enzyme (E) and substrate (S) reversibly form an enzyme-substrate 
complex (ES) which reacts to give product (P) whilst regenerating E. The rate 
equation derived from the M-M model (derived in appendix A) is given by. 
\)= 
Vmox[S] 
Km+ [S] 
Vmox =kcotET (4.2) 
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where Eris the total concentration of enzyme in the system (ET = [E] + [ES]), kcat b, 
k·l + k2 
and Km = kl . 
The important kinetic parameters of the reaction, Km and Vmax may be 
determined from the measurable quantities: 0, [S]and D. 
A plot of the rate vs substrate concentration for a reaction obeying the M-
M mechanism is a rectangular hyperbola (Figure 4.8). At high substrate 
concentrations the rate approaches the limiting value of Vmax; however, the 
limiting rate is never reached experimentally and the value of Vmax can only be 
estimated. Inspection of the M-M rate equation 4.2, reveals that the Km 
parameter is equal to the substrate concentration when the rate is equal to half 
Vmax. Thus a direct plot of rate vs [S] also provides only an estimate of Km. 
Vmaxf····· ...... ········································· ..................................................................................... . 
Rate 
[S1 
Figure 4.8: Graph of rate vs substrate concentration for a reaction obeying the M-M model. 
More accurate kinetic parameters are obtained by transforming the data 
and plotting it in a linear fashion. Two commonly used transformations result in the 
Lineweaver-Burk plot and the direct linear plot (Appendix B). 
4.3.1.3 METHOD AND RESULT S 
The experimental protocol for determining Km and Vmax for alpha-amylase 
involved measuring the initial rate of reaction at various substrate concentrations, 
as detailed in Chapter 7. The enzyme was barley-malt alpha-amylase. 
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Figure 4.9: (A) Uneweaver-Burk (double-reciprocal) plot generated by ENZFITIER. (8) Direct linear plot 
constructed using Microsoft EXCEL. 
A kinetics computer programme (ENZFITIER) measured the fit of the raw 
kinetic data to the M-M equation, and extracted values for Km and V max along 
with the associated, statistically determined, standard errors (SE). It also 
generated a linear Lineweaver-Burk plot with a weighted line-of-best-fit (Figure 4.9 
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AJ: which provides a visual presentation of the goodness-of-fit between 'the 
experimental data and the model. 
For comparison, the kinetic parameters were also determined using a direct 
linear plot of the raw data (Figure 4.9 BJ. 
The results of these two methods (Table 4.5) gave comparable results: Km = 
1.2 X 10-3 - 1.6 X 10-3 M; Vmax = 1.11 X 10-7 - 1.23 X 10-7. These compare with results 
reported by MacGregor et a/. 18 who have reported Km values of 0.35 x 10-3 M and 
0.8 xlO-3 M for the action of type 1 and type 2 barley-alpha-amylase isozymes on 
BPNPG7. 
Table 4.5: Kinetic parameters of barley-malt alpha-amylase. 
Method Km(mM) S.E (mM) Vmax{Ms-1) S.E (Ms·1) 
Direct linear plot 1.20 1.11 xlO-7 
Double reciprocal 1.62 0.04 1.23 X 10-7 1.31 x 10-9 
plot 
.2 KINETICS OF INH I SITED ALPHA .. AMYLASE 
Having established Km and Vmax for the barley-malt-a/pha-amylase system, 
we set about investigating the mode of inhibition of ascorbic acid and product 
3.1. 
4.3.2.1 MODES OF INHIBITION 
Inhibitors are generally described as irreversible or reversible.1,l5-17 
Irreversible inhibitors effectively destroy the catalytic ability of the enzyme thus 
preventing the catalysed reaction from occurring at any appreciable rate. 
Reversible inhibitors often regulate enzyme activity. They bind to the enzyme 
through hydrogen bonding, hydrophobic interactions, or other weak attractive 
forces, and their activity can be weakened by dilution of the inhibitor, by 
increased substrate concentration, or by dialysis.15,16 
Inhibitors can be further ciassified into four main categories: competitive, 
uncompetitive, non-competitive and mixed inhibitors (Figure 4.10). 
* The best-fiHine for the Lineweaver-Burk plot is weighted so as to lower the 
importance of the larger l/S and l/u values, which are inherently less accurate than the 
smaller values (see appendix A). 
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Competitive 
.. 
E + S ES 
+ + 
EI + S ESI 
k-1 
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Noncompetitve ~~-------- ~-------~ y 
Mixed Inhibition 
E + P 
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Oil( 
Figure 4.10: Simple schematic mechanistic moc;:lel of the modes of inhibition. Competitive inhibitors 
bind to the free enzyme while uncompetitve inhibitors bind to the enzyme-substrate complex. Non-
competitive inhibitors bind to the enzyme is such as way as to not affect the binding of the substrate, 
and mixed inhibitors exhibit a combination of these characteristics. 
(i) Competitive Inhibitors 
Competitive inhibition occurs when the substrate and inhibitor bind the 
same form of the enzyme such that when one is bound the other cannot. The 
successful formation of an enzyme-substrate (ES) complex results in conversion of 
substrate to product, but the formation of an enzyme-inhibitor (EI) complex leads 
to a dead-end readion. 
(ii) Uncompetitive Inhibitors 
Uncompetitive inhibitors have no effect on the rate of ES complex 
formation; however, they do affect the rate of product formation once the ES 
complex is formed. This can be thought of in terms of 'the inhibitor binding the ES 
complex to form an Inhibitor-enzyme-substrate (ESI) complex, without binding the 
free enzyme. The probability of an inhibitor exhibiting such selective binding is 
very small. 16 
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(iii) Non~competitive Inhibitors 
Non-competitive inhibitors bind to both E and ES in a site other than the 
active site. This binding does not affect the rate of ES {or ESI)complex formation, 
however, it does slow the efficiency of product formation. 
(Iv) Mixed Inhibitors 
An inhibitor that displays a mixture of inhibition characteristics is termed a 
mixed inhibitor. These inhibitors affect both the rate of product formation and the 
apparent affinity of the enzyme for substrate. The simplest example of such an 
inhibitor is one that binds both the free enzyme and the enzyme-substrate 
complex, and interferes with the formation of both the ES complex and the 
product. 
4.3.2.2 GRAPHICAL DETERMIN A TION OF THE MODE OF INHIBITION 
In the case where an inhibitor reacts with E or ES in a simple one-to-one 
fashion as in Figure 4.10, the rate-laws for each of the four modes of inhibition 
discussed above are linear with respect to the concentration of inhibitor (see 
Appendix A for a derivation of these rate-laws). In these cases, the reaction still 
obeys the M-M model; that is, a plot of rate vs substrate concentration is a 
rectangular hyperbola from which an apparent Km and Vmox can be determined. 
If a series of experiments is performed in which the concentration of 
inhibitor is varied, then values for Km, Vmox and KI (or KI') in the presence of inhibitor, 
(as in Figure 4.10), can be determined. As with the uninhibited case, to accurately 
assess these kinetic parameters, it is most useful to transform the data and plot it in 
a linear form. Useful transformations include the Lineweaver-Burk, Dixon and 
modified Dixon plots,16.19 examples of which are shown, for each of the four types 
of inhibitors in Appendix B. 
In combination, these graphs are useful diagnostic tools for determining the 
mode of inhibition. The Dixon and modified Dixon plots provide an estimate of the 
EI dissociation constant KI and KI' respectively; an absolute measure of the degree 
of inhibition. 
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4.3.2.3 METHOD AND RESULT S 
The kinetic parameters KI/KI', Km and Vmax in the presence of inhibitor were 
determined by measuring the initial reaction rate at varying substrate and inhibitor 
concentrations while keeping the enzyme concentration constant (see Chapter 
7). 
The mode of inhibition was determined using ENZFITTER. The raw data (that 
is, rate vs substrate concentration for a sequence of inhibitor concentrations) was 
fitted to the M-M equation and analysed for goodness of fit for the four modes of 
inhibition. The results for ascorbic acid using this analysis are shown in Table 4.6 
and Table 4.7. 
The kinetic parameters calculated by ENZFITrER are shown for each inhibitor 
concentration in Table 4.6; Km and V max are calculated along with an associated 
standard error (SE) for each, and a measure of the overall goodness-of-fit is given 
by the statistical parameter r2. This parameter gives a measure of the strength of 
correlation between the experimental and predicted data; a value of 1 indicates 
perfect correlation, and 0, a complete absence of correlation. Assuming that the 
data does obey the M-M model, then a 95% confidence interval for the 
calculated parameters is given by ±2SE. 
While at low ascorbic-acid concentrations our data fits the M-M model well 
(Table 4.6), as the concentration of inhibitor increases the fit is poor, as indicated 
by the large errors associated with V max and Km. 
The values of KI, Km and V max calculated by ENZFITrER assuming competitive, 
non-competitive, and uncompetitive modes of inhibition are shown in Table 4.7. 
The absence of values for the mixed mode of inhibition is due to an extremely 
poor fit of the data to this model. Based on these values, the mode of inhibition of 
alpha-amylase by ascorbic acid is most characteristic of a competitive inhibitor, 
with a calculated KI value of 4.34 x 10-5 M. However, care must be taken 
interpreting these results as the calculations are based on the goodness of fit to 
the M-M model, which is shown in Table 4.6 to be not strongly held for the more 
concentrated solutions of inhibitor. 
For comparison wi'rh the ENZFITrER data a Dixon plot was also constructed. 
This was consistent with that expected for a competitive inhibitor and gave a KI 
value of 4.55 x 10-6 M. 
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The Lineweaver-Burk plot generated by ENZFIHER, and the Dixon plot 
constructed using Microsoft EXCEL, is shown in Figure 4.11 . 
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Figure 4.11: (A) Lineweaver-Burk double reciprocal plot, IB) Dixon plot of inhibition by ascorbic acid. 
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b To Ie 4.6: Goodness 0 f f h f . . .. b' It to t e M-M equation or Inhibition byascor IC aCid. 
[INHIBITOR] Km(M) SE (mM) Vmax (Ms-I) SE (Ms-I) r2 
0 1.62 x 10-3 4.36 X 10-4 1.23 X 10-7 1.36 xl 0-8 0.944 
2.56 x 10-5 1.07 X 10-2 3.15 X 10-3 2.67 X 10-8 2.65 X 10-7 0.993 
5.11 x 10-5 3.20 X 10-2 1.52 X 10-1 8.27 X 10-7 3.57 X 10-6 0.823 
7.26 x 10-5 9.72 X 103 1.97x 107 1.13 x 101 2.27 x 102 0.904 
10.0 x 10-5 8.37 X 107 2.93 X 1013 9.00 X 102 3.14x lOS 0.825 
T bl 4 7 A I . f th a e nalysls 0 d f' h'b'f b' 'd e mo e 0 In I I Ion or ascor IC aCI . 
MODE Km (M) SE (mM) Vmax (Ms-I) SE (Ms-I) KI/KI' (M) SE (M) r2 
C 3.62xlO-3 2.47x10-3 1.84x10-7 7.20x10-s 4.34xlO-s 1.70x10-s 0.78 
non-C 8.38xlO-3 6.87x10-3 3.14xlO-7 1.91 x 10-7 8.32xlO-6 2.33xlO-s 0.76 
unC 2.31 X 10-2 5.09x10-2 6.80x10-7 1.33xlO-6 1.01 x 10-5 2.31 x 10-5 0.69 
The mode of inhibition for product 3.1 was also studied in this way. The 
results obtained using ENZFlnER are shown in Table 4.8 and Table 4.9 
T bl 48 G d f ft t th M M f f . h'b'f b d 31 a e . . 00 ness 0 I 0 e - equa Ion or In I I Ion )y compoun .. 
rtNHIBITORl Km (M) SE (M) Vmax (Ms-I) SE (Ms-I) r2 
0 1.53 x 10-3 7.0 X 10-4 1.08 X 10-7 1.80 X 10-8 0.819 
1.64 x ]-5 2.84 X 10-3 1.66 X 10-3 1.13 X 10-7 3.25 X 10-8 0.829 
3.27 x 10-5 9.0 X 106 . 3.03 X 10.11 1.7-0 X 102 5.69 X 106 0.942 
4.91 x 10-5 2.11 X 104 1.34 X 107 3.10 X 104 1.96 X 102 0.69 
6.54 x 10-5 1.43 X 102 3.49 X 104 2.30 X 10-4 5.43 xl 0-2 0.27 
I . f th Table 4.9: AnalysIs 0 emo eo In I I Ion 0 compoun d f' h'b'f d 3.1. 
MODE Km SE Vmax SE KI/KI' SE r2 
C 2.08x10-3 2.04x10-3 6.56xlO-3 2.74xlO-3 1.78x10-s 1.13xlO-s 0.66 
non-C 3.71 X 10-3 3.12x10-3 8.66x10-3 4. lOx 10-3 4.41x10-s 1.28x10-s 0.65 
unC 4.92xlO-3 5.54x10-3 1.01x10-2 7.14xlO-3 1.71x10-s 1.31 xl 0-5 0.62 
mixed 2.63x103 1.57x102 3.29 x 103 1.97x102 KI: 4.31 xl 0-5 KI: 8.16x1 0-6 0.60 
KI': 6.96xlO-s KI': 1.64xlO-s 
Like ascorbic acid, compound 3.1, also shows a good fit to the M-M 
equation at low inhibitor concentrations, but deviates strongly at higher 
concentrations. The mode of inhibition exhibited by compound 3.1 is most 
characteristic of the mixed model with KI = 4.31 X 10-5 M and KI' = 6.9 X 10-8 M; 
however, for this compound the fit to the M-M model is not as good as for 
ascorbic acid, and little significance can be attached to this result. 
4.4 CONCLUSIONS 
The work presented in this chapter has described the inhibitory activity of 
ascorbic-acid derivatives prepared, as detailed in chapter 3. Assays of all 
compounds prepared were performed using the Megazyme alpha-amylase kit. 
The SAR studies for ascorbic acid and its derivatives have revealed the 
necessity for the ene-diol moiety for potent activity. The inhibitory activity of the 
Inhibitory Activity of Ascorbic Acid and Derivatives 77 
ring-open ene-dial analogue, DHFA, and the reduced activity of dehydroascorbic 
acid and the saturated 3.13 derivative, provide strong support for this hypo"rhesis. 
In addition, inhibitory activity was relatively unaffected by modification of the dial 
chain, including epimerisation at C5. 
The ICso values calculated for ascorbic acid, 3.12, and 3.14 show high 
degrees of potency; for ascorbic acid the value is 2.85 x 10-5 M. 
Kinetic analysis has revealed that the inhibited reaction does not obey the 
M-M model at high inhibitor concentrations. Never-the-Iess the mode of inhibition 
of ascorbic acid is most characteristic of a competitive model with KI = 4.3 xl 0-5 M. 
In comparison, acarbose has a reported KI of lOx 10-6 M.20 These results suggest 
that ascorbic acid may bind non-specifically in the adive site of alpha-amylase 
interrupting productive binding of the substrate. 
Product 3.1 obeyed the M-M model even more poorly than ascorbic acid 
at high concen"rra"l"ions, so little can be taken from the result that its mode of 
inhibition was most characteristic of a mixed-inhibitor model 
4.5 FUTURE WORK 
The potency of substrate-analogue inhibitors for alpha-amylase, such as 
acarbose (section 2.3.3.1), suggests that attachment of glucose residues onto the 
ascorbic-acid strudure may lead to an inhibitor with increased potency relative to 
the unmodified compound. The glucose molecules may provide more sites for 
binding interactions between the enzyme and the inhibitor. 
Our SAR results suggest that the attachment of the glucose residues onto 
the diol chain of ascorbic acid would be most beneficial, as modification of this 
part of the ascorbic-acid molecule does not interfere with the ene-dial 
functionality which is essential for ascorbic acid's activity. Given that alpha-
amylase functions by hydrolysing a-l A-glucosidic linkages, it is proposed that 
attachment of the glucose residues to ascorbic acid through an ether linkage at 
either the C4 or the C 1 positions of the glucose ring would most resemble the 
natural substrate of a/pha-amylase (Figure 4.12). The catalytic subsite of most 
a/pha-amylase species is located in the centre of the active site surrounded by 
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other residue binding subsites. Therefore either of the postulated compounds 
shown in Figure 4.12 should display increased binding to the active site. 
(A) ~OH OH HO l~ HO 
HO OH 0 1 -:: 0 0 
HO OH O~ 
HO OH 
(8) 
OH 
OH LC" OH O~07"'\'s~o/ ~ ...Le·· 
n 6 HO OH O/~ 
HO OH HO OH OH 
Figure 4.12: Potential potent ascorbic"acid-bas'ed inhibitors of alpha-amylases. (A) Linkage through 
the C1 anomeric carbon of the glucose residue. (B) Linkage through the C4 carbon of the Glucose 
residue. 
4.6 REFERENCES 
[1) Cornish-Bowden, A Fundamental Enzyme Kinetics. Revised Edition: Portland 
Press: Portland, 1995. 
[2) Schomburg, D.; Salzmann, M., Eds. Enzyme Handbook; Springer-Verlag: 
Berlin, 1990. 
[3) Boyer, P. D., Ed. The Enzymes, 3rd ed.: Academic Press: New York, 1971; Vol. 
5. 
[4) Searcy, R. L.; Wilding, P.; Berk, J. E. C1in. Chim. Acta 1967,15,189-197. 
[5) Somogyi, M. C1in. Chem. 1960,6,23-35. 
[6) Close, J. R.; Street, H. V. C1in. Chim. Acta 1958,3,476-479. 
[7) Approved Methods of the American Association of Cereal Chemists; 
American Association of Cereal Chemists: St Paul, 1976. 
[8) Babson, A L.; Tenney, S. A; Megraw, R. E. Clinical Chemistry 1970, 16, 39-43. 
[9) Ceska, M.; Bira'~h, K.; Brown, B. C1in. Chim. Acta 1969,26,437-444. 
Inhibitory Activity of Ascorbic Acid and Derivatives 79 
(10) Pierre, K. J.: Ker-Kong, T.: Rauscher, . Wahlefeld, A. W.; Foo, Y.: Rosalki, S. B. 
In Methods of Enzymatic Analysis, 3rd ed.; Bergmeyer, H. U.: Bergmeyer, J.: 
Grapl, M., Eds.; Verlag Chemie: Weinheim, 1984; Vol. IV, pp. 145-177. 
(11) McCleary, B. V.: Sheehan, H. Journal of Cereal Science 1987,6,237-251. 
(12) Blair, H. E. USA Patent 4649108 
(13) Palla,J.C.;Verrier,J.Ann. Technol. agric.1974,23, 151-159. 
(14) Davies, M. B.: Austin, J.; Partridge, D. A. Vitamin C. Its Chemistry and 
Biochemistry: The Royal Society of Chemistry: Letchworth, 1995. 
(15) Voet, D.; VoeL J. G. Biochemistry; John Wiley and Sons: New York, 1990. 
(16) Cornish-Bowden, A: Wharton, C. W. Enzyme Kinetics; IRL Press: Oxford, 1988. 
(17) Keleti, T. Basic Enzyme Kinetics: Akademiai Kiad6: Budapest, 1986. 
(18) MacGregor, A W.: Morgan, J. E.: MacGregor, E. A. Carbohydrate Research 
1992,227,301-313. 
(19) Henderson, P. J. F. In Enzyme Assays A Practical Approach: Eisenthal, R.; 
Danson, M. J., Eds.; IRL Press at OUP: Oxford, 1992; N. 
(20) Mosi, R.; Sham, H.; Uitdehaag, J. C. M.; Ruiterkamp, R.; Dijkstra, B. W.: 
Withers, S. G. Biochemistry 1998, 37, 1 7192-1 7198. 

S ROI Sa- DUCTASE 
S.1 THE FUNCTION OF STEROID Sa-REDUCTASE 
Steroid 5a-reductase (SR) is a membrane-bound enzyme that is found 
predominantly in the skin, liver, and prostate tissues. 1-3 Its function is to catalyse 
the reduction of testosterone (TJ to the androgen dihydrotestosterone (DHT) using 
nicotinamide adenine dinucleotide phosphate (NADPH). Both T and DHT bind a 
common receptor protein, but DHT has an increased affinity for the receptor and 
thus is a more potent hormone. 
. SR 
.. 
o 
Testosterone rTl Dihydrotestosterone (DHTJ 
Figure 5.1 : Testosterone (T) and Dihydrotestosterone (DHTJ. 
The biological functions of DHT and T have been extensively investigated.1,3 
During embryonic development in male foetuses, T has been shown to be 
responsible for the differentiation of the wolfian ducts into seminal vesicles and 
epididymis, while DHT is required for the masculinisation of the external genitals. At 
the onset of puberty, T induces the maturation of the male external genitalia while 
DHT is necessary for full male body-hair growth patterns and subsequent male 
pattern baldness. 
The various roles of T and DHT have been determined to some extent via 
the study of individuals who are SR deficient and who are thus unable to produce 
DHT. Whilst having male internal genitals, these people display ambiguous 
external female genitalia when born and are usually raised as girls. At puberty 
they undergo masculinisation including enlargement of the penis, descent of the 
testes increased muscle mass and deepening of the voice. However their 
prostates remain undeveloped and their body hair patterns stay predominantly 
female. Interestingly, these patients are also seldom reported to exhibit male 
pattern baldness or acne. 
82 Steroid Sa-Reductase 
The isolation and characterisation of a cDNA, encoding human prostatic SR 
type 1, has revealed the presence of this gene in people suffering SR deficiency.3 
This information, coupled with the knowledge that SR expressed by this gene was 
poorly inhibited by finasteride, (a known potent inhibitor of human prostatic SR), 
lead to the conclusion that more than one isozyme of SR existed. This was 
confirmed by the subsequent isolation of a second isozyme (type 2), which is 
inhibited by finasteride. 
For the SR type-l and type-2 isozymes, the homology is approximately 50%. 
They differ in respect to their biochemical and pharmacological properties and 
also the region of the body in which they are predominantly expressed.1,3 Type 1 is 
mostly associated with non-genital skin while the type-2 isozyme is generally 
located in the prostate and genital fibroblasts. Populations deficient in SR have 
been shown to be lacking an active type-2 isozyme, which has lead to the 
proposal that type-2 SR is responsible f9r prostate development and the growth of 
male body-hair patterns. The full role of type-l SR is unclear, but it is thought to be 
associated with skin condition due to its prominent location in this organ. 
Due to the importance of DHT for proper masculine development, the 
conversion of T into DHT is an essential process. However, elevated levels of DHT 
have been associated with various pharmacological disorders of the prostate and 
skin.l,2 Benign prostatic hyperplasia (BPH) is a common non-cancerous 
enlargement of the prostate that leads to various urological disorders in ageing 
men. Treatment usually includes various pharmacological interventions and/or 
surgery involving a transurethral resection of the prostate.2 Another more serious 
complaint is the development of prostatic cancers. The link between androgens 
such as DHT and prostatic carcinomas is well documented1 and treatment usually 
involves tumour ablation by chemotherapy or castration. Less serious disorders 
such as acne, male pattern baldness and female hirsutism are also thought to be 
promoted by elevated levels of DHT. 
Due to the suspected role of DHT in these conditions, it has been proposed 
that inhibition of SR would result in decreased levels of DHT and aid in the 
treatment of these ailments. It has also been suggested that selective inhibition of 
the different isozymes of SR may lead to greater accuracy in treating disorders 
thought to be specific to each type. 
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As SR has yet to be isolated and characterised, numerous SAR studies have 
been undertaken to identify key structural features of SR inhibitors responsible for 
potency and isozyme selectivity. SAR studies provide not only possible new drugs, 
but also information about the enzyme itself. which ultimately leads to better 
inhibitor design. The following is a brief review of the current findings of these 
investigations. Where possible activities are reported for human SR enzymes rather 
than for animal models. Many studies have shown differences in inhibition 
activities across species, which may be due to low enzyme homology.l This 
strongly suggests that care must be taken when choosing in vivo models for 
ascertaining activity. 
INHIBITORS STEROID Sa-REDUCTASE 
The SR-catalysed reduction of T to DHT has been postulated to occur via an 
enolate transition-state as shown in Fjgure 5.2. The reaction is thought to proceed 
by the stereospecific transfer of the C-4 pro-S hydride from (NADPH) to the Sa 
position of T.1,2 
(\-
NADPH NADP 
Testosterone (T) Enolate Intermediate Oihydrotestosterone (OHTJ 
Figure 5.2: Enolate intermediate proposed for the reduction of T to OHT. 
The oxyanion of the enolate intermediate is thought to be stabilised by "rhe 
coordination of T near an electrophilic residue in the active site of SR. The enolate 
intermediate is protonated non-enzymatically to give DHT via an essentially 
irreversible process. The kinetic mechanism is believed to occur as shown in Figure 
5.3.4 The substrate is bound to "rhe pre-formed enzyme-NADPH complex to give a 
ternary complex. Following the catalysed reaction, DHT is released from the 
binary enzyme-NADP+ complex, which subsequently dissociates to give the free 
enzyme. Competitive inhibitors are thought to bind the enzyme-NADPH binary 
structure, while uncompetitive inhibitors interact with the enzyme-NADP+ complex. 
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NADPH T DHT NADP+ 
ENZ ! ENZ-NADPH ! ENZ-NADPH-T~ENZ-NADP+-DHT~ ENZ-NADP+~ ENZ 
lllNH lr INH 
ENZ-NADPH-I ENZ-NAD P+-I 
Competitive Inhibition Uncompetitive Inhibition 
Figure 5.3: Proposed kinetic mechanism of SR. 
5.2. 1 STEROID-BASED INHIBITORS 
In many instances, potent enzyme inhibitors are structurally similar to the 
natural substrate of an enzyme.s This is assumed to be due to similar binding 
affinities of the enzyme for both compounds. The initial designs of steroid Sa-
reductase (SR) inhibitors included a structural element similar to that of the natural 
substrate (Figure 5.4) and a mimic of the putative enolate intermediate utilising 
vartous functionalities. 
fl side 
6 
..... 
aside 
Figure 5.4: Basic steroid structure and numbering system. 
5.2.1 . 1 4~AzASTEROIDS 
The first steroidal SR inhibitors developed, by Merck, were the 4-azasteroid 
class compounds; the basic structural skeleton resembling the natural substrate, 
and the enolate mimic provided by the amide functionality in the A-ring. 
Extensive SAR studies have revealed many factors that contribute to the potency 
of these inhibitors and their isozyme selectivity. 1,2 This work resulted in the 
development of the potent type-2 inhibitor finasteride {Type 1: ICso::: 500 nM; type 
Steroid Sa-Reductase 85 
2: IC50 = 4.2 nM), which is currently marketed world-wide as a treatment for BPH, 
and more recently, male pattern baldness (Figure 5.5). 
o 
5.1 
Figure 5.5: Finasteride. 
Modification of the A-ring generally results in a decrease in inhibitory 
activity {Figure 5.6}. Unsaturation at A1,2 and N·6 reduces potency, as does 
substitution at the 4 position. Interestingly, it has been shown that A1.2 unsaturation 
is necessary for in vivo inhibition by finasteride. The effect of substituents on the A-
ring of the 4-aza class of inhibitor has also been studied. It was proposed that the 
in'rroduction of a halogen would lower the pKa of the enolate mimic and enhance 
potency. However, the addition of halogen, methoxy, hydroxy or alkyl groups 
have no affect on activity. 
The optimum ring size in this steroidal inhibitor has also been invesj'igated. 
Increasing the A-ring to a 7-membered system reduces potency, however, 
changes in the size of the Band D-rings shows little influence on activity. 
p-steroechemistrypreferred 
A1.2 toleratedif R I =H 
" 7-memberedringtolerated _ 2 1 
~ __ p-steroechemistrypreferred 
""-- methyl group tolerated 
5-memberedringless potent 0 N I 7 -7~-substitutiontolerated 
/ R1 H ~ a-stereochemistry preferred 
HON=. MeN=. S=. H 2 not w ell tolerated , 
H orsmall hydrophobic group preferred 
R, =CH 3 increasesandrogenreceptoraffinlly 
Figure 5.6: Summary of the results from SAR studies on the 4-azasteroid inhibitors of SR. 
The type of substituent at the ~-C17 position is most important for potency 
and selectivity, with amides based on small lipophilic amines preferred. The 
introduction of simple esters or ketones at C 17 gives reasonably potent type-2 
inhibitors; however, increasing the lipophilic nature of these groups also increases 
the potency of 4-aza inhibitors toward the type-1 isozyme (Table 5.1). 
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Table 5.1: The effect of different f3-C 17 substituents on the inhibitory activity of the 4-azasteroid 
compounds. 
4 
o N 
I 
H 
ICso (nM) 
No. Rl R2 Human SR 1 Human SR 2 
5.2 Ph H 20 < 0.1 
5.3 Ph CH3 350 0.2 
5.4 Ph Ph >1000 25.2 
5.5 1-indolinyl 120.2 0.4 
5.6 2-CF3C6H4 H 5.6 <0.1 
5.7 3-C6HsC6H4 H 14.0 <0.1 
5.B 1-napthyl H 8.1 0.2 
5.9 2,5-CF3-C6H3 H 2.4 0.5 
SAR studies also led to the development of the potent dual inhibitor 4-MA 
which contains a fully saturated A-ring relative to finasteride. Activity in this 
compound is increased by N-alkylation, with a methyl group most preferred. 
However, commercial development of 4-MA has not been undertaken due its 
toxicity.2 
To bl f ·t 1ft f t'd e 5.2: Ac IVlly 0 4-MA re a Ive 0 Inas en e. 
ICso (nM) 
Compound structure Human SR 1 Human SR 2 
4-MA o#NEI' 1.7 1.9 
5.10 
o N 
Me 
Finasteride t:ifoNHI" 410 9.4 
5.1 
o N' H H 
Analogues of the 4-azasteroid inhibitors containing an enone-enolate 
mimic prepared by Mann et 01.6 generally exhibit reduced activity relative to the 
lactam containing compounds, with only the 4-cyano-enone compound 
displaying significant inhibitory activity. However, a recently reported 4-
triflouromethyl-subs·l"ituted enone has shown increased potency over finasteride 
(Table 5.3 (a) and (b)),7 
steroid Sa-Reductase 87 
Table 5.3(a): Summary of results from SAR studies of 4-substituted-3-oxo-4-androstene inhibitors of SR. 
R1 
o 
ICso (nM) 
No. R1 R2 Human SR 1 Human SR 2 
5.11 CONHtBu CN - 2.9 
5.12 CONHtBu SH 709 437 
5.13 CONHtBu CI > 1000 192 
• 
5.14 CONHtBu Br 981 387 
Table 5.3(b): Summary of results from SAR studies of 4-substituted-3-oxo-androstene inhibitors of S R. 
SR Kl values (nM) 
No. I Rl R2 [3H]-OHT NAOPH 
5.15 CONH1Bu CF3 20.9 20.2 
5.16 CH3CO CF3 » 1000 » 1000 . 
5.17 0,0 CF3 95.2 28.8 
5.18 finasteride 88.2 54.7 
5.2.1.2 6·AZASTEROIDS 
Table 5.4: Summary of results from SAR studies of 6-azasteroid inhibitors of Human SR. 
R 
o 
No. R SR 1 KI (nM) SR 2 ICso (nM) 
5.19 OMe 150 3.2 
5.20 0-2-ada mantyl 6.9 0.04 
5.21 NEh 750 1.5 
2 NH-l-adamantyl 11 0.07 
5.23 NH1Bu 820 0.88 
5.24 N[iPr)2 i 190 0.36 
5.25 NHCHPh2 30 0.09 
5.26 iBu 9 0.08 
5.1 finasteride 150 0.18 
The 6-azasteroid inhibitors are another example of amino-containing 
compounds developed to mimic the enolate intermediate.1•2•8-10 The 
ketoenamine moiety provides structural and electronic features similar to those of 
the enzyme reaction intermediate. Activity is dominated by the choice of p-C 17 
substituent and like the 4-azasteroid inhibitors, lipophilic groups are favoured 
(Table 5.4). These compounds display dual inhibition against SR and with 
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appropriate ~-C17 substitution display potent, selective inhibition of type-2 SR. N6 
substitution with small alkyl groups increases type-l potency, as does sUbstitution 
at C4 with small lipophilic groups. Large substituents in either of "these positions 
reduce the inhibition against both isozymes significantly. 
5.2.1.3 NOR- 1 O-AzASTEROIDS 
One of the most recent series of steroid-based SR inhibitor developed is the 
nor-10-azasteroids. 11 As with other steroidal SR inhibitors, activity against both 
isozymes is enhanced by '~he presence of a lipophilic ~-C17 subsmuent. The 
position of the double bond in the A-ring is critical to activity. Unsaturation at ~1.2 
relative to ~4,5 decreases potency, whilst complete saturation of the A-ring 
removes all inhibitory activity. Potency is also increased if unsaturation of the C-
ring is at the ~8,9 position. Selective type-l inhibition is achieved in the presence of 
a keto or hydroxy group at C17. 
Table 5.5: SAR of 19-nor-1O-azasteroids against human SR. 
-
No. R Unsaturation leso (nM)Q Selectivity 
SR 2: SR 1 
5.27 =0 fl 4,s 1265 1:15 
5.28 =0 fll,2 18843 -
5.29 =0 »100000 -
5.30 S-CONHtBu fl4,s , fl9(1l) 21.5 1:1 
5.31 S-CONHtBu fl4,s, fl8(9) 2.9 1:1 
a Inhibition against SR type-2 human prostate homogenate 
5.2.1.4 CARBOXYLATE STERO IDS 
A carboxylic-acid series of inhibitors, developed by Smi'~h-Kline Beecham, 
mimic the putative enolate intermediate by use of a charged carboxylate 
group.1.2,12 These inhibitors are postulated to preferentially bind the enzyme-NADP+ 
complex due to favourable electrostatic interactions between the negatively-
charged carboxylate and the positively-charged binary complex. They are 
potent inhibitors of type-2 SR. 
The first of these inhibitors developed were the steroidal acrylates, which 
contain a carboxylate at the C3 position and unsaturation at ~3.4. Development 
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then led to compounds incorporating dienes with unsaturation at ~3.4 and ~5,6 and 
aryl acids (Figure 5.7). 
CaN(iPr)2 CaN(iPr)2 
Haoc I 4 H Haac ~ Haac 
(A) (8) (el 
Figure 5.7: (A) .1.3.4 unsubstituted acids, (8) diene acids, and (C) aryl acids. 
The position of A-ring unsaturation in these inhibitors has no influence on 
potency; however, complete saturation of the A-ring significantly reduces activity. 
Incorporation of an electronegative subsHtuent onto the A-ring of the aryl acids 
was expected to decrease the electron density and lower the pKa of the 
carboxylate. The use of fluoro and cyano groups for this purpose was proposed to 
also provide a hydrogen-bonding site.12 However, introduction of this type of 
functionality results in no increased activity and substituents at C4 were actually 
fou nd to decrease potency. 
Extension of the carboxylate moiety by one carbon to increase 
conformational flexibility shows no adverse effects on the potency of inhibitors 
containing this group (Table 5.6). However, extension by two carbons or the 
presence of an exocyclic double bond reduces the potency significantly. 
The greatest influence on potency for these inhibitors is the choice of 
substituent at C17. Like the 4-azasteroid inhibitors, lipophilic groups such as 
carboxamides are favoured. 
Inhibitors have also been prepared with a negatively-charged species 
provided by phosphinic, phosphonic, and sulfonic substituents at the C3 position 
(Table 5.6). All show good potency against SR with the diene inhibitors showing 
slightly increased potency over the aryl compounds. Inhibitors containing 
phosphinic and sulfonic groups at C3 show no tolerance for chain extension. 
Recently a diene steroidal analogue was reported that contained a phenyl 
acetylene group at the C3 position.13 This compound was reported to have good 
activity against SR despite the fact that it possesses none of the basic structural 
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features considered necessary for inhibitory action (KI of rat SR = 45.8 nM versus 
finasteride = 54.7 nM). 
Table 5.6: SAR studies of the aryl acid inhibitors on Human prostate SR. 
R 
A 8 C 
B C 
R No. No. 
COOH 5.33 5.34 
5.36 5.37 
5.38 
CHCOOH 
5.41 500 > 10000 
5.43 25 50 
40 
5.46 7 13 
20-40 
> 5000 
5.2.1.5 SUMMARY 
In general, steroid-based inhibitors are shown to exhibit preferential 
potency against the type-2 isozyme of SR over the type-1 enzyme. The potency is 
mostly determined by the substituent at ~-C 17, with lipophilic amides favoured. 
The choice of functionality for the enolate mimic does not seem to have much 
influence on the inhibitor's activity. 
5.2.2 NON"STEROIDAL INHIBITORS 
As an alternative to steroid-based inhibitors many non-steroidal inhibitors 
have been developed. Initial efforts involved compound screening to reveal 
possible lead compounds and also the testing of tricyclic analogues of active 
steroid-based inhibitors. More recent trends to improve isozyme selectivity and to 
prepare dual inhibitors involve the connection of structural features known to be 
necessary for selective isozyme inhibition. 
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5.2.2.1 ONO 3805 
Compound screening has revealed many different classes of non-steroidal 
SR inhibitors including retanoic acid, linolenic acid, and gossypol, which, though 
structurally dissimilar to the steroidal substrate, exhibit good inhibitory activity 
against SR (Figure 5.8). 
HDDe ~ ~ ~ ~ 
Gossypol Retanoic acid 
Figure 5.8: Non-steroidal inhibitors of SR. 
Compound screening also led to the discovery of the non-steroidal SR 
inhibitor ONO 3805.],2 A good inhibit,or against the type-2 enzyme, ONO 3805 has 
also been a good lead compound for the development of novel potent dual 
inhibitors (Figure 5.9). 
Figure 5.9: ONO 3805. 
Initial SAR studies revealed that the amide linkage to the central phenyl 
spacer and the ether-linked butyric acid are necessary for activity. Replacement 
of the hydroxyaniline moiety to incorporate a structurally analogous acylindole 
group significantly improves the inhibitory action. 14 As can be seen from Table 5.7 
the S-enantiomer of the methyl benzyl group is essential for increased potency; 
thus, the conformations of these inhibitors are important for their activity, Reversal 
of the central ether linkage also gives comparable results. 
Given the increased activity of inhibitors containing an indole functionality, 
this moiety has been incorporated into several new inhibitors (Figure 5.10) capable 
of acting as dual inhibitors against SR and Ul-adrenoreceptor {another receptor 
implicated in the onset of BPH}.15-17 
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Table 5.7: Summary of results from SAR of ONO-3085-analogue inhibitors on human SR. 
No. structure QL ~ON03805 
5.50 '>-. N "" 
OH I~ ~ o I"" 
!eooH ~ 
o Me 
5.51 ~"O'"= ~ ~o~ I~ 
eOOH 
0 
5.52 0:J0~ ~ N "'" 0 "" ~ I ~ 
eOOH 
0 
5.53 ecro 7 ~N ""'o~ ~ I ~ 
eOOH 
0 
5.54 ec:JQ I ~ I I"", 0 
N ~~ ~ - ~ 
eOOH . 
Meo~ 
~ 0 rN~ I~ NjUO~N~ H I HOOC~O ~ O~ 
IC50 (nM) 
Human SR 1 Human SR 2 
- 256 
113 481 
40 4 
574 69 
8 10 
lVIeoy) 
o rNAV 
cduO~N~ I I I ~ N 0 O~ 
IC so 490 nM 
V ~ V HOOC IC so 11 nM 
Figure 5.10: Inhibitors developed incorporating an indole functionality exhibit improved potency. 
5.2.2.2 BENZOQUINOLINONES 
One of the most widely-studied classes of non-steroidal inhibitor is the 
benzoquinolinones. 1,2,18,19 These compounds are structurally analogous to the 4-
azasteroid class of inhibitor previously mentioned (Figure 5.11). Unlike the 4-
azasteroids however, benzoquinolinones show selectivity for the type-1 isozyme of 
SR only. 
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/,-yf:(CI 
f"Lr o N I I H 
Me 
5.55 
o 
5.1 
93 
Figure 5.11: Comparison of the structures of finasteride (5.l) and the potent benzoquinolinone 
inhibitor L Y 191704 (5.55). 
SAR studies [Figure 5.12) have shown certain requirements for potency in 
the benzoquinolinone type inhibitors.18 Activity is increased by inclusion of a C8 
substituent that has either electron withdrawing or electron donating ability; a 
chloride group gives the greatest potency. For molecules which posses a ClO 
angular methyl substituent a trans ring junction is preferred over a cis 
conformation for potency. The cis conformation results in a deviation from the 
planar system thought to be important for activity. For molecules that contain no 
angular substituent both cis and trans conformations provide similar potency.19 
The presence of an N-methyl group also increases potency; however, substituents 
larger than a methyl group decrease the activity of the inhibitor. This trend is also 
observed for the 4-azasteroid inhibitors. 
Favom H. although Me 
group alSO gives a potent 
When lOasubstltutedtrans inhibitor 
AlB ringjunction favoured I 
~~ri~d~~'~:~~~~t~~~y \ R3 I 
2 1 10n 
When R 3 = H, cis and trans 4 
Favours electronw ithdraw ing 
~ /' R2 -- and electrondonating groups 
8 
d 
Satuated AlB ringjunction fovoured 
over unsaturatedring junction junctions have similarpotency 0 ~ H 
R1 
Small alkyl grout increase potency 
Figure 5,12: Summary of results from SAR studies for the benzoquinolinone inhibitors of SR. 
Another observed trend in these studies, which is similar to the 4-azasteroid 
inhibitors, is the dependence of A-ring size on potency. A contraction of the A-
ring to a 5-membered structure shows no significant difference in potency relative 
to the parent benzoquinolinone, but expansion to a 7-membered A-ring, results in 
decreased activity against the type-1 isozyme.2° Thus, the order of potency for 
lactam A-rings is 6-membered > 5-membered » 7 -membered. 
94 Steroid Sa-Reductase 
A recent study by Lilly4 has shown that the inclusion of large hydrophobic 
groups at the C8 position increases the potency of non-steroidal 
benzoquinolinone inhibitors for the type-2 SR isozyme while maintaining the type-l 
activity (Table 5.8). This result forms the basis of some of the work described in this 
thesis (Chapter 6). 
Table 5.B: Summary of results from SAR studies for CB-substituted-benzoquinolinone inhibitors of SR. 
",~ej(JR 
i .. V o NI 
I H 
Me 
No. R 
5.55 CI 
5.56 H ONy I"", 0 
5.57 0 V--
5.58 S . V 
5.59 ~ 
5.60 Vi 
5.61 V I"", 
5.62 ~ - ~ - -
5.63 ~ I"", "'" 
"" 5.64 ~ 
"" N' "'" 
a human scalp; b human prostate 
5.2.2.3 PHENANTHRIDIN-3-0N ES 
IC50 (nM) 
HumanSR 10 
B 
> 10000 
59 
1000 
21 
6 
23 
63 
3.4 
32 
10000 
520 
> 10000 
> 10000 
52 
1400 
1BO 
1340 
320 
550 
The phenanthridinones are tricyclic analogues of the 6-azasteroid class of 
inhibitor.21 Although selective for type-l SRI these tricyclic inhibitors show similar 
structural requirements to the parental steroid compound with respect to 
potency; it increases with the presence of methyl substituents at C4, and/or a 
small alkyl substituent at C6 (Table 5.9J. 
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Table 5.9: Summary of results from SAR studies for phenanthridinone inhibitors of SR. 
~ CI 
a 
No. R1 R2 Human SR 1 KI (J,.tM) I 
5.65 H CH3 »10 ! 
i 5.66 CH3 CH3 1.1 
5.67 CH3 H 0.92 I 
5.2.2.4 DIENE ACIDS 
Due to the potency exhibited by the tricyclic benzoquinolinone inhibitors a 
series of tetrahydrophenanthrene-2-acetic and phosphinic acids has also been 
prepared as tricyclic analogues of the potent diene acid inhibitor, epristeride 
(Figure 5.13). 22 
HOOC 
5.68 
KI,apptype 1 = 1200nM. 
type 2 = 260 nM 
epristeride 
KI,app type 1 = 410 nM. 
type 2 = 0.2 nM 
Figure 5.13: Comparison of epristeride with a tricyclic diene acid analogue. 
Table 5.10: Summary of results from SAR studies for tricyclic-diene-acid inhibitors of SR. 
C R2 10 R3 R1 ::::,.., ::::,.., 
KI,app (nM) 
No. R1 R2 =t R3 
=t Human SR 1 Human SR 2 5.68 COOH CI H 1200 260 
5.69 COOH OMe H Nla >2500b 
5.70 E COOH H OMe 1900 1600 
5.71 PHOOH CI H 1900 1600 
5.72 PHOOH H OMe 1900 1600 
... 
a no Inhibition at 2.5 IlM; b 30% Inhibition at 2.5 IlM 
The diene acids show preferential inhibition of the type-2 SR isozyme; 
however, these tricyclic analogues exhibit a decrease in potency relative to the 
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steroidal diene acids. Like the benzoquinolinone tricyclic inhibitors the diene acid 
inhibitors show increased inhibitory activity when they contain a C7 chloro 
substituent. The presence of a methoxyl substituent at either C7 or C8 results in a 
decrease in both type-2 selectivity and potency. The phosphinic acid 
compounds are modest inhibitors of SR (Table 5.10). 
5.2.2.5 ARYL ACIDS 
Tricyclic aryl acids have been prepared based on the steroidal-aryl-acid 
compounds.23 They show potent type-1 inhibitory activity relative to the parent 
steroidal compounds (Figure 5.14) 5.73, which are selective for type-2 SR. Their 
potency is influenced by the choice of C7 substituent: a bromo substituent gives 
significantly greater type-1 activity than either the chloro (KI,app type 1 == 320 nM, 
type 2 == 2500 nM) or unsubstituted compound (KI,app type 1 == 315 nM, type 2 == 
>10000 nM). 
W Br 10 V' I Hooe ~ Hooe 
5.73 
KI, app type 1 == 26 nM, 
type 2:= 10000 nM 
5.34 
KI'app type 1 1600 nM, 
type 2 20nM 
Figure 5.14: Structural comparison of steroidal and non-steroidal aryl acid SR inhibitors. 
5.2.2.6 BENZOPHENONES AND INDOLE CARBOXYLIC ACIDS 
The inhibitory activity of the indole acids and benzophenone acids (Figure 
5.15) was discovered whilst screening for non-steroidal aryl carboxylic acid, which 
retains the A-ring features necessary for activity in the steroidal aryl-acid 
inhibitors.24 Both classes of compound are potent type-2 SR inhibitors. 
Hooe 
o 
o 
Benzophenone 
~oMe 
Hooe-\,M V ~ 0 1 "':; H 0 
Indole acid 
Figure 5.15: Benzophenone- and indole-acid inhibitors of SR. 
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SAR studies have shown that for the benzophenone carboxylic acid series, 
C-ring substitution or saturation is well tolerated. The carbonyl linker between the 
C and B rings may be exchanged without loss of activity and a direct link, 
between the two rings, is also tolerated. However, replacing the carbonyl group 
between rings A and B results in reduced activity [Table 5.11). 
Table 5.11: Summary of results from SAR studies for benzophenone-carboxylic-acid inhibitors of type-2 
SR. 
I~ I~ ;:/ D XUv HOOC 0 0 y ~ R 
No. X Y R Type-2 SR 
Kl,OPP (nM} 
5.74 C=O 0 H 5 
5.75 C=O CH2 4-Me 15 
5.76 C=O C=O 4-Me 10 
5.77 C=O C=O H 40 
5.78 C=O C=O 4-CI 35 
5;79 C=O C=O Hexahydro 30 ! 
5.80 CH2 0 H 35 . 
5.81 - COCH2 H 60 
For the indole-acid compounds, the position of the substituent on the B-ring 
is important for potency, and the C5 and C6 positions are more highly favoured 
for good activity, then the C4 position. Interestingly for C5-substituted derivatives, 
N-methylation is not favoured: however, for C5,C6-disubstituted compounds, N-
methylation gives increased potency. 
As the carboxylic-acid group provides an enolate mimic in both classes of 
inhibitor, this functionality is also necessary for activity. 
Table 5.12: Summary of results from SAR studies for indole-carboxylic-acid inhibitors of SR. 
-oa
R2 
~ R3 
HOOC Ij I 0 
N 6 R4 
I 
R1 
No. R1 R2 R3 R4 Type HnM} Type 2 (nM) 
5.82 H H OCH2Ph H > 2500 40 
5.83 Me H OCH2Ph H > 2500 310 
5.84 H H OMe OCH2Ph 460 20-30 
5.85 Me H OMe OCH2Ph 500 10 
5.86 H OCH2Ph H H > 2500 550 
5.87 H H H H NI 230 
5.88 Me H H H NI NI 
Two series of inhibitors have also been developed incorporating the 
biphenyl-acid structure of the benzophenone-type inhibitors. The first, based on 
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the tricyclic aryl acids, includes a phenyl-acid substituent at the C8 position of the 
parent compound. As seen in Table 5.13, inhibitors containing the phenyl-acid 
group show improved type-2 activity over the bromo-substituted compounds 
whilst still maintaining the type-1 potency.25 
Table 5.13: Summary of results from SAR stUdies for C8-substituted non-steroidal-aryl-acids inhibitors of 
SR. 
No. R 
5.73 Br 
5.89 COOH 
• 
5.90 H 
5.91 Ph 
5.92 4-HOOCPh 
£ R ~I I~ Hooe a 
Type-1 SR % inhibition 
Klapp 26 nM 
20% (2.5 !-1M) 
Klapp 315 nM 
45% (2.5 JiM) 
80% (2.5 JiM] 
Type·2 SR % inhibition 
50% (10 !-1M) 
50% (10 JiM) 
20% (10 JiM) 
Klapp 2.2 !-1M 
Klapp 2.2 !-1M 
The second type of inhibitor developed with the biphenyl template 
includes a substituted-indole functionality as a mimic of the steroidal C and D 
rings. The substituents chosen for the indole ring were those that gave optimal 
activities in the ONO 3805 series described previously. As can be seen from Table 
14, these compounds show selective activity against type-l SR. 
Table 5.14: Summary of results from SAR stUdies for N-substituted indoylbenzoic-acid inhibitors of SR. 
R 
I 
'/" N 
~ I ~ 
Hooe 
No. R Human SR type 2 Human SR type 1 
% inhibition (10JlM) % inhibition (10JlM) 
5.93 Benzyl 60 67 
5.94 Benzhydryl 40 81 
5.95 1-Butyl 24 72 
5.96 4-Heptyl 10 75 
5.97 Cyciohexanemethyl 50 81 
5.98 Cyclohexyl 36 -
5.2.2.7 BENZO[C]QUINOLIZIN-3 -ONES 
Two tricyclic analogues based on the 19-nor-10-azasteroid inhibitors have 
been developed.26 These two non-steroidal inhibitors differ only in the position of 
unsaturation in the A-ring (Figure 5.16). One is a proposed SUbstrate-like transition-
state mimic (5.99), and the other, a product-like mimic (5.100). Both compounds 
Steroid Sa-Reductase 99 
were selective for type-l SR inhibitors and their potency dependent on the 
position of unsaturai"ion. 
WI N ~ o /./ o o 
5.31 5.99 5.100 
Substrate-like mimic Product-like mimic 
Figure 5.16: Tricyclic analogues of the 19-nor-1 O-azasteroid inhibitors. 
5.2.2.8 SUMMARY 
Unlike the steroidal inhibitors, the non-steroidal compounds that have been 
identified exhibit selectivity for both type-l and type-2 SR. Inhibitors incorporating 
a charged carboxylate enolate mimic tend to display type-2 selectivity, as is 
shown by the tricyclic diene acids, the benzophenone and indole carboxylic 
acids. On the other hand, the neutral mimics incorporating amide or enamine 
grou ps, such as the benzoquinolinone and phenathridinones, show selectivity for 
type-l SR. The majority of non-steroidal inhibitors discussed give increased activity 
when a lipophilic group is incorporated into their structure in a location that might 
be considered analogous to that of the steroidal D-ring. 
Recent work by Ahmed et 01. 27,28 has revealed that the most important 
feature of a SR inhibitor is the presence of an enolate mimic. The NADPH 
molecule has been shown to be positioned close to C5 in the enzyme-cofactor 
complex and therefore, the area about C4 and C5 is sterically hindered. This 
finding may account for decreased activity for inhibitors containing large 
substituents, in these locations. 
The area surrounding the binding position of the C17 substituent has been 
shown to be very large, and it is postulated that this location is the entry and exit 
point for substrate molecules. The C17 binding area is also thought to lack H-
bonding residues, and it is assumed that binding of substituents in this position 
occurs through polar interactions. These findings are based on conformational 
analysis of a selection of potent type-l and type-2 SR inhibitors superimposed 
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upon a calculated low energy conformation of the proposed enolate 
intermediate. 
5.2.2.9 OUR WORK ON SR INH I BITORS 
Our interest in SR inhibitors is in the area of non-steroidal inhibitors, which 
have been developed from steroid-based compounds. In particular the 
benzoquinolinone (section 5.2.2.2) and tricyclic-aryl-acid compounds (section 
5.2.2.5) "rhat are potent type-1 inhibitors. 
The work presented in the following chapter is based on three areas on 
investigation; 
1) Improving the activity and selectivity of two known tricyclic inhibitors by 
incorporating hydrophobic substituents shown to improve the activity of related 
compounds . 
. 2) An investigation of bicyclic analogues of the 4-azasteroid and 
benzoquinolinone compounds for use as inhibitors of SR. 
3) An investigation of the activity of a novel enolate mimic; a thiolactam. 
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STEROl Sa- EDUCTASE INHIBITORS 
This chapter describes the synthesis and attempted synthesis of a series of 
potential SR inhibitors. 
6. 1 TRICYCLIC INH I ITORS 
A recent study by C. R. Smith et 01. 1 reported the synthesis of tricyclic non-
steroidal benzoquinolinone-type inhibitors of SR, incorporating various 
hydrophobic substituents at C8 of the parent compound (Table 5.8). The phenyl-
acetylene-substituted compound, 5.59, proved to be the best dual isozyme 
inhibitor (ICso type 1 = 21 nM, type 2 52 nM), with the most potent isozyme-
selective compound being the cis-styryl-substituted compound 5.60 (ICso: type 1 = 
6 nM, type 2 ICso = 1400 nM). 
o o N 
I 
Me 
5.59 5.60 5.61 
Figure 6.1 : Acetylene- and styryl-substituted benzoquinolinones. 
We were interested by the potent type 1 selective inhibition, of the cis-styryl-
substituted benzoquinolinone compound, 5.60, relative to its trans isomer, 
5.61 (lCso: type 1 = 23 nM, type 2 = 180 nM, Figure 6.1). This result presented an 
opportunity to exploit the selective inhibition of each isomer and develop an 
isozyme-switchable inhibitor. 
We postUlate that the incorporation of a photoisomerisable-phenylazo 
substituent at the C8 position of a benzoquinolinone-type compound would 
effectively give access to both the cis and trans isomers within a single molecule. 
The sterically-favoured trans isomer potentially provides a dual inhibitor against 
type-1 and type-2 SR, while the cis conformation provides a potent, selective, 
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type-l agent. The incorporation of a phenylazo group also provides a structural 
mimic to the hydrophobic styryl moiety, shown to give good activity.1 
Given that the cis and trans isomers display such different activity and 
selectivity, we were interested in the concept of a single molecule that could be 
made to exhibit two different activities and selectivities through an easily applied 
photoisomerisation procedure. The phenylazo group effectively acts as a 'switch' 
by which the desired activity can be obtained. This type of switchability is a 
potentially useful tool, with possible applications in 'the design of other enzyme 
inhibitors.2 
6.1.1 THE Azo SUBST ITUENT 
We chose to incorporate the phenylazo substituent into the most basic 
benzoquinolinone structure to allow easy comparison against other inhibitors of 
the same class (Figure 6.2). Substitution of the azo moiety at the C8 position would 
enable direct comparison with the styrl-substituted benzoquinolinone inhibitors 
prepared by Smith et a/. 1 
o N 
J 
Me 
6.1 
Figure 6.2: Target phenylazo compound. 
The synthesis of an azo functionality can be achieved by a number of 
methods.SA Common reactions involve oxidation of hydrazines or primary amines, 
or diazo coupling. Alternatively, condensation of a primary aromatic amine with 
nitrosobenzene will result in an azo compound. Except for the diazo coupling 
reaction, in which both nitrogen atoms are supplied by a diazo salt, these 
methods require the presence of a nitrogen-containing group at the C8 position 
of the benzoquinolinone skeleton to afford the desired target compound 6.1. 
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The synthetic approach we selected for azo formation was a condensation 
reaction between nitrosobenzene and the appropriately substituted amino 
benzoquinolinone. 
6. 1 . 1 . 1 RETROSYNTHETIC ANA LYSIS 
Figure 6.3 shows a retrosyn'~hetic analysis for the attempted routes to our 
target compound 6.1. Synthesis of the C8-amino-substituted benzoquinolinone 6.2 
was considered approachable from two directions. Route A involved preparation 
of the basic benzoquinolinone 6.3, which could be nitrated, then reduced to 
afford the amine 6.2. Alternatively, route B involved synthesis of the 
benzoquinolinone using an appropriately substituted starting material such as 
compound 6.4. 
As compound 6.4 is not commercially available, possible routes to this 
reagent were also considered (Figure 6.3). We proposed that nitration of ~­
tetralone followed by reduction could possibly afford compound 6.4, or a Friedel-
Crafts cyclisation using 4-amino phenylacetic acid (6.S) might give the desired 
compound. 
6.1 
6.6 
NHz 
o A 
6.2 
B~ 
8~2 ====> 
o 
6.4 
Figure 6.3: Synthetic approach to target compounds. 
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As a literature preparation of compound 6.3 was available, we decided to 
first attempt the synthesis of 6.2 using route A. 
106 Steroid Sa-Reductase Inhibitors 
Synthesis of 4-Methyl-l ,2,3,4,40,5,6,1 Ob-Octohydrobenzo[f]quinolln-3-one (6.3). 
The benzoquinolinone 6.3 was synthesised as described by Jones et a/. 5 
(Scheme 6.1). f3-Tetralone (6.6) and pyrrolidine were refluxed together in toluene 
for 4 hours. Removal of the solvent gave the enamine 6.7 in a 88% yield. 
Characterisation of the product by proton I'lMR revealed two four-proton 
resonances at 8 1.93 and 3.28 due to the pyrrolidine group, and a one-proton 
singlet at 85.14 ascribed to the olefinic proton of the enamine. 
Reaction of 6.7 with acrylamide gave compound 6.8 in a 62% yield after 
recrystallisation. The proton-NMR spectrum of 6.8 relative to 6.7, revealed an 
additional four-proton multiplet resonance at 0 2.69 due to the C1 and C2 
protons. Loss of the pyrrolidine and olefinic resonances was also observed. Aza 
annulation reactions of this type are reported to give isomeric products,6 but no 
attempt was made to isolate or quantify any minor products formed. 
Reaction of 6.8 with NaH and iodomethane gave 6.9 in a 67% yield after 
recrystallisation. Methylation was confirmed by the presence of a singlet 
resonance at 0 3.14 in the proton-NMR spectrum. 
6.6 
D9 
o ~ H 
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Me 
6.3a 
6.7 
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oJNJJ 
I H 
Me 
6.3b 
III 6.8 j ... 
6.9 
Scheme 6.1: [i) pyrrolidine, toluene reflux 4 hours; (ii) acrylamide, p-TSA heat 100ce 1 hour; (iii) NoH, 
glyme. Mel reflux 5 hours; [Iv) triethylsilane. trifluroacetic acid, dichloromethane, stir 5 days. 
Compound 6.9 was reacted with triethylsilane and TFA and stirred for five 
days. Workup gave 6.3 as a mixture of four stereoisomers: the (±) cis and (±) trans 
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compounds. The cis and trans products were separated by radial 
chromatography to give yields of 13% and 42% respectively. 
The proton spectrum for each isomer contained two additional one-proton 
multiplets corresponding to reduction of the ring junction. Each isomer was 
identified by the characteristic chemical shift of the C4a and C10b hydrogens 
(Figure 6.4); the resonances due to the cis isomer (0 3.55 and 3.15), shifted 
downfield relative to the trans (0 3.14 and 2.72).7 The mass spectrum contained 
the expected parent ion for each product. 
Previous SAR studies on the benzoquinolinone inhibitors (section 5.2.2.2) 
have shown that the (±) 6.3 cis enantiomers give comparable inhibition results, as 
do the (±) trans enantiomers.8 Because of this, and the inherent difficulty in 
separating (f) enantiomers, no attempt was made to separate the racemic cis or 
trans products. However, the trans geometry is slightly favoured over the cis for 
inhibitory activity against SR, as the increased planarity of the molecule more 
ciosely resembles that of the SR substrate.5 The racemic trans isomer 6.3b was 
therefore used in subsequent reactions. 
We next turned our attention to the nitration of the benzoquinolinone 6.3b 
and subsequent reactions in an attempt to synthesise the target compound 6.1. It 
has been reported that nitration of 6.3 occurs predominantly at the C9 position 
rather than at C8.9 However, we were interested to see if we could detect any of 
the desired C8-nitro compound. 
SyntheSis of 4-methyl·9·Phenylozo-l,2,3,4,4o,5,6,'Ob-Trans-
octohydrobenzo[f]quinolln-3-one (6.12). 
The nitration of 6.3b to form 6.10 was carried out using a literature method9 
(Scheme 6.2). Compound 6.3b was dissolved in a mixture of concentrated H2S04 
and acetic acid and cooled in an ice bath. HN03 was added slowly over 20 
minutes and the resulting mixture was stirred for 2 hours. Workup gave the C9-
substituted compound 6.10 as a yellow precipitate in a 41 % yield. 
A proton-NMR spectrum revealed a downfield shift in the aromatic 
resonances of 6.10 relative to 6.3, from an unresolved multiplet at 0 7.14 to 
resonances at 0 8.15, 8.03 and 7.28, which is attributed to the presence of the nitro 
group. Analysis by mass spectrometry confirmed nitration had occurred by the 
detection of a molecular ion with a mass of 260 g/mol. 
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Figure 6.4: Proton-NMR spectra of the racemic cis and trans isomers of compound 6.3. 
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The lack of a C8-nitro product may be due to the activating effects of the 
sUbstituents on the C-ring in conjunction with inductive effects of the A-ring 
nitrogen, providing a more stabilised environment for the formation of the C9-
substituted product. 
Reduction of 6.10 to form 6.11 was achieved in a 39% yield as shown in 
Scheme 6.2. Compound 6.10 was dissolved in acetic acid and hydrogenated for 
three days. Workup and purification gave 6.11. 
Characterisation by proton-NMR spectroscopy revealed an upfield shift in 
the aromatic-proton resonances of 6.11 to () 6.93, 6.62 and 6.56 relative to the 
chemical shifts of product 6.10, indicating reduction had occurred. 
n9 .. ON.: 0 
I H 
Me 
6.3b 6.10 
Q I ii
N~N 
iii 
• 
0 0 
6.12 6.11 
Scheme 6.2: Ii) HN03, conc H2S04: acetic acid (1:1), stirred 2 hours; (ii) Pt02, acetic acid, H2, balloon, 
stirred 3 days; (iii) nitrosobenzene, acetic acid, stirred overnight. 
Formation of the phenylazo group was achieved using a general 
procedure reported by Luckner et 01.10 The amine 6.11 and nitrosobenzene were 
stirred in ace'l"ic acid overnight as shown in Scheme 6.2. Workup and purification 
by column chromatography gave compound 6.12 as a yellow oil in a 88% yield. 
Characterisation by proton-NMR spectroscopy revealed resonances at () 7.90 
(three-proton), 7.77 (one-proton), 7.50 (three-proton) and 7.28 (one-proton) 
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corresponding to the incorporation of a trans-phenylazo group. Low-intensity 
resonances were also observed further upfield, (87.36 - 6.69) corresponding to the 
cis isomer.ll From the integral heights of the trans and cis isomers the fraction of 
cis present was determined to be 12%. 
Irradiation of a sample of 6.12 in CDCI3 for one hour at 330 - 370 nm, and 
subsequent NMR analysis, resulted in a mixture with 77% of the cis product, while 
further irradiation at wavelengths >400 nm for one hour gave a mixture with 85% of 
the trans product. These results are consistent with reported photostationary-
equilibrium2 ratios for azo isomers following irradiation.12 No by-products due to 
photoisomerisation were detected in the NMR spectra. 
As the major product of 6.3 ni"tra"j"ion was the C9-subs"l"ituted compound 
6.10, we were unable to synthesise our target compound 6.1 by route A and 
therefore turned our attention to route. B (Figure 6.3). This involved the synthesis of 
the precursor 6.4. 
This synthesis was initially attempted using 4-amino phenylacetic acid as 
the starting material in a Friedel-Crafts cyclisation reaction to form the 
appropriately substituted te"tralone (Figure 6.5). 
(yNH2 
~ 
eOOH 
6.5 6.4 
Figure 6.5: Desired Friedel-Crafts cyclisation. 
Although Friedel-Crafts reactions involving aromatic molecules containing 
an activating substituent might be expected to form the desired tetralone, amines 
are not known to facilitate these reactions. This is due to their ability to coordinate 
the catalyst, thus removing it from the reaction mixture. Compounds containing 
an amine group are only known to undergo Friedel-Crafts alkylation reactions 
when the reagent is an olefin and the catalyst an aluminium anilide.3.13 An 
additional problem with this type of cyclisation reaction is the requirement to form 
an acid chloride selectively at the carboxyl group, to allow chain extension by the 
introduction of an ethylene group, while leaving the amine unchanged. 
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We considered using 4-nitro phenylacetic acid as a starting material, but, 
Friedel-Crafts reactions, in which the aromatic ring contains deactivating 
substituents, such as N02, do not proceed well. Attempts by Burckhalter et 01. to 
form a nitro containing tetra lone using a Friedel-Crafts reaction had proved 
unsuccessful. 14 
We decided that protecting the amino group of 4-aminophenylacetic 
acid, to reduce its reactivity, before carrying out the cyclisation reaction, might 
be a viable approach. Amine protection has been extensively studied due to its 
applications in peptide synthesis. 15•16 We required a protecting group that would 
be stable under the reaction conditions, easily removed, and cause no 
interference with the reactions being carried out. With this in mind, we tried 'rhree 
different protections: benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl 
(Fmoc) and a phenylazo substituent (Figure 6.6). 
Cbz Fmoc Phenylazo 
Figure 6.6: Protecting groups for 4-aminophenylacetic acid. 
Synthesis and Reaction of 4-(Aminobenzocarbamate)-Phenylacetic Acid (6.13). 
4-Aminophenylacetic acid (6.5) and benzylchloroformate were slirred 
together in an aqueous solution of NaHCOs. Workup gave compound 6.13 as a 
white solid in a 90% yield. Characterisation by proton NMR revealed resonances 
at 0 7.37, 6.73 and 5.20 due to the carbamate group. 
Compound 6.13 was then reacted with oxalyl chloride and DMF in 
acetonitrile at -20°C for 3 hours. Removal of the solvent by vacuum distillation 
gave a yellow oil that was stored overnight under vacuum. A proton-NMR 
spectrum of the oil gave a similar pattern of resonances to those of product 6.13. 
The next procedure required that the oil be dissolved in dichloromethane 
and reacted with AICIs and ethylene gas at -76°C. However, the oil was only 
partially soluble in the solvent and reaction and workup resulted in a mixture of 
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products that were not identified. It is thought that the acid-labile Cbz group was 
hydrolysed from 6.13 during reaction to form the acid chloride. 
6.13 
6.5 jii 
6.14 
Scheme 6.3: (i) benzylchlbroformate, NaHCOs, water, stirred overnight; (ii) oxalyl chloride, DMF, 
acetonitrile, -20°C stirred 3 hours; (iii) AICI3, dichloromethane, ethylene -76°C, stirred overnight. 
Synthesis and Reaction of 4-(Amino-(9-Fluromethylcarbamate}-Phenylacetic Acid 
(6.9) 
H NNH2 
~ . NNi(O ~O 
eOOH eOOH 
6.5 6.16 
6.18 6.17 
Scheme 6.4: (i) 9-fluoromethylchlorocarbamate, 10% Na2C03, dioxane, stirred overnight; (ii) oxalyl 
chloride, DMF, toluene stirred overnight; (iii) AICb, dichloromethane, ethylene -76°C , stirred 
overnight. 
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The Fmoc-protected 4-aminophenylacetic acid 6.16 was prepared by 
reacting 9-fluoromethylchlorocarbamate and 4-aminophenylacetic acid (6.5) 
with 10% aqueous Na2C03 in dioxane overnight (Scheme 6.4). Reaction and 
subsequent workup gave 6.16 as a solid in a 73% yield. Characterisation by 
proton NMR revealed additional aromatic resonances between (5 7.54 - 6.91, a 
two-proton doublet at 4.23, and one-proton multiplet at 4.02 due to the Fmoc 
group. 
Compound 6.16 was then reacted with oxalyl chloride and DMF in toluene 
overnight. Removal of the solvent by vacuum distillation gave 6.17, a yellow solid, 
which was used immediately. Proton-NMR analysis of the acid chloride showed 
resonances similar to those seen in product 6.16. 
Compound 6.17 was dissolved in dichloromethane and added dropwise to 
a stirred mixture of AICb in dichloromethane at -76°C. Ethylene gas was bubbled 
though the mixture for an hour, before warming to room temperature and stirring 
overnight. Workup gave a yellow solid, however, proton-NMR analysis failed to 
show any new resonances corresponding to the desired cyclised product. This is 
thought to be due to both the deactivating effect of the protecting group and 
the ortho-, para-directing effects of this substituent (given the desired position of 
attachment was meta to the amine). 
Synthesis and Reaction of Phenylazo Acetic Acid (6.19) 
4-Aminophenylacetic acid (6.5) and nitrosobenzene were stirred together 
in acetic acid overnight (Scheme 6.5). Workup and purification by column 
chromatography gave compound 6.19 as an orange solid in a 83% yield. Proton-
NMR spectroscopy revealed additional aromatic resonances at (5 7.90 (four-
proton) and 7.39 (five-proton) corresponding to the phenylazo group. 
Compound 6.19 was reacted with oxalyl chloride and DMF in acetonitrile 
for 3 hours. Removal of the solvent gave 6.20 as a dark-coloured residue that was 
used without purification. Compound 6.20 was reacted with AICIs and ethylene in 
dichloromethane at -76°C (Scheme 6.5). Workup of the reaction mixture resulted 
in the formation of a brown insoluble precipitate that was not characterised. A 
red oil was also isolated from the reaction mixture, but analysis by proton-NMR 
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spectroscopy revealed none of the expected resonances for the desired cyclic 
product 6.21. 
rr NNH2 NN~N~ ~ --~~ 
eOOH eOOH 
Scheme 6.5: (i) nitrosobenzene, acetic add, stirred overnight; (ii) oxalylchloride, acetonitrile stirred 3 
hours; (iii) AICb, dichloromethane, ethylene -76°C, stirred overnight. 
Synthesis of 7·Nitrotetralone (6.22) and 6·Nitrotetralone (6.23) 
Given the difficulty in forming 6.4 via a Friedel-Crafts cyclisation, we 
attempted to directly nitrate f3-tetralone. 
The nitration of f3-tetralone can conceivably occur in any of the positions, 
C5 - C8, due to the ortho-/para-directing effects of the alkyl substituents present 
on the aromatic ring. 
+ 
6.6 6.22 6.23 
Scheme 6.6: (i) KN03, conc H2S04, stirred 2 hours. 
The conditions we employed for nitration of f3-tetralone are shown in 
Scheme 6.6. f3-Tetralone and KN03 were stirred together in concentrated 
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aqueous H2S04 for 2 hours. Workup gave a mixture of 6.22 and 6.23 as a reddish 
oil with a total yield of 63%. The product was not purified further. 
From the proton-NMR integrals the ratio of 6.23 to 6.22 was determined to 
be -1 :5. The spectrum of 6.22 had three new single-proton aromatic resonances 
relative to ~-tetralone: a multiplet at 0 8.10, a singlet at 8.03 and a doublet at 8 
7.42; the more downfield resonances (8 8.10 and 8.03) indicative of aromatic 
protons directly adjacent to the nitro substituent. Compound 6.22 was established 
as the major isomer using an nOe experiment which showed an interaction 
between the singlet proton resonance at 8 8.03 and the C 1 protons at 8 3.69. This 
indicated that the resonance at 8 8.03 was the C8 proton and therefore, nitration 
in the major product had occurred at C7. 
These NMR spectra were consistent with those of Pollack et al. 17 who 
reported that nitration of ~-tetralone, using concentrated nitric acid, results in two 
products; C7 nitration in a 40% yield and C6 nitration in a 26% yield. 
Synthesis and Reaction of 7-Nitro-2-(1-pyrrolidinyl)-3A-Dlhydronapthalene (6.24) 
Although the nitration of ~-tetralone did not yield large quantities of the 
desired C8-substitued isomer, the yield of product 6.22 was appreciable (52%). 
We therefore proposed that a route to compound 6.12, using 6.22 (Scheme 6.7), 
might improve the final yield relative to the nitration of compound 6.3 as detailed 
above (Scheme 6.2). 
oJ' B' 1> I 
0 0 
6.22 6.24 6.25 
Scheme 6.7: (i) pyrrolidine, toluene, reflux overnight; (ii) acrylamide, p-TSA, heat. 
The impure 6.22 and pyrrolidine were refluxed in toluene (Scheme 6.7). 
Analysis of the crude mixture by proton-NMR spectroscopy revealed the presence 
of the enamine 6.24 in a mixture of unidentified products as indicated by two four-
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proton resonances at 8 1.97 and 3.36 due to the pyrrolidine group, and a one-
proton singlet at 8 5.20 due to the olefinic proton of the enamine. 
Attempts to completely purify the compound using flash chromatography 
(20% e·~hyl acetate/petroleum e·~her) were unsuccessful. Therefore, ·~he cleanest 
fraction was used in the subsequent reaction with acrylamide (Scheme 6.7) but 
failed to give the desired tricyclic product. This non-reaction can possibly be 
attributed to the deactivating effect of the nitro substituent, which reduces the 
nucleophilicity of the enamine, and prevents attack by the ~-carbon centre of the 
enamine on the acrylamide. 
Our attempts to prepare the C8-phenylazo substituted benzoquinolinone 
6.1 by either of the routes outlined in Figure 6.3 were unsuccessful. Direct nitration 
of the benzoquinolinone compound gave predominantly the C9-substituted 
compound 6.10 in limited yield. We were, however, able to prepare the 9-
phenylazo-benzoquinolinone compound 6.12 from this precursor. Synthesis using 
4-amino phenylacetic acid also proved problematic. However, given our 
disappointing results for aza annulation of the 7-nitrotetralone 6.22, successful 
cyclisation by a Friedel-Crafts reaction to give 6.4 may not have resulted in the 
desired tricyclic precursor of our targe·~ product 6.2. 
6.1.2 THE STYRYL SU BSTITUENT 
Abell et al. 18 reported a study on the synthesis of dual SR isozyme inhibitors 
incorpora·~ing features of the type-1-selective aryl acid tricyclic compounds, such 
as 5.73, and the potent type-2 biphenyl-acid inhibitors, such as 5.81, thought to be 
important for their activity and potency (Figure 6.7). 
o eooH 
d7Br I 7 -;:/ ~ Hooe ~ I Hooe Hooe 
1 
5.73 5.81 5.92 
Figure 6.7: Compound 5.92 incorporates structural features of both 5.73 and 5.81. 
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Results of this study suggested that incorporation of hydrophobic groups 
onto the C7 position of aryl-acid inhibitors, improves their selectivity towards the 
type-2 isozyme, without significantly reducing the potency for the type-1 enzyme 
(Table 5.13). 
Based on the positive effects of styryl sUbstitution on the tricyclic 
benzoquinolinone inhibitors [Figure 6.1), we decided to investigate the possibility 
of improving the potency of aryl-acid tricyclic inhibitors against type-2 SR, by 
incorporating a styryl substituent at C7 (Figure 6.8). The results from the study by 
Abell a/. suggested that the potency of the parent tricyclic aryl-acid inhibitor 
toward type-1 SR should not be adversely affected, and a potent dual inhibitor 
with increased activity towards type-2 SR might be expected from this 
modification. 
HOOC 
6.26 
Figure 6.8: Target compound 6.26. 
The chemistry described by Smith et a/. 1 for the preparation of the styryl-
substituted benzoquinolinone derivatives utilised a palladium-catalysed coupling 
of styrene to the appropriately halo-substituted tricyclic compound. We chose to 
utilise this chemistry for the preparation of the styryl-substituted tricyclic aryl-acid 
inhibitor 6.26, as is shown in Scheme 6.8. 
Synthesis of 7-Styryl-9,10-Dihydrophencmthrene-2-Carboxylic Acid (6.26) 
Styrene, compound 6.27, Pd{Ac)2, (o-tolbP, EhN and MeCN, were reacted 
together in a sealed tube at 1 aaoc for 24 hours. Workup afforded a white powder, 
a solution of which, gave purple luminescence in daylight, indicating the 
presence of a highly conjugated system. Hydrolysis of the methyl ester to give 
6.26 was achieved by refluxing 6.28 in methanolic KOH. 
Characterisation by NMR spectroscopy revealed appropriate additional 
resonances for the formation of the styryl substituent. Mass spectrometry gave a 
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molecular ion with a mass of 340, which is consistent with the incorporation of a 
styryl group. 
Br 
.. 
MeOOC ii HOOC 
6.27 6.26 
Scheme 6.8:(i) styrene, Pd(OAc)2, (o-tol)3P, EhN, acetonitrile, lOO°C 24 hours; (ii) K2C03, methanol: 
water [10: 1), refluxed 18 hours. 
6.2 BICYCLIC INHI B ITORS 
The carboxylic acid series of non-steroidal inhibitors (section 5.2.2.5), which 
are based on the potent steroidal type-2 inhibitor epristeride (5.33), includes 
tricyclic analogues such as 5.73 in which the steroid D-ring has been removed, 
and more recently, biphenyl structures such as 5.81 in which '~he B-ring is also 
deleted. While the tricyclic aryl acids have been shown to be potent type-1 
inhibitors, the bicyclic compounds, like the parent steroid structures, are more 
active against type-2 SR (Figure 6.9). 
a 
d7: Br ;:/1 Haac ~ HaaC 
epristeride 5.73 5.81 
KI, app type 2 = 0.2 nM KI,app type 1 = 26 nM KI,app type 2 = 60 nM 
Figure 6.9: Steroid, tricyclic and biphenyl SR inhibitors incorporating a carboxylic acid enolate mimic. 
Similarly, the tricyclic benzoquinolinone compounds, which are analogues 
of the potent 4-aza-steroiodal inhibitors, have also been shown to be potent SR 
inhibitors. However, related 4-aza compounds, in which the B-ring has also been 
deleted (6.29), have not been investigated with regard to their inhibitory activity 
against SR (Figure 6.10). 
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Figure 6.10: 4-ozo series of SR inhibitors 
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While the preparation of potential inhibitors such as 6.29 is useful for 
comparison against the steroidal and tricyclic compounds of the 4-aza series of 
inhibitors, these bicyclic lactam-based inhibitors might also be considered to 
represent analogues of the potent type-2 benzophenone inhibitors exemplified by 
5.81 (Figure 6.11). This analogy allows a comparison to be made of the efficacy 
and effectiveness of the neutrallactam enolate mimic of compound 6.29, versus 
the charged carboxyl species utilised in the benzophenone class of inhibitor. 
£P o N 
I 
6.29 
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Me 
enolate mimic enolate mimic 
Figure 6.11: 4-ozo ond 3-corboxylote biphenyl inhibitors . 
. 1 TARGET MOLEC U LES 
We decided to prepare the basic piperidone compound 6.29 and 
derivatives containing substituents that have been shown to enhance inhibitor 
potency in the benzoquinolinone tricyclic series of inhibitors (section 5.2.2.2). Our 
target molecules are shown in Figure 6.12. 
The piperidone 6.30, the 1-methyl-piperidone 6.29 and the 5-(4-
chlorophenyl}-1-methyl-2-piperidone 6.31 allow direct comparison of activity and 
selectivity against the tricyclic benzoquinolinone inhibitors. Due to the reported 
potency of tricyclic inhibitors containing hydrophobic groups, it was envisioned 
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that the incorporation of a similar substituent into compound 6.29 would result in 
potent SR inhibitors. Therefore, we decided to also prepare compound 6.33 
incorporating a styryl moiety, and compound 6.32, containing a 
photoisomerisable phenylazo group, using synthetic methods previously described 
in section 6.1. The styryl moiety, in which the predominant isomer is trans, provides 
a control for the phenylazo-substituted compound against which both cis and 
trans isomers may be compared. Preparation of 6.32 and 6.33 also allows a 
measure of any effects, which may result due to the nitrogen double bond, 
compared with the carbon double bond. 
f o N f o N 
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6.30 6.29 6.31 
6.32 6.33 
Figure 6.12: Target bicyclic lactam compounds. 
Preparation of the target compound 6.32, using previously described 
methods (section 6.1.1), required a p-amino substituent on the phenyl ring of the 
basic piperidone structure. We considered two approaches to achieve this. The 
first involved the use of p-nitrobenzyl cyanide as the starl'ing material. 
Alternatively, the unsubstituted methyl piperidone could be nitrated and 
subsequently reduced to the amine (Figure 6.13). 
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Figure 6.13: Synthetic approaches to phenyla;zo piperidone 6.32. 
Sy~thesis of the styryl-substituted compound 6.33 using previously discussed 
methods (section 6.1.2), required a p-bromo-substituted piperidone. Two 
alternative routes to this compound were considered. The first involved use of the 
p-bromobenzyl-cyanide starting material, while the second utilised a Sandmyer-
type reaction (Figure 6.14). 
Br 
> ;. 
o N o o N 
I I 
Me Me 
6.33 6.36 6.34 
~ 
N Br ~ 
eN 
6.37 
Figure 6.14: Synthetic approaches to styrl piperidones 6.33. 
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6.2.2 PIPERIDONES 
All the target compounds were successfully prepared for this series of 
bicyclic inhibitors. 
Synthesis of 5-Phenyl-l-Methyl-2-Piperidone (6.29) 
The preparalion of the basic bicyclic lactam compound 6.29 was by a 
known literature procedure 19,20 (Scheme 6.9). To a stirred mixture of benzyl 
cyanide, hydroquinone, and Triton B at 140°C was added methyl acrylate. 
Workup and purification by vacuum distillation gave compound 6.390 in a 17% 
yield. 
Characterisation by proton-NMR spectroscopy revealed two two-proton 
resonances at 0 2.21 and 2.49 due to the acrylate, and a change in the coupling 
pattern of the C4 proton, relative to' 6.380, from a singlet to a multiplet. An 
infrared spectrum contained an absorption band at 1735 cm-1 corresponding to 
the carbonyl group, and a band at 2259 cm-1 due to the cyano group. Mass 
spectrometry revealed the expected molecular ion, further confirming that 
coupling had occurred. 
R = H 6.38a 
R = C16.38b 
Me02C~R __ ii __ 
CN 
R = H 6.39a 
R = C16.39b 
o 
R = H 6.29 
R = C16.31 
R 
Me02C 
iv 
R = H 6.40a 
R = C16.40b 
o N 
H 
[iii 
R = H 6.30 
R = C16.41 
R 
R 
Scheme 6.9:(i) methyl acrylate, Triton B, hydroquinone; (ii) Pt02, glacial acetic acid, H2, 40 psi. 3 days; 
(iii) xylene or toluene, reflux, 20 hours; (iv) NaH, glyme, Mel, reflux 5 hours. 
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6.390 was then dissolved in acetic acid and hydrogenated at 40 psi for 3 
days. Workup and solvent evaporation gave compound 6.40a. Reflux of 6.40a in 
toluene, followed by solvent evaporation gave the cyclised product 6.30 in a 61% 
yield. Characterisation by proton-NMR showed an absence of the methoxy 
resonance and the appearance of a broad singlet at 0 6.18 attributed to the 
amide. 
Methylation of 6.30 was achieved by deprotonation with NaH followed by 
addition of iodomethane to give 6.29 in a 87% yield. The proton-NMR spectrum 
contained a resonance at 02.97 indicating methylation had occurred. 
An equivalent series of reactions were carried out to form the 5-(4-
chlorophenyl)-1-methyl-2-piperidone compound 6.31. 
Synthesis of 5-(4-Chlorophenyl)-1-Methyl-2-Piperidone (6.31) 
To a mixture of p-chlorobenzyl cyanide (6.3Bb), hydroquinone and Triton B 
at 140°C was added methyl acrylate. Workup and purification by vacuum 
distillation gave compound 6.39b in a 24% yield. Characterisation by proton-NMR 
spectroscopy revealed a three-proton singlet at 0 3.70, two two-proton 
resonances at 0 2.20 and 2.51 due to the acrylate, and a change in the coupling 
pattern of the C4 proton from a singlet to a multiplet. Mass spectrometry revealed 
the expected parent ion confirming that coupling had occurred. 
6.39b was dissolved in acetic acid and hydrogenated at 40 psi for 1 day. 
Filtration to remove the Pt02 catalyst and solvent evapora"l"ion gave compound 
6.40b. Reflux of 6.40b in xylene afforded a white precipitate that was collected by 
filtration to give the cyclised product 6.41 in a 46% yield. Characterisation by 
proton-NMR spectroscopy revealed two new resonances at 0 3.49 and 3.35, 
relative to 6.39b, corresponding to the reduction of the cyano group, a loss of the 
methoxy resonance, and the appearance of a broad singlet at 0 6.09 attributed 
to the amide. 
Methylation of 6.41 was achieved by reaction with NaH and Mel to give 
6.31 in a 59% yield. The proton-NMR spectrum contained a resonance at 0 2.98 
indicating methylation had occurred. 
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Synthesis of 5-(4-Aminophenyl)-Piperidone (6.44) 
Reaction of nitro benzyl cyanide (6.35) with methyl acrylate at reflux gave 
"the desired nitrophenyl butyrate 6.42 as a red oil in a 13% yield, following repeat 
extractions with cold ether and vacuum distillation to remove the unreacted 
cyanide starting material. A proton-NMR spectrum of 6.42 contained a three-
proton singlet at 0 3.71, two two-proton multiplets at 0 2.55 and 2.24 due to the 
coupled acrylate, and a change in the coupling pattern of the C4 proton from a 
singlet to a mul"tiplet. 
o N 
H 
6.44 
6.35 
.. 
iii 
NN02 Me02C~ 
CN 
6.42 
6.43 
Scheme 6.10:(i) methyl acrylate, Triton B, hydroquinone; (iiJ Pto2, glacial acetic acid, H2, 40 psi, 3 
days; (iii) toluene, reflux, 20 hours. 
Compound 6.42 was then dissolved in acetic acid and hydrogenated at 40 
psi for 3 days. Workup gave compound 6.43, which unfortunately underwent 
polymerisation to give a gel like substance that was quite insoluble in most 
solvents. However, a small sample was able to be dissolved in excess toluene and 
reacted at reflux overnight. Analysis by NMR spectroscopy revealed resonances 
indicative of the cyclised product 6.44, but, this product was unable to be 
successfully purified. 
Synthesis of 5-(p-Phenylazobenzyl)-1-Methyl-2-Piperidone (6.32) 
Due to the difficulty we experienced in obtaining a clean sample of 
compound 6.44, the alternative synthetic route to 5-(4-aminophenyl)-1-methyl-2-
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piperidone (Figure 6.13) involving direct nitration of 5-phenyl-4-methyl-2-
piperidone (6.29) was attempted. 
f o N o 
I 
Me 
6.29 6.45 
o 
6.32 6.34 
Scheme 6.11 :(i) KN03. conc HzS04. stirred 2 hours; (ii) PtOz, glacial acetic acid, Hz, 3 days; (iii) 
nitrosobenzene, acetic acid, stirred overnight. 
Compound 6.29 and KN03 dissolved in concentrated aqueous H2S04 were 
stirred for 2 hours. Workup and purification by column chromatography gave 6.45 
as a yellow oil in a 49% yield. Characterisation by proton-NMR spectroscopy 
revealed two two-proton doublets at () 8.21 and 7.43. This resonance pattern is 
characteristic of symmetric para-substitution on the phenyl ring. Analysis by mass 
spectrometry revealed a molecular ion of mass 234 g/mol corresponding to the 
presence of a nitro group. 
Hydrogenation of 6.45 giving the amino product 6.34 was achieved using 
Pt02 and 40 psi of H2. Workup and purification by radial chromatography gave 
6.34 as an oil in a 51% yield. Reduction of the nitro substituent was indicated by 
an upfield shift of the aromatic-proton resonances, to () 7.02 and 6.66, relative to 
compound 6.45. 
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Figure 6.15: Product 6.32 (trans) before irradiation and product 6.32 (cis) following irradiation at 330-
370 nm for 1 hour. 
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Compound 6.34 and nitrosobenzene were then dissolved in acetic acid 
and the solution stirred at room temperature overnight. Workup and purification 
by column chromatography gave 6.32 as an orange solid in a 62% yield. Proton-
NMR analysis reveal two isomers in the ration of 1: 5.7 as determined by inspection 
of the respective integrals. The main isomer had resonances at 8 7.89, 7.50 and 
7.37, due to the phenylazo group, that corresponded with a trans geometry.ll 
Mass spectrometry revealed the expected parent ion. 
Irradiation of 6.32 in CDCI3 for one hour at 330 - 370 nm resulted in a mixture 
with 87% of the cis product, as determined by proton-NMR analysis (Figure 6.15). 
Further irradiation at wavelengths > 400 nm for one hour resulted in a reversion 
such that a mixture containing 83% trans was obtained. These results are 
consistent with reported photostationary-equilibrium ratios for azo isomers 
following irradiation. 12 No by-products due to photoisomerisation were detected 
in the NMR spectra. 
Synthesis of 5-(Stilbenyl)-1-Methyl-2-Piperidone (6.33) 
The preparation of amino piperidone 6.34 provided a useful starting 
material for the synthesis of the styryl-substituted methyl piperidone 6.33 via a 
Sandmyer reaction (Figure 6.14) 
Br 
ii 
o N .. o N 
I I 
Me Me 
6.34 6.36 6.33 
Scheme 6.12:(i) CuBr2, t-butylnitrite, acetonitrile, stirred 3 hours; Iii) styrene, Pd(OAc)2, (o-tol)3P, EbN, 
acetonitrile, lOO°C 24 hours. 
The bromo piperidone 6.36 was prepared using a general method 
described by Doyle et a/. 21 (Scheme 6.12). Compound 6.34 was stirred in 
acetonitrile, together with CuBr2 and t-butylnitrite then quenched with 2 M HCI. 
Workup and purification by radial chromatography gave 6.36 as an oil in a 13% 
yield. 
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Characterisation by proton-NMR spectroscopy revealed a downfield shift in 
the aromatic resonances, relative to 6.34, from 0 7.a2 and 6.66 to 7.46 and 7.12 
respedively. The detection of molecular ions with mass 269 and 267 in the mass 
spectrum confirmed the presence of a bromo substituent. 
Given the relative ease with which compound 6.36 was prepared from 
6.34, no attempt was made to prepared the bromo piperidone compound using 
p-bromobenzyl cyanide. 
Styrene, 5-(4-bromophenyIJ-1 methyl-2-piperidone ,6.36), Pd(Ac)2, (o-tolhP, 
EhN and MeCN, were readed together in a sealed tube at 1 aaeC for 24 hours. 
Workup and purification using pic gave 6.33 as a white solid in a 68% yield. 
Characterisation by NMR spectroscopy showed resonances due to a styryl 
substituent. and the detection of a molecular ion with a mass of 291 was also 
consistent with the attachment of a styryl moiety. 
6.3 ENOLATE MIM ICS 
In all the inhibitors of SR surveyed, one feature is considered essential to 
ensure inhibitory activity: a functionality that acts as a mimic for the proposed 
enolate intermediate formed during -the reduction of T to DHT (see section 5.2). A 
variety of different functionalities have been used to achieve this, including 
lactams, acrylates, dienes and aryl acids, enones, ketoenamines and enols (see 
section 5.2.1 for a discussion). A necessary property of all these functionalities is 
the ability to bind an electrophilic residue in the active site postulated to stabilise 
the negatively-charged enolate intermediate. 
One possible enolate mimic that is, as yet, unreported is a thiolactam. We 
postulated that this functionality would mimic the proposed enolate via a 
resonance structure that is similar those proposed for lactams (Figure 6.16). The 
large sulfur atom may provide enhanced binding to the proposed electrophilic 
residue in the active site and thus increase the potency of inhibitors that contain 
this group. 
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Figure 6.16: Postulated mechanisms of thiolactam enolate mimic. 
Apart from any medical benefits that might be gained by the preparation 
of these mimics, they also provide SAR information, which gives insight into the 
active site of the enzyme. To this end we decided to prepare compounds 6.46, 
6.47, 6.48 and 6.49 (Figure 6.17). The simple structure of compound 6.47 provides 
a control against which the activity of the other derivatives can be compared. 
CI R CI CI 
S S S S 
6.46 6.47 6.48 6.49 
Figure 6.17: Target thioiactams. 
The conversion of a lactam functionality into a thiolactam is readily 
achieved by reaction with Lawesson's reagent.22 A positive result in terms of 
inhibition activity and isozyme selectivity of the thiolactam enolate mimic, means 
that any previously reported lactam-based inhibitoL whether steroidal or non-
steroid-based, can theoretically be converted into the corresponding thiolactam. 
This simple procedure is therefore, a potentially powerful source of novel SR 
inhibitors. 
6.3.1 THIOLACTAMS 
Preparation of all the target thiolactam derivatives was achieved, 
however, the ease with which the transformation to a thiolactam occurred 
seemed to have some dependence on the starting compound. 
Synthesis of Thiolactams 
The preparation of compounds 6.46,6.47,6.48 and 6.49 was via a general 
method described by Lawesson et 01.22 as detailed below. 
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Scheme 6.13:(i) Lawesson's reagent, THF, stir 15 minutes. 
Lactam 6.31, dissolved in dry THF was stirred with Lawessons reagent for 15 
minutes. Filtration and removal of the solvent gave compound 6.46 in a 87% yield 
after recrystallisation. Characterisation by NMR revealed a downfield shift for most 
resonances relative to 6.31. Most notable was a Cl shift of the NMe singlet to (5 
3.49 from 2.98. Analysis by mass spectrometry resulted in the detection of the 
expected parent ion. 
~~D 
OiNU 
I H 
Me 
6.3 
Scheme 6.14:(i) Lawesson's reagent, THF, stir 30 minutes. 
~~D 
SiNU 
I H 
Me 
6.47 
Lactam 6.3, dissolved in dry THF was stirred with Lawesson's reagent for 30 
minutes. Workup and purifica'l'ion using radial chromatography gave compound 
6.47 in a 45% yield. Characterisation by NMR showed a downfield shift for most 
resonances relative to 6.3. Most notable was a downfield shift from (5 2.95 to 3.54 
for the NMe singlet resonance. Mass spectrometry confirmed the transformation 
to the thiol group with the detection of the expected parent ion. 
CI CI CI 
ii 
s 
6.50 6.51 6.48 
Scheme 6.15:(i) NoH, glyme, Mel, reflux 5 hours; (ii) Lawessons reagent, THF, reflux 6 hours. 
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Reaction of compound 6.50 With NaH and iodomethane gave the 
methylated compound 6.51 in a 82% yield. Characterisation by proton-NMR 
spectroscopy revealed an addition resonance, relative to 6.50, at 8 3.19, 
corresponding to the incorporation of a methyl group. 
Lactam 6.51, dissolved in dry THF was stirred wi'th Lawessons reagent for 6 
hours at reflux. Workup and purification using radial chromotogaphy gave 6.48 in 
a 58% yield. Characterisation by NMR showed the characteristic downfield shift 
for most resonances relative to the starting product. Most notable were: the 
resonances for the C5 proton moving from 8 5.29 to 5.70, the C2-proton 
resonances moving from 8 2.70 to 3.23 and the NMe singlet resonance moving 
down field to 8 3.81 from 3.19. 
CI 
s 
6.52 
Scheme 6.16:(i) Lawessons reagent, THF, stir 60°C overnight. 
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Compound 6.52, dissolved in dry THF was stirred with Lawesson's reagent 
overnight at 60°C. Workup and purification using radial chromatography gave 
compound 6.49 in a 54% yield. Characterisation by proton-NMR spectroscopy 
revealed a downfield shift for the C4a resonance, relative to 6.52, from 3.49 to 3.72 
and a shift for the NMe singlet resonance down field to 8 3.57 from 3.03. 
6.4 SUMMARY 
Twelve potential SR inhibitors have been synthesised. Compound 6.12 
contains a photoisomerisable phenylazo group that is envisioned to provide dual-
isozyme-selective properties to the known base benzoquinolinone-type inhibitor. 
Although the position of azo substitution at C9 will not allow direct comparison 
with the styryl-substituted inhibitors prepared by Smith et al.(see section 6.1), the 
activity of this compound will hopefully provide information regarding the 
suitability of substitution in this location. Given the postulated large binding area in 
the SR enzyme for substituents bound in this location of the substrate, this 
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compound is expected to possess good activity. In compound 6.26 the 
incorporation of a styryl moiety is hoped to improve the potency and selectivity of 
the aryl-acid class of tricyclic inhibitor. 
The piperidone compounds have been prepared as bicyclic analogues of 
both the steroidal and tricyclic 4-aza series of SR inhibitors. Incorporation of 
appropriate substituents onto the bicyclic structure, enables direct comparison of 
activity with known potent 4-aza inhibitors. It is envisioned that the piperidone 
compounds might display similar activity and selectivity as observed in the 
benzophenone bicyclic compounds such as 5.81. 
The preparation of four thiolactam derivatives allows investigation of a new, 
potential enolate mimic. As the four derivatives prepared are based on the 4-aza 
series of inhibitor, differences in activity due to the structural differences of 'rhe 
compounds will also provide information about the preferred substrate of the 
enzyme. 
6.5 STRUCTURE A CTIVITY RELATIONSHIPS 
6.S.1 SR ASSAYS 
The compounds prepared were analysed for activity against the SR type-l 
and type-2 isozymes at Lilly Pharmaceuticals. 
6.5.1.1 TYPE-1 ASSAY 
The type-l analysis utilised an assay which measured the conversion of 3H-
labelled T into 3H-labelled DHT by type-l SR isolated from human scalp in a 
method previously described.s The test compounds were dissolved in methanol to 
10, 1 DO, 1000, and 10000 nM concentrations. labeled T (80 nM, 8.07 x 10-3 IlCi 
specific activity 92.41 Ci/mmol) and unlabelled T (0.92 11M) were combined with 
the test compounds to give a total substrate concentration of 1.0 11M in a volume 
of 200 Ill. 
The assay was initiated by the addition of 0.015 0.025 mg of type 1 SR 
homogenate to the substrate and the mixture was then incubated for 1 hour at 
37Q C. Substrates and metabolites were quantified by HPlC separation and in-line 
flow radioactivity detection of the labelled androgens. 
Steroid Sa-Reductase Inhibitors 133 
The activity of the assay was characterised using a known type-1 inhibitor, 
which gave an ICso result of 4.5 nM .. 
6.5.1 .2 TYPE-2 ASSAY 
This assay utilised SR isolated from human prostate 'I'issues in a concentration 
of 11.34 mg per reaction. The concentration of testosterone added was 50 nM 
(specific activity 40.3 Ci/mmol). The reaction was incubated at 25°C for 1 hour. 
The inhibitors were prepared and tested as described for the type-1 assay. The 
assay was calibrated using a known type-2 inhibitor, which gave an ICso value of 
10 nM. A type-1 specific inhibitor was also analysed for activity against the 
enzyme preparation and showed no detectable inhibition at 1 JlM concentration. 
6.5.2 RESULTS 
Compounds 6.26, 6.29, 6.31,,6.32, 6.33, 6.46, 6.47, 6.48 and 6.49 were 
analysed for activity against type-1 and type-2 SR preparations. The results for this 
analysis are shown in Table 6.1 and are reported as ICoo values in either nM 
concentrations or as a percentage inhibition at a constant concentration. 
Table 6.1: Activity of the prepared tricyclic, bicyclic and thiolactam compounds against type-1 and 
t e-2 SR. 
6.26 
6.29 
6.31 I 
6.32 
6.33 
6.46 
I 
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6.5.2. 1 TRICYCLIC COMPOUNDS 
Analysis of compound 6.26 revealed good potency against type-l SR with 
an IC50 value of 152 nM. This shows increased potency relative to the phenyl-
substituted compound 5.91, which gave 45% inhibition of type-1 SR at 2500 nM. 
The potency of 6.26, however, was not as good as that given by the bromo 
substituted aryl acid 5.73 (type-l KI, app 26 nM) .18 The type-2 analysis of compound 
6.26 showed an IC50 value of 340 nM. This value indicates that 6.26 is also a 
respectable type-2 inhibitor and has significantly improved potency relative to the 
bromo-substituted inhibitor 5.73 which has very poor type-2 activity of IC50 =10000 
nM. The potency of 6.26 however is not as great as that found in the styryl-
substituted tricyclic lactam-based inhibitors 5.60 (IC5o type-1 = 6 nM, type-2 = 1400 
nM) and 5.61 (IC5o type-1 = 23 nM, type-2 180 nM),1 
These combined results suggest that the inclusion of a styryl substituent, in 
the appropriate position of the lactam-based and aryl acid-type tricyclic 
inhibitors, results in no significant change to type-1 potency, but gives significant 
improvement in the inhibition of type-2 SR. This type of substituent can 'therefore 
be considered important for the design of dual SR inhibitors. 
6.5.2.2 BICYCLIC COMPOUND S 
An inspection of the results in Table 6.1 shows that the piperidone 
compounds prepared, are in general poorer type-1 SR inhibitors, relative to their 
tricyclic analogues, which show selective, potent inhibition of the type-l isozyme 
(see Table 6.2).5 Potency for this series of bicyclic compounds is increased with a 
lipophilic para substituent on the phenyl ring. The styryl substituted 6.33 showing 
greatest potency with a type-1 IC50 107 nM relative to IC50 values of 302 nM and 
I 
• 
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1690 nM for compounds 6.32 and 6.31 respectively. The unsubstituted compound 
6.29 gave the least potency against type-1 SR with and ICso of 2477 nM. 
The type-2 analysis of the bicyclic compounds has revealed a general 
trend in which the bicyclic derivatives have less potency against the type-2 
enzyme, relative to results found for type-1 activity, However compounds 6.32 
and 6.33 which contain the phenylazo and styryl subs"l"ituents respectively, still 
possess reasonable activity with type-2 ICso values of 579 nM and 617 nM 
respectively. This is in keeping with the tricyclic derivatives 5.60 and 5.61, which 
display good inhibition of type-2 SR, relative to tricyclic inhibitors lacking the styryl 
substituent. This result also points to the usefulness of the styryl group for improving 
type-2 selectivity. 
Overall these results suggest that the B-ring of the tricyclic derivatives is 
important for inhibitor potency. This is possibly due to the increased planarity of 
the tricyclic structure relative to the bicyclic compounds, which have free rotation 
about the piperidone-phenyl bond. 
Table 6.2: Comparison of the type-l and type-2 SR activities of the prepared thiolactam compounds 
1ft th I t I rea Ive 0 e ac am ana ogues. 
Structure Compound Type-l ICso (nM) Type-2 ICso (nM) 
£pCI R S 6.46 I 3360 14%@40IlM I"" 
R N R = 0 6.31 1690 12350 +/- 4300 , 
Me 
& R = S 6.47 1450 19.9% @ 40 IlM R N = ,& R = 0 6.3 560 
'H Me &CI R S 6.48 377 13.2% @ 40 IlM 1,& 
R N '" R = 0 6.50 120 
Me &CI R=S 6.49 183 21.6% @40 IlM 
R 'l'~ R:: 0 6.52 17 
Me 
6.5.2.3 ENOLATE MIMICS 
Table 6.1 shows "rhe thiolactam compounds 6.46, 6.47, 6.48 and 6.49 have 
reasonable potency against type-1 SR. However, their potency relative to the 
lactam inhibitors (6.31, 6.3, 6.50 and 6.52) is significantly reduced as can be seen 
in Table 6.2.5 Given that the major difference between the two sets of inhibitors is 
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the relative sizes of the oxygen and sulfur atoms, these results suggest the enolate-
binding pocket of SR is of a limited size. 
The potency of the thiolactam compounds against the type-2 isozyme is 
poor. This is not unexpected given the general lack of type-2 inhibition displayed 
by the lactam containing compounds. 
6 .. 6 CONCLUSIONS 
The work presented in this chapter has detailed the synthesis and analysis of 
various SR inhibitors. 
This SAR study has shown the importance of a styryl-type substituent for 
improving the type-2 isozyme-selectivity of the inhibitors. This selectivity is 
achieved in most instances without significantly affecting the potency of the 
inhibitors against the type-1 enzyme. 
Our investigations into the effectiveness of bicyclic derivatives have shown 
that the potency of these inhibitors is reduced relative to their tricyclic analogues. 
This result points to the importance of the B-ring for the inhibitory activity of 'rhis 
class of inhibitor, 
The novel enolate-mimic investigated, the thiolactam, displays less potency 
than the analogous lactam mimic. This suggests that the SR enolate binding 
pocket is of limited size. The thiolactam functionality also appears to have no 
influence on the selectivity of the inhibitor for the type-lor type-2 isozyme. 
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7 TA 
7 .. 1 ALPHA ... AMYLA S E PROTOCOL 
1 . 1 GENERAL EQUIP M ENT AND TECHNIQUES 
The "Megazyme" alpha-amylase kit used to assay the prepared derivatives 
was purchased from Deltagen, Australia. 
The alpha-amylase enzymes assayed were obtained from Sigma. The 
inhibitors and reagents used to prepare them are detailed in section 7.2.1. 
Assay solutions were prepared using Eppendorf micropipettes. Unless 
otherwise stated, all aqueous solutions were prepared using triply distilled water. 
The pH of solutions was measured using an in-house digital testmeter. 
The absorbance of the samples was measured at 410 nm using a 
Pharmacia spectrophotometer. 
The assay reagents were prepared and used as described below. 
7. 1 . 1 . 1 ASSAY KIT 
The "Megazyme" alpha-amylase kit contained two vials of substrate, one 
vial of concentrated enzyme extract buffer, one vial of concentrated stopping-
reagent and one vial of control malt flour. 
(I) Substrate 
Each substrate vial contained 
CD Blocked p-nitrophenol maltoheptaoside (BPNPG7, 54.5 mg) 
• Glucoamylase (100 U at pH 5.2) 
• a-Glucosidase (100 U at pH 5.2) 
The entire contents of the vial were dissolved in distilled water (10 mL), and 
the solution was divided into 1 mL aliquots and stored at -24°C. The substrate is 
indefinitely stable at -24°C, and stable for up to seven days when refrigerated. 1 
The concentration of the substrate in solution was 4.03 xl 0-3 M and is referred to as 
either the standard or 1 X concentration of substrate. 
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(ii) Extraction Buffer 
The concentrated extraction buffer contained, 
EfI 1 M sodium malate 
(j 1 M sodium chloride 
e 40 mM calcium chloride 
• 0.1% sodium azide 
The entire contents (50 mL) were diluted to 1 L with distilled water and the 
solution was stored at 6°C. The pH was measured to be 5.2 
(iii) Stopping Reagent 
The concentrated stopping reagent was 20% (w/V) Trizma base. The entire 
contents (25 mL) was diluted to 500 mL with distilled water and stored at room 
temperature. 
7, 1 . 1 .2 INHIBITORS 
Each inhibitor tested was prepared as a O.l-mM solution in deoxygenated 
water. The water was degassed by bubbling N2 through for 5 minutes. In the case 
where the inhibitor was insoluble in water, either a suspension was made or the 
sample was dissolved in distilled ethanol. Solutions were made just prior to use; 
either a 0.50-mL or 0.25-mL volume. 
Five different alpha-amylase enzymes were used in the assay. Solutions of 
these enzymes were prepared such that the absorbance at 410 nm of each at 
the end of the 10 minutes assay, without inhibitor, was between 0.6 and O.B. 
(i) Type VIII-A Barley Malt (2.1 U / mg solid) 
Barley malt (2.3 mg) was dissolved in enzyme extract buffer (20 mL) and 
stored on ice until required. New solutions were prepared every 3 hours. For the 
purposes of description, this concentration of enzyme is referred to as the 
standard or 1 x concentration. 
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(Ii) Type X-A Fungal Crude from Aspergillus Oryzae (40.0 U / mg solid) 
Fungal alpha-amylase (l.0 mg) was dissolved in enzyme extract buffer (1 
mL). This solution was used as the enzyme concentrate from which later dilutions 
were prepared. This stock solution was stored at -24°C. An aliquot of the stock 
solution (5 J.lL) was diluted with enzyme extract buffer to a volume of 1 mL. An 
aliquot of this new solution (250 J.lL) was further diluted with buffer to 1 mL and 
stored on ice until required. New solutions were prepared every 3 hours. 
(iii) Type II-A Bacillus Species (1,820 U / mg solid) 
Bacillus-species alpha-amylase (l.0 mg) was dissolved in enzyme extract 
buffer (1 mL). This solution was used as the enzyme concentrate from which later 
dilutions were prepared. This stock solution was stored at -24°C. An aliquot of the 
stock solution (20 !lL) was diluted with enzyme extract buffer to a volume of 1 mL. 
An aliquot of this new solution (20 J.lLJ was further diluted with buffer to 1 mL and 
stored on ice until required. New solutions were prepared every 3 hours. 
(iv) Type I-A OFP Treated from Porcine Pancreas (790 U / mg protein) 
Porcine-pancreas alpha-amylase (33.33 J.lL) was mixed with enzyme extract 
buffer (1 mL). This solution was used as the enzyme concentrate from which later 
solutions were prepared. This stock solution was stored at 6°C. An aliquot of the 
stock solution (50 J.lL) was diluted with enzyme extract buffer to a volume of 1 mL. 
An aliquot of this new solution (30 J.lL) was further diluted with buffer to 1 mL and 
stored on ice until required. New solutions were prepared every 3 hours. 
(v) Type XIII-A Crude from Human Saliva (72.0 U / mg solid) 
Human-saliva alpha-amylase (1.0 mg) was dissolved into enzyme extract 
buffer (1 mL). This solution was used as the enzyme concentrate from which later 
solutions were prepared. The stock solution was stored at -24°C. An aliquot of the 
stock solution (20 mL) was diluted with enzyme extract buffer to a volume of 1 mL 
and stored on ice until required. New solutions were prepared every 3 hours. 
7.1 METHOD 
The following methods were used to collect data for determination of 
inhibition activities and kinetic analysis. 
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7.1.2.1 INHIBITION ASSAYS 
The inhibition results were obtained using the following assay procedures. 
Unless otherwise stated all measurements were collected in triplicate. 
(i) The Blank 
Into a plastic cuvette was placed 50 !!L of water. The cuvette was allowed 
to equilibrate to 40°C for 2 minutes in a water bath. The assay substrate (50 !!L), 
also equilibrated to 40°C, was then added and after exactly 10 minutes,stopping 
reagent (750 !!L) was added to the cuvette. The cuvette was removed from the 
water bath and used as a blank for all subsequent readings. The absorbance 
reading of this solution at 410 nm was set to zero. 
(ii) The Controls 
Prior to running any assays, a control was used to determine the 
absorbance of the substrate in the absence of any inhibitors. A control was also 
run with each inhibitor assayed, in order to monitor any decrease in the activity of 
the enzyme over time. 
Into each plastic 1 mL cuvette was placed an aliquot of water' (5 !!L) and 
an aliquot of alpha-amylase enzyme solution (45 !!L). The mixture was allowed to 
equilibrate at room temperature for 20 minutes. The cuvettes were then placed 
into a 40°C water bath and allowed to reach equilibrium over 2 minutes. The 
substrate (50 !!L) also equilibrated to 40°C was then added to the cuvette. After 
exactly 10 minutes, stopping reagent (750 ""L) was added to the cuvette, which 
was then removed from the water bath. The absorbance at 410 nm of each 
control was measured relative to the blank. 
(iii) The Inhibitors 
Into each plastic 1-mL cuvette was placed an aliquot of inhibitor solution (5 
""L) and an aliquot of alpha-amylase enzyme solution (45 ""L). The mixture was 
allowed to equilibrate at room temperature for 20 minutes. The cuvettes were 
then placed into a 40°C water bath and allowed to reach equilibrium over 2 
minutes. The substrate (50 ""L), also equilibrated to 40°C, was then added to the 
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cuvette. After exadly 10 minutes, stopping reagent (750 J..lL) was added to the 
cuvette, which was then removed from the water bath. The absorbance of each 
inhibitor at 410 nm was measured. 
(iv) Calculation of Inhibitor Activity and Errors 
The inhibitory activity of the prepared derivatives was determined by 
calculating the average absorbance for each inhibited sample as a percentage 
of the average of the controls. These values were then converted to a 
percentage inhibition of the enzyme. The reported values are the average of at 
least three measurements. 
The absolute error associated with these values was determined to be 
approximately 10% by taking the 95% confidence interval for the mean of each 
set of measurements as a percentage of the average uninhibited absorbance. 
7.1.2.2 LINEARITY OF THE ASSAY 
Linearity of the assay over time was measured at six different enzyme and 
six different substrate concentrations. The different enzyme concentrations were 
measured against the standard substrate concentration and the different 
substrate concentrations were measured against the standard enzyme 
concentration (see section 4.3.1.1 for results). 
Into a plastic l-mL Eppendorf tube was placed an aliquot of water [50 J..lLJ 
and an aliquot of enzyme solution (450 J..lLJ, (2x, 3/2x, lx, 3/4x, 1/2x and 1/4x 
original concentration). The mixture was allowed to equilibrate at room 
temperature for 20 minutes. The Eppendorf was then placed into a 40°C water 
bath and allowed to reach equilibrium over 2 minutes. The substrate (500 J..lL; 2x, 
1 x, 1/2x, 1 14x, 1 16x and 1/8x original concentration), also equilibrated to 40°C, was 
then added to the Eppendorf and the mixture shaken. At 1-, 3-, ..... , 10-minute 
intervals after initiation, an aliquot (100 J..lL) was removed from the bulk mixture and 
added to 750 J..lL of stopping reagent in a cuvette. The absorbance at 410 nm of 
each aliquot was then measured . 
• When a control was required for an inhibitor prepared in ethanol, a 5 I-lL aliquot of 
ethanol was added to the cuvette instead of water. 
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The linearity of the assay over time was also measured in the presence of 
inhibitor. Into ten plastic 1-ml cuvettes was placed an aliquot of O.l-mM inhibitor 
solulion (5 Ill) and enzyme solution (45 Ill). The mixtures were allowed to 
equilibrate to room temperature for 20 minutes. The cuvettes were then placed 
into a 40°C water bath and allowed to reach equilibrium over 2 minutes. To each 
cuvette, an aliquot of substrate (50 Ill) also equilibrated to 40°C, was added. 
Each of -the ten cuvettes was reacted for a different leng-th of -time, ranging from 1 
minute, to 10 minutes. After the allocated time, the reaction was quenched by 
the addition of stopping reagent (750 Ill) to the cuvette. The absorbance at 410 
nm of each sample was measured relative to the blank. 
7.1 .2.3 INHIBITOR INCUBATION: SUBSTRATE VERSUS ENZYME 
The following experimental protocol was used to compare -the incuba'l'ion of -the 
inhibitor with the enzyme versus incubation of the inhibitor with the substrate. 
(i) Inhibitor Plus Substrate 
Into three 1-ml cuvettes was placed an aliquot of O.l-mM ascorbic-acid 
solution (5 Ill) and substrate solution (50 Ill). The mixtures were equilibrated to 
room temperature for 20 minutes, -then placed into a 40°C water ba-th and 
allowed to reach equilibrium over 2 minutes. To each cuvette, an aliquot of 
enzyme solution (45 Ill) also equilibrated to 40°C, was added. Each of the 
cuvettes was reacted for 10 minutes, then quenched by the addition of stopping 
reagent (750 Ill). The absorbance of each sample at 410 nm was then measured. 
(ii) Inhibitor Plus Enzyme 
The inhibitor was incubated with enzyme and reacted as previously 
described in section 7.1.2.1. 
T bl 7 1 R It f' h'b't ' b r a e .. esu s 0 In I I or Incu a Ion expenmen s. 
Experimental protocol Average absorbance at 410 nm 
Incubation of the inhibitor with the substrate 0.073 
Incubation of the inhibitor with the enzyme 0,062 
Control experiment containinQ no inhibitor 1.011 
7.1.2.4 ACETAL HYDROLYSIS 
The following procedure was carried out to determine if acetal hydrolysis 
occurred in inhibitors under the reaction conditions of the assays. 
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Product 3.1 and product 3.12 were dissolved in D20 and CDCi3 respectively 
and immediately analysed by proton-NMR spectroscopy (for proton-NMR data 
see section 7.2.2.1). The samples were then subjected to the same temperature 
and time conditions as occur in the Megozyme assay: They were equilibrated at 
room temperature for 20 minutes, then placed in a 40°C water bath for 12 minutes 
and subsequently re-analysed by proton NMR spectroscopy. 
7.1.2.5 UNINHIBITED-ENZYME KINETIC ASSAYS 
The following reagents and protocols were used to gather data for kinetic analysis. 
(i) Substrate 
Substrate solutions were prepared, based on the standard (1 xl 
concentration recommended by the suppliers as described in section 7.1.1.1 (il. 
Concentrations of 2x, l.7x, 1.5x, l.4x, 0.75x, O.7x, 0.5x, 0.25x were made by suitable 
dilution with distilled water. 
(Ii) Enzyme 
The enzyme used for the kinetic analysis was barley-malt alpha-amylase. 
The concentration of the enzyme solution was such that the absorbance at 410 
nm after the 10 minutes assay, with no inhibitor and standard substrate 
concentration, was between 0.6 and O.B. Solutions were prepared as described in 
section 7.1 .1 .3. 
(iii) Inhibitors 
The inhibitors used for kinetic analysis were ascorbic acid and product 3.1. 
The concentrations of the inhibitor solutions were prepared such that the highest 
and lowest values would give absorbance readings of between 0.0 and 1.0 over 
all substrate concentrations at 410 nm. For each inhibitor, four solutions were 
prepared within the concentration ranges shown below. 
.. Ascorbic acid = 5.1 2 x 10-4 M - 2.00 x 10-3 M 
.. Product 3.1 = 3.27 x 10-4 M - 1.31 X 10-3 M 
(Iv) Blanks and Controls 
Assay blanks and controls were determined using the same protocols as 
described previously for the inhibition assays (section 7.1.2.1). 
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7.1.2.6 INHIBITED-ENZYME KIN ETIC ASSAYS 
Solutions of each inhibitor were prepared at four different concentrations 
and assayed against a standard enzyme solution at various concentrations of 
substrate. The concentrations reported below refer to the concentration in the 
assay mixture. 
Each assay was performed using "the standard procedures previously 
described in section 7.1.2.1. 
(i) Ascorbic acid 
Enzyme concentration: equal to the standard enzyme solutions as 
described in section 7.1.1.3. 
Inhibitor concentrations: = lx (2.0 xlO-3 M), O.72x [1.453 x 10-3 M), O.5x 
(01.022 x 10-3 MJ, O.25x (5.11 x 10-4 M). 
Substrate concentrations: = 2x (4.031 X 10-3 MJ, 1.5x (3.023 x 10-3 M), lx 
(2.016 xl 0-3 M), O.75x (1.512 x 10-3 M), O.5x (1.008 x 10-3M). 
(ii) Product 3.1 
Enzyme concentration: = equal to the standard enzyme solu1"ions as 
described in section 7.1.1.3. 
Inhibitor concentrations: lx (1.309 x 10-3 M), O.75x (9.815 x 10-4 M), O.5x (6.544 
x 10-4 M), O.25x (3.272 x 10-4 M). 
Substrate concen"tra"l"ions: 2x (4.0311 x 10-3 M), 1.7x (3.4264 x 10-3 M), lAx 
(2.822 x 10-3 MJ, lx (2.016 X 10-3 M), O.7x (1.411 x 10-3 M). 
7.2 SYNTHESIS 
7.2.1 GENERAL EQUIP MENT AND TECHNIQUES 
7.2.1.1 REAGENTS AND EQUIP MENT 
All reaction vessels were either flame-dried or oven-dried overnight (> 
110°C), assembled and then cooled to room temperature under a dry N2 
atmosphere. All solvents were distilled using known literature procedures.2•3 Dry 
solvents were distilled and collected just prior to use. 
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L-ascorbic acid was obtained from PSM Holdings Ltd., D-isoascorbic acid 
and dihydroxyfumaric acid were purchased from Sigma, dehydroascorbic acid 
was kindly gifted by S. Fayle. 1 Ob-methyl-8-chloro 1 ,2,6-trihydrobenzo [f] quinolin-3-
one, 1 Ob-methyl-8-chloro-4-methyl-1 ,2,4a,5,6-pentabenzo[f]quinolinone and 9,10-
dihydrophenanthrene-2-carboxylic acid were kindly gifted by Eli Lilly. 
Reaction temperatures reported refer to oil bath temperature. 
Melting points were recorded on an electrothermal melting-point 
apparatus and are uncorrected. 
The rotary vein vacuum pump had a measured pressure of 2 mmHg. 
Hydrogenation procedures were carried out using a Parr Instruments 
Company Inc. pressure reaction apparatus model 4513 with 40 psi H2 at room 
temperature. 
Vacuum distillations were performed using a Buchi GKR 50 Kugeral 
distillation apparatus connected to a vacuum pump. 
All radial chromatography was performed on a Harrison Research Inc. 
Chromatotron model 7924. Radial chromatography plates of 1 and 2 mm 
thickness were prepared using silica gel 60 
in the instruction manual.4 
containing gypsum as described 
All column chromatography was performed using Silica 60 200-400 mesh 
flash silica. Thin layer chromatography (tic) and preparative thin layer 
chromatography (pic) was run on aluminium-backed Silica gel 60 h45 sheets. 
Unless otherwise stated eluting solvents are appropriate mixtures of ethyl acetate 
and petroleum ether (boiling fraction 50 - 70°C) or ethyl acetate and methanol. 
Irradiation of compounds for photoisomerisation experiments was 
performed using a 200-watt mercury high-pressure arc lamp. The required 
wavelengths were selected using appropriate filters. 
7.2.1.2 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
All proton spectra, nOe, and 2D experiments (HMQC, HMBC) were 
recorded on a Varian Unity 300 instrument (300 MHz). Carbon spectra were 
recorded on either a Varian Unity 300 or a Varian XL 300 (75 MHz). The solvent 
used was either COCl3 containing tetramethylsilane (TMS) as an internal standard, 
020 referenced at 4.7 ppm, or C03COC03 referenced to 2.17 ppm. Chemical 
shifts are reported as parts per million [ppm) downfield from the TMS resonance (8 
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0.0) or referenced to the D20 or CD3COCD3 resonances for proton spectra. For 
carbon spectra resonances are referenced relative to the CDCb resonance (6 
77.0) or the CD3COCD3 resonances (6 29.2, 204.1). Resonances in the proton 
spectra are described as singlet (sL broad singlet (bs), doublet (d), triplet (t), 
quartet (q] doublet of doublets (dd) doublet of triplets (dt) or multiplet (mJ. 
Resonances are assigned as H#, where # represents the numbering of the carbon 
atoms to which the protons that contribute to the resonances are attached, in the 
compound concerned. 
7.2.1.3 MASS SPECTROMETRY 
Mass spectra were recorded on either a Kratos MS80RFA mass 
spectrometer, for samples analysed by electron impact (EI-MS) or fast atom 
bombardment (FAB-MS), or a Micromass LCT mass spectrometer, for samples 
analysed using an electrospray (ES-MS) technique. El-MS was performed typically 
at 70eY with 4kY accelerating voltage. FAB-MS analysis utilised a ni'trobenzyl 
alcohol matrix with xenon as the carrier gas. The ion gun used was a lontech 
ZN1'I NE. Found masses are reported, along with a calculated mass, accurate to 
four decimal places. 
7.2. 1 .4 INFRA-RED SPECTROM ETRY 
Infrared spectra were recorded on a Shimadzu FTIR 8201 PC 
spectrophotometer. Compounds were prepared as nujol mulls on KBr discs. 
Bands are reported using the wavenumber scale in cm-'. 
7.2.1.5 X-RAY CRYSTALLOGRA PHY 
Crystallography intensity data were collected with a Siemens P4s four-circle 
diffractometer using monochromatised Mo Ka. radiation. Cell parameters were 
determined by least-squares refinement of at least 25 accurately centred 
reflections (20 > 24°). Throughout the data collections the intensities of three 
standard reflections were monitored at regular intervals, which showed no 
significant crystal decomposition. The structures were solved by direct methods 
using SHELXS90,5 and refined using SHELXL93,6 on F2 using all data. The functions 
minimised were (:2:co(Fo2 -Fe2) with co == [cr2(Fo2) + aP2 + bP]-' where P == [max(Fo2 + 
2Fc)J/3. The hydrogens were included in calculated positions and assigned 
isotropic displacement parameters 1.3 times the isotropic equivalent of their 
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carrier atoms. In all cases the final Fourier synthesis did not show any significant 
residual electron density in chemically-sensible locations. 
EXPERIMENTAL CHAPTER 3 
7.2.2.1 ASCORBIC-AcID DERry ATIYES 
Where indicated, ascorbic-acid derivatives were prepared according to 
literature procedures. 
Me 
Me+~ 0 
O~O 
HO OH 
(i) 5,6 -Isopropylidene-L-Ascorbic Acid {3.1)7 
Ascorbic acid (10 g, 0.06 mol), acetone (40 mL) and acetyl chloride (1 mL, 
0.02 mol) were stirred at room temperature for 3 hours, then refrigerated for 8 
hours. The precipitate that formed was isolated by vacuum filtration and washed 
with a small amount of cold acetone, then air-dried. Recrystallisation from 
acetone-petroleum ether gave 3.1 as a white solid (10.3 g, 84%): mp 209-211 °C (lit 
mp7 195 - 200°C); lH NMR (020) (54.85 (d, J = 2.5 Hz, 1 H, H4), 4.52 (m, 1 H, H5), 4.23 
(m, 1H, H6a), 4.10 (dd, J = 4.0 Hz, 9.5 Hz, lH H6b), 1.30 (s, 6H, 2 x Me); 13C NMR 
(020) (526.09,26.91, 67.20, 75.06,77.99,112.94,134.15,145.12,174.14; IR: \)max 1665, 
1753 cm-1; EI-MS: mlz 216 [M+], HRMS C9H1206 requires 216.06339, found 216.06355. 
(ii) 3-0-Methyl-5,o-lsopropylldene-L-Ascorbic Acid {3.2)B, 2-Acetyl-3-0-Methyl-
5,o-lsopropylidene-L·Ascorbic Acid (3.3) 
Ory NaHC03 (0.25 g, 2.97 mmol) was added to a solution of compound 3.1 
(0.5 g, 2.34 mmol) in OMSO (10 mL) and the mixture vigorously stirred for 20 
minutes. lodomethane (0.2 mL, 2.16 mmol) was added drop-wise to the mixture 
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over 30 minutes and then the mixture was heated to 50°C and stirred overnight. 
The mixture was cooled to room temperature, diluted with water (20 mL), 
neutralised with 2M aqueous HCI (universal indicator paper) and then extracted 
with ethyl acetate (3 x 20 mL). The organic layers were combined, dried over 
Na2S04 and "rhe solvent was evaporated under reduced pressure to give a yellow 
oil which was purified by radial chromatography (30% ethyl acetate/petroleum 
ether) to give 3.2 (0.1 g, 19%) lH NMR (CDCI3) 84,54 (d, j = 3.9 Hz, 1 H, H4), 4.25 (m, 
1H, H5), 4.18 (s, 3H, 3-0Me), 4.13 (dd, j = 8.3 Hz, 6.3 Hz, 1H, H6a), 4.04 (dd, j = 8.3 
Hz, 6,3 Hz, 1H, H6b), 1.39 (s, 3H, Me), 1.36 (s, 3H, Me). 
Compound 3.3 was isolated during the purification of product 3.2, the 
preparation of which is reported above. Removal of the eluting solvent under 
reduced pressure gave 3.3 as a white solid (0.05 g, 8%), mp 89-90°C: I H NMR 
(CDCI3) 84.67 (d, j = 3.0 Hz, 1 H, H4), 4.36 (m, 1 H, H5), 4.16 (dd, j = 8.8 Hz, 6.8 Hz, 1 H, 
H6a),4.08 (m, 4H, H6b & 3-0Me), 2.29 {s, 3H, COMe}, 1.40 (s, 3H, Me), 1.36 (s, 3H, 
Me); 13C NMR (CDCI3) 820.20,25.50,25.72,59.27,65.13,73.50,75.08, 110.63, 114.59, 
160.76, 168.01; IR: Umax 1695, 1769, 1780 cm-l; EI-MS: m/z 272 [M+], HRMS Cl2H1607 
requires 272.08960, found 272.08960. 
HO 
-:; 0 HO~O 
MeO OH 
(iii) 3-0-Methyl-L-Ascorbic Acid (3.4) 
2 M HCI (1 mL) was added to product 3.2 (0.1 g, 0.43 mmol) dissolved in 
methanol (1.5 mL) and the mixture stirred at 50°C overnight. The mixture was 
cooled to room temperature and the solvent evaporated under reduced 
pressure. Purification by radial chromatography (30% ethyl acetate/petroleum 
ether) gave product 3.4 as an oil in a 56% yield: IH NMR (CDCI3) 84.82 (d, j = 1.9 
Hz, 1 H, H4), 4.08 (s, 3H, 3-0me), 3.91 (m, 1 H, H5), 3.62 (d, j = 6.8 Hz, 2H, H6), EI-MS: 
m/z 190 [M+], HRMS, ClOH1406 requires 190.04774, found 190.04767. 
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Me 
Me+~ 0 
O~O 
MeO OMe 
(iv) 2t3-Di-O-Methyl-St6-lsopropylidene-L-Ascorbic Acid (3.5) 
To a stirred solution of 3.1 (0.10 g, 0.46 mmol) and K2C03 (0.19 g, 1.4 mmol) 
in acetone (1 mL, 0.023 mol) was added dimethyl sulfate (0.2 mL, 2.2 mmol) 
dropwise over 15 minutes. The mixture was then heated and refluxed overnight. 
The resulting yellow solution was cooled to room temperature and the excess 
K2C03 was removed by vacuum filtration. The solid residue was washed with cold 
acetone until the yellow colour was removed and the combined acetone 
solutions were concentrated under vacuum. The residue was refrigerated and 3.5 
crystallised out of solution as white needles, which were vacuum filtered, washed 
with a small amount of cold ether and air-dried (0.33 g, 29 %): mp 93-96°C (lit mp7 
90-94°C); lH NMR (CDCb) 04.51 (d, J = 3.5 HZ, 1 H, H4), 4.28 (dt, J 3.0 Hz, 6.5 Hz, 
1H, H5), 4.15 (s, 3H, 3-0Me), 4.13 (dd, J = 6.5 Hz, 8.5 Hz, lH, H6a), 4.03 (dd, J = 6.5 
Hz, 8.5 Hz, 1 H, H6b), 3.86 (s, 3H, 2-0MeL 1.39 (s, 3H, Me), 1.36 (s, 3H, Me); 13C NMR 
(CDCb) 0 25.54, 25.80, 59.45, 60.32, 65.22, 73.83, 74.44, 110.36, 123.20, 156.67, 
168.90; IR: Umax 1679, 1760, 2853, 2928 em-I; EI-MS: mlz 244 [M+], HRMS CllH1606 
requires 244.09469 found 244.09421. 
HO 
-== 0 HO~O 
MeO OMe 
(v) 2,3-Di-O-Methyl-L-Ascorbic Acid (3.6) 
Compound 3.S (0.5 g, 2.05 mmol) was dissolved in dry methanol (8 mL). To 
this solution was added 2 M aqueous HCI (5 mL) and the mixture was heated to 
50°C and stirred for 4 hours. The mixture was cooled to room temperature and the 
solvent evaporated under reduced pressure. The resulting yellow solid was dried 
under vacuum to give 3.6, which was recrystallised from ether (0.3 g, 70%): mp 56-
57°C (lit mp9 63°C); lH NMR (CDCb) 0 4.68 (d, J = 2.5 Hz, 1 H, H4), 4.17 (s, 3H, 3-
OMe), 3.93 (m, 1 H, H5), 3.85 (s, 3H, 2-0Me), 3.80 (m, 2H, H6); 13C NMR (CDCb) 0 
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59.49, 60.54, 63.23, 69.92, 75.80, 122.90, 157.97, 169.84; IR: Umax 1678, 1769 cm-1; El-
MS: mlz 204 [M+], HRMS CSH1206 requires 204.06339, found 204.06319. 
HO 
-:: 0 Meoco~O 
MeO OMe 
(vi) 2,3-Di-O-Methyl-6-Acetyl-L-Ascorblc Acid (3.7) 
The above procedure for preparation of compound 3.6 was repeated 
using compound 3.S (l.0 g, 4.1 mmol), methanol (15 ml) and 2M aqueous HCI (8 
ml). After refluxing the mixture for 4 hours at 50°C, the solution was cooled and the 
product extracted with ethyl acetate (3 x 20 mL). The organic layers were 
combined, washed with brine and dried over Na2S04. The solvent was 
evaporated under reduced pressure to give a pale yellow oil that was dried under 
vacuum to give 3.7 as a solid which was recrystallised from ether as colourless 
prisms (0.74g, 74%): mp 95-99°C; lH NMR (CDCh) 04.66 (d, J = 2.5 Hz, 1 H, H4), 4.34 
(dd, J = 7.0 Hz, 12.0 Hz, 1H, H6a), 4.22 (dd, J 5.0 Hz, 12.0 Hz, 1H, H6b), 4.16 (s, 3H, 
3-0MeJ, 4.09 (m, 1H, H5), 3.85 (s, 3H, 2-0Mel, 2.11 (s, 3H, Me); 13C NMR (CDCI3) 0 
20.81, 59.55,60.47,64.83,68.01, 75.09,123.15,156.95,169.13,171.01; IR: Umax 1672, 
1735, 1747 cm-1; EI-MS: mlz 246 [M+], HRMS ClOH1407 requires 246.07395, found 
246.07362 
MeOeO 
-:: 0 MeOCO~O 
MeO OMe 
(vii) 2,3-Di-O-Methyl-S,6-Diacetyl-L-Ascorbic Acid (3.8) 
Compound 3.6 (0.2 g, 1 .14 mmol) was dissolved in pyridine (2 mLJ, acetic 
anhydride (1 mL 0.014 mol) added drop-wise and the mixture stirred for 2 hours. 
The solvent was removed under reduced pressure and the resulting oil was dried 
under vacuum overnight. The resulting solid was recrystallised from ether to give 
3.13 as platelets (0.08 g, 24%): mp 68-70°C; lH I\JMR [CDChl 05.35 (m, 1 H, H5J, 4.78 
(d J = 2.0 Hz, 1 H, H4J, 4.36 (dd, J = 5.5 Hz, 11.5 Hz, 1 H, H6a), 4.26 (dd, J = 7.0 Hz, 11.5 
Hz, 1 H, H6b), 4.10 (s, 3H, 3-0Me), 3.84 (s, 3H, 2-0Me), 2.07 (s, 6H, 2 x Me); 13C NMR 
Experimental 153 
(CDCl3) 8 20.36, 20.55, 59.41, 60.33, 61.95, 67.59, 73.29, 123.16, 155.72, 168.36, 
169.38,170.22; IR: Umax 1690,1744,1774,2341, 2360 cm-'; EI-MS: m/z (228,11), (186, 
100). 
MeOCO 
-::: 0 MeOCO~O 
HO OH 
(viii) 5,o-Diacetyl-L-Ascorbic Acid (3.9)10 
Ascorbic acid (0.88 g, 5.0 mmol) and acetic anhydride (1.2 mL 0.02 mol) 
were mixed together with 2 drops of concentrated aqueous H2S04. The 
temperature of the mixture increased to approximately 40°C and was stirred for 2 
hours with gentle heating. The resulting amber-coloured syrup was evaporated 
under reduced pressure, seeded with ascorbic-acid crystals and left standing for 3 
days. Product 3.9 formed as needle-shaped crystals, which were washed with 
cold ether to remove the syrup, air-dried and recrystallised from nitromethane 
(O.24 g 18%): mp 144-146°C (lit mplO 154°C): lH NMR (CD3COCD3) 8 5.43 (m, "!H, 
H5), 4.99 (d, J == 2.93 Hz, 1 H, H4), 4.37 (dd, J = 4.88 Hz, 11.72 Hz, 1 H, H6a), 4.23 (dd, J 
7.32 Hz, 11.27 Hz, 1 H, H6b), 2.00 (s, 3H, Me), 1.97 (s, 3H, Me); 13C NMR 
(CD3COCD3)) 819.81, 19.92,62.22,67.89,73.70,87.90, 102.99; IR: Umax 1670, 1707, 
1742 cm-l. 
HO 
-::: 0 EtOOO~O 
MeO OMe 
Ox) 2,3-Di-O-Methyl-o-Propionyl-L-Ascorbic Acid (3.10) 
Compound 3.0 (O.5 g, 2.45 mmol) and a catalytic amount of p-
toluenesulfonic acid (p TSA) were dissolved in ethyl propionate (10 mL 0.14 mol). 
The mixture was heated to 70°C and stirred for 16 hours. The solution was then 
cooled to room temperature, washed with a saturated NaHC03solution and dried 
over Na2S04. The solvent was removed under reduced pressure to give a yellow 
oil that was dried under vacuum overnight. Purification by radial chromatography 
(30% ethyl acetate/ petroleum ether) gave 3.10 as a yellow oil; (0.08 g, 12%) 'H 
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NMR (CDCI3) 84.65 (d, J = 2.0 Hz, 1 H, H4), 4.35 (dd, J = 12.2 Hz, 6.3 Hz, 'I H, H6a), 4.24 
(dd, J = 10.7 Hz, 4.8 Hz, 1 H, H6bJ, 4.16 (s, 3H, 3-0Me), 4.08 (m, 'jH, H5J, 3.84 (s, 3H, 2-
OMeJ, 2.38 (q, J = 6.8 Hz, 15.0 Hz, 2H, CH2MeJ, 1.15 (t, J = 7.5 Hz, 3H, CH2Me); 13C 
NMR (CDC13) 88.97,27.38,59.51, 60.43, 64.71, 68.05, 75.05,123.12,156.88,169.06, 
174.45; IR: l)max 1678, 1765 cm-1; EI-MS: mlz 260 [M+J, HRMS Cll H1607 requires 
260.08960, found 260.08782 
HO 
-:: 0 PrOco~o 
MeO OMe 
(x) 2,3-Di-O-Methyl-6-Butyryl-L-Ascorbic Acid (3.11) 
Compound 3.6 (0.5 g, 2.45 mmol) was dissolved in ethyl butyrate (10 mL, 
0.12 mol) and a catalytic amount of pTSA added. The mixture was heated and 
stirred for 16 hours at 70cC. The solution was then cooled to room temperature, 
washed with a saturated NaHC03solution and dried over Na2S04. The solvent was 
removed under reduced pressure to give a yellow oil that was dried under 
vacuum overnight. Purification by radial chromatography (30% ethyl acetatel 
petroleum ether) gave 3.11 as a yellow oil (0.05g, 7%) lH NMR (CDCI3) 84.65 (d, J = 
2.5 Hz, 1 H, H4J, 4.35 (dd, J = 11.7 Hz, 6.8 Hz, 1 H, H6aJ, 4.23 (dd, J = 11.7 Hz, 4.8 Hz, 
1 H, H6bJ, 4.16 (s, 3H, 3-0MeJ, 4.09 (m, 1 H, H5), 3.85 (s, 3H, 2-0Me), 2.34 (t, J = 7.3 
Hz, 2H, CH2CH2Me), 1.67 (q, J = 15.0 Hz, 8.0 Hz, 2H, CH2CH2Me), 0.96 (t, J = 7.3 Hz, 
3H, CH2CH2Me); 13C NMR (CDCl3) 8 13.61, 18.32,35.93,59.51, 60.43, 64.57, 68.02, 
75.06, 123.11, 156.93, 169.13, 173.64; EI-MS: mlz 274 [M+], C12H1807 requires 
274.10525, found 274.10519 
HO 
-:: 0 0 Me(H2C)140CO~ 
HO OH 
(xi) 6-Palmitate-L-Ascorbic Acid (3.12)11 
Palmitic acid (4.15 g, 0.016 mol) was added to a solution of ascorbic acid 
(2.11 g, 0.012 mol) in H2S04 (10 mL). The mixture was heated and stirred for 2 hours 
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at 2S-30°C until it became homogenous. The resulting yellow syrup was left to 
stand for 2 days at room temperature during which time the colour intensified. 
The syrup was then poured onto crushed ice, stirred, then extracted with ether, 
washed gently with brine and dried over Na2S04. The solvent was evaporated 
under reduced pressure to give a white solid, which was washed extensively with 
petroleum ether to remove umeacted palmitic acid and the remaining 3.12 was 
air dried [2.B g, 42%): mp 112-116aC [lit mpll 11S-116°C); lH NMR [COCb/OMSO) 0 
4.66 (d, J == 2.S Hz, 1 H, H4), 4.2B (dd, J == 6.B Hz, 11.2 Hz, 1 H, H6a), 4.20 (dd, J == S.B Hz, 
11.2 Hz, 1 H, H6b), 4.0B (m, 1 H, HS), 2.33 (t, J == 7.S Hz, 2H, COCH2), 1.61 (m, 2H, 
COCH2CH2), 1.2S (s, 26H, (CH2)13), 0.B7 (t, J == 6.S Hz, 3H, Me). 
HO 
-:: 0 HO~O 
HO OH 
(xli) l-Gulono-1.4-Lactone (3.13)12 
A solution of ascorbic acid (S g, 0.03 mol) in water (40 mL) was 
hydrogenated over 10% Pd/C (O.S g) in a Parr Hydrogenator at room temperature 
and 40 psi of hydrogen for 72 hours. The resultant solution was then filtered 
through celite to remove the Pd/C and the water evaporated under vacuum to 
give a white solid. 3.13 was recrystallised from methanol-ethyl acetate as 
colourless prisms (1.29 g, 2S%): mp 1B2-1BSoC (lit mp12 1BO-1B1 aC): lH NMR (020) 0 
4.64 (d, J == 4.4 Hz, 1 H, H4L 4.43 (m, 2H, H2 & H3), 3.97 (m, 1 H, HS), 3.7 (dd, J == 12.2 
Hz, 3.4 Hz, 1H, H6a), 3.S9 (dd, J == 12.2 Hz, S.8 Hz, 1H, H6b); 13C NMR (020) 063.62, 
71.70,72.21, 72.93, 83.47, 1 BO.07; IR: Umax 1782 cm-'; EI-MS: m/z (147, 6), (11B, 9), (BS, 
26), (73, 100) 
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O. H 0 
HO OH 
(xiii) 5,6-lsopropylldene-D-lsoascorbic Acid (3.14)13 
D-isoascorbic acid (10.0 g, 0.06 mol) and dimethoxypropane (10 mL 0.13 
mol) were suspended, with stirring, in boiling acetone (100 ml). To this mixture 
SnCI3 (0.02 g, 0.35 mmol) was added and the suspension dissolved to give a clear 
solution. The mixture was reacted for 15 minutes, quenched by the addition of 
pyridine (50 Ill) and then cooled to room temperature. The solvent was 
evaporated under reduced pressure to give a white, waxy solid, which was 
washed with dichloromethane to give 3.14 as a white solid which was vacuum 
filtered then washed with dry ether r8.12 g, 64%) mp 135-137°C; lH NMR (D20) 
54.88 (d, J 3.0 Hz, 1H, H4), 4.53 (m, 'IH, H5), 4.04 (dd, J = 9.3 Hz, 7.3 Hz, 'IH, H6a), 
3.89 (dd, J = 9.3 Hz, 5.3 Hz, 1 H, H6b), 1.34 (s, 3H, Me), 1.27 (s, 3H, Me); 13C NMR 
(D20) (525.790,26.924,65.208,76.452,77.586,112.814, 142.149, 158.372, 174.886; El-
MS: m/z 216 [M+], C9H1206 requires 216.06339, found 216.06349. 
Me 
Me+~oy 
0_ H 0 
MeO OMe 
(xiv) 2,3-Di-O-Methyl-5,6-lsopropylidene-D-lsoascorbic Acid (3.15) 
To a stirred solution of compound 3.14 (0.5 g, 2.31 mmol) in acetone (30 ml) 
was added K2C03 (1.0 g, 7.25 mmol) to give a very viscous mixture. Dimethyl 
sulfate (1.5 mL 0.016 mol) was added drop-wise and the mixture was refluxed 
gently overnight. The resulting yellow solution was cooled to room temperature 
and the excess K2C03 removed by vacuum filtration. The solid residue was 
washed with cold acetone until all yellow colour was removed and the resulting 
solution evaporated under vacuum to give an oil. Purification by radial 
chromatography (40% ethyl acetate/ petroleum ether) gave 3.15 as a brown oil; 
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(0.388 g, 68%)lH NMR (COCb) & 4.67 (d, J = 5.0 Hz, 1H, H4), 4.28 [m, 1H, H5), 4.15 (5, 
3H, 3-0MeJ, 4.02 (dd, J = 8.8 Hz, 6.8 Hz, 1 H, H6d), 3.91 (dd, J 8.8 Hz, 5.9 Hz, 'I H, 
H6b), 3.85 (5, 3H, 2-0Me), 1.45 (5, 3H, Me), 1.37 (5, 3H, Me); EI-MS: m/z 244 [M+], 
HRMS CllH1606 requires 244.09469, found 244.09454. 
HO 
~~o 
MeO OMe 
(xv) 2,3-Di-O-Methyl-D-lsoascorbic Acid (3.16) 
Compound 3.16 is a colourless oil that resulted from slow hydrolysis of the 
acetonide group off product 3.15: lH NMR (020) & 4.85 (d, J = 3.0 Hz, 1 H, H4), 4.07 
(5, 3H, 3-0Me), 4.03 (m, 1 H, H5), 3.67 (5, 3H, 2-0Me), 3.50 (d J:= 6.3 Hz, 2H, H6) 
(xvi) Attempted Synthesis of C2 and C3 Methoxy Derivatives Using Diazomethane7 
Ascorbic acid (0.5 g, 2.8 mmol) was dissolved in a 1: 1: 1 solution of ether, 
methanol and water (15 mL). To this swirled solution was added dropwise an 
ethereal solution of diazomethane (10 mmol). The mixture was left for 4 days to 
allow the excess diazomethane to evaporate and then the solvent was removed 
under reduced pressure to give a yellow oll. 
(xvii) Attempted Synthesis of 2-0-Methyl-5,6-lsopropylidene-L-Ascorbic Acid 
To deoxygenated water (7 mL) at 60°C was added compound 3.1 (0.49 g, 
2.29 mmol) and 10M aqueous NaOH (dropwise) until pH 10 was reached (universal 
indicator paper) . To this stirred solution was added dimethyl sulfate (0.3 mL 0.032 
mol) dropwise whilst maintaining the pH and temperature, and the mixture was 
stirred for 1 hour. After cooling to room temperature, the solution was acidified 
with 10% aqueous H2S04 until pH 3 was reached and extracted with ethyl 
acetate. The organic layer was dried over Na2S04 and evaporated under 
reduced pressure to give a yellow oil. 
(xviii) Attempted Synthesis of 2,3-Di-O-Methyl-6-Benzoyl-L-Ascorbic Acid 
Compound 3.6 (0.056 g, 0.27 mmol) was dissolved in ethyl butyrate (5 mL 
0.12 mol) and a catalytic amount of pTSA added. The mixture was heated and 
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stirred overnight at 50°C. The solution was then cooled to room temperature, 
washed with a saturated NaHC03solution and dried over Na2S04. The solvent was 
removed under reduced pressure to give a yellow oil that was dried under 
vacuum overnight. 
7.2.3 EXPERIMENTAL CHAPTER 6 
Where indicated, derivatives were prepared according to literature 
procedures. 
7.2.3.1 GENERAL PROCEDURE S 
The following are general procedures employed in the synthesis of some SR 
inhibitors 
(i) (A) Namethylation 
2 molar-equivalents of sodium "hydride were washed three times with dry 
pet ether and then dried under nitrogen. Dry glyme and 1 molar-equivalent of 
lactam-containing compound were added to the sodium hydride and the 
mixture stirred at reflux under nitrogen for 2 hours. The mixture was cooled to room 
temperature and iodomethane (6 molar-equivalents) was added carefully to the 
solution, which was then stirred at reflux for 3 hours. The mixture was cooled to 
room temperature and water added cautiously to destroy any excess sodium 
hydride. Solvents were removed under vacuum and the resulting residue was 
extracted with ethyl acetate. The organic layer was washed with water (3x) and 
brine before being dried over MgS04. The solvent was removed under vacuum 
and if required, the resulting oil was purified by radial chromatography to give the 
N-methylated product. 
(Ii) (8) Nitration 
The aromatic compound [l molar-equivalent) was added to concentrated 
aqueous H2S04 (40 mL) previously cooled in a ice bath. To this stirred solution, 
KN03 (1 molar-equivalent) was added portion-wise over 20 minutes. The mixture 
was then stirred at O°C for 1 hour, warmed to room temperature and stirred for a 
further 1 hour, before being poured onto ice (30 mL) and left to stand until the ice 
had melted. The aqueous solution was extracted with ethyl acetate (3xJ, the 
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extracts combined and then washed with water. The organic layer was washed 
with saturated bicarbonate solution and brine before being dried over Na2S04. 
The solvent was evaporated under reduced pressure to give the nitrated product. 
(iii) (C) Palladium Coupling14 
Bromo starting-material (1 molar-equivalent), Pd(OAc)2 (0.1 molar-
equivalent), (0-tol)3P (0.5 molar-equivalent), triethylamine (l.25 molar-equivalent), 
styrene (1.25 molar-equivalent), and dry acetonitrile were combined together 
under a nitrogen atmosphere in a sealed tube and heated at lOO°C overnight. 
The tube was then cooled to room temperature and the contents diluted with 10% 
aqueous HCI (10.0 mL). The aqueous mixture was extracted with ethyl acetate, 
washed with water and dried over NaS04. The solvent was removed under 
vacuum and the resulting residue purified via radial chromatography. 
(iv) (D) Friedel-Crafts Cyclisation Reaction 
To a mechanically stirred solution of dichloromethane and AICb (2 molar-
equivalents) cooled to -76°C, was added dropwise, the acid chloride (l-molar 
equivalent) dissolved in dichloromethane. Ethylene gas was then bubbled 
through the stirred solution for 1 hour at -76°C and then for a further hour while the 
mixture warmed to room temperature. It was then stirred overnight. The mixture 
was cooled in an ice salt bath and water (70 mL) was added dropwise to quench 
the reaction. Mechanical stirring was continued until all solids had dissolved. The 
organic layer was separated, washed with water, 10% aqueous HCI and saturated 
NaHC03 solution before being dried over Na2S04. Evaporation of the solvent 
gave the product. 
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7.2.3.2 TRICYCLIC DERIVATIVE S 
(I) 2-(1-Pyrrolidinyl)-3A-Dihydroncpthclene (6.7)15 
To a solution of dry toluene (100 mL) and pyrrolidine (9.10 mL 0.11 mol) was 
added f3-tetralone (2.20 mL 0.06 mol). The mixture was refluxed for 4 hours under 
a Dean-Stark condenser containing 4A molecular sieves. The solution was then 
cooled to room temperature and the solvent was evaporated under vacuum. 
The resulting residue was dried overnight under vacuum to give a brown solid that 
was not purified further (9.6 g, 8B%): mp BO-B1°C: lH NMR (CDCb) b 7.04-6.B1 (m, 
4H, H5 - HB), 5.14 (s, lH, H1), 3.2B (m, 4H, H1'), 2.B4 (m, 2H, H4), 2.49 (m, 2H, H3), 
1.93 (m, 4H, H2') 
(ii) 1 ,2.3A,5,6-Hexahydrobenzo[f]qulnolin-3-one (6.8)15 
A flask containing acrylamide (6.B6 g, 0.10 mol) was submerged into an oil 
bath at B5°C and allowed to equilibrate. Product 6.7 (9.60 g, 0.05 mol) and pTSA 
(0.10 g) were quickly added to the molten liquid and the mixture was heated to 
100°C for 1 hours. The mixture was further heated at 140°C for 30 minutes to 
polymerise excess acrylamide, and then cooled to room temperature. The syrup 
was added to water, (100 mL) and the resulting precipitate was filtered overnight. 
Purification of the residue by chromatography (50% ethyl acetate/petroleum 
ether), gave the desired product 6.8, which was recrystallised from 
dichloromethane/petroleum ether (5.90 g, 62%): mp 172 - 173°C; lH NMR (CDCb) b 
7.53 (bs, 1 H, NH), 7.17 (m, 4H, H7 - H 10), 2.91 (m, 2H, H6), 2.69(m, 4H, H 1 & H2), 
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2.37(m, 2H, HS); IR: Umax 1664 cm-1; EI-MS: m/z 199 [M+], HRMS, C13H131'lO requires 
199.09971, found 199.09970. 
JX9 o N 
I 
Me 
(iii) 4-Methyl-l ,2,3.4,5,6-Hexahydrobenzo[flquinolin-3-one (6.9)15 
This product was prepared as is described in general procedure A. Sodium 
hydride (0.024 g, 1.0 mmol), dry glyme (7.S mL) and product 6.8 (0.103 g, O.S 
mmol) were refluxed under nitrogen for 2 hours. lodomethane (0.2 mL, 3.02 mmol) 
was added and the mixture stirred at reflux for 3 hours. The mixture was worked up 
to give compound 6.9 as a brown solid that was recrystallised from 
dichloromethane/petroleum ether (O.07 g, 67%): mp 98 - 100°C; lH NMR (CDCb) 8 
7.14 (m, 4H, H7 - HlO), 3.14 (s, 3H, NMe), 2.90 (m, 2H, H6), 2.64 (m, 4H, H2 & H1), 
2.50 (m, 2H, HS). 
119 
o ~ H 
Me 
(iv) Cis and Trons-4-Methyl-l,2,3.4,40,5,6, 1 Ob-Octahydrobenzo[flquinolin-3-one 
(6.30 & 6.3b)15 
To a solution of product 6.9 (0.38 g, 1.8 mmol) in dichloromethane (7 mL) 
was added triethylsilane (0.86 mL, S,4 mmol). The solution was cooled below O°C 
and trifluroacetic acid (2.28 mL, 0.03 mol) added dropwise. The mixture was 
warmed to room temperature and stirred under nitrogen for five days. Volatiles 
were removed under vacuum and the resulting residue was extracted with 
dichloromethane, washed with sodium bicarbonate solution and dried over 
Na2S04. Purification by radial chromatography (gradient elution 10 - 100% e'rhyl 
acetate/petroleum ether) gave the trans isomer, followed by the cis compound. 
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TRANS:(0.16 g, 42%): mp 118 -122°C; IH NMR (CDCI3) () 7.14 (m, 4H, H7 - HlO), 
3.14 (m, "IH, H4d), 2.95 (s,3H, NMe), 2.93 (m, 2H, H2), 2.72 (m, "IH, HlObL 2.66-2.37 
(m, 4H, H5 & H6), 1.617 (m, 2H, H 1); 13C NMR (CDCI3) () 23.39, 27.49, 27.87, 29.98, 
32.00, 40.79, 60.46, 124.31, 125.65, 126.23, 128.10, 134.86, 136.53, 169.87; IR: \)max 
1637 em-I; EI-MS: mlz 215 [M+J, HRMS C14H17NO requires 215.13101, found 
215.13164. 
CIS:(0.05 g, 13%): mp 129 -131°C; lH NMR (CDC13) () 7.10 (m, 4H, H7 - HlOL 
3.55 (m, 1 H, H4a), 3.15 (m, 1 H, H lOb), 3.01 (5, 3H, NMe), 2.86 (m, 2H, H6), 2.47 (m, 
2H, H2), 2.16 (m, 1H, H1a), 1.99 (m, 2H, H5J, 1.85 (m, 1H, Hlb); 13C NMR (CDC13) () 
23.72,27.83,28.11, 31.47,33.32,37.59,58.72,125.92,126.14,128.37, 128.73, 134.6L 
137.67,169.19; IR: \)max 1643, 2341, 2361 em-I; EI-MS: mlz 215 [M+], HRMS C14H17NO 
requires 215.13101, found 215.13160. 
o 
(v) 4-Methyl-9-Nltro-l,2,3,4,4a,5,6, 10b-Trans-Octahydrobenzo[f1quinolin-3-one 
(6.10)16 
Product 6.3b (19.7 mg, 0.1 mmol) was dissolved in a solution of 
H2S04/acetic acid (1:1 vlv, 0.8 mL) which had been cooled below o°c. Fuming 
nitric acid (5.5 JlL 0.14 mmol) was added carefully to the cooled solution so that 
the temperature remained below 10°C. The mixture was stirred for 2 hours at O°C 
and then poured into water (10 mL) where product 6.10 formed as a yellow 
precipitate which was collected by filtration (9.7 mg, 41 %): lH NMR (CDCI3) () 8.15 
(5, 1 H, H 10),8.03 (m, 1 H, H8), 7.28 (d, J = 8.79 Hz, 1 H, H7), 3.25 (dt, J = 3.418 Hz, 11.23 
Hz, "IH, H4bJ, 3.30 - 2.50 (m, l"IH, NMe, H4a, HlOb, H2, H6 & H5), 1.78 (m, 2H, Hl); 
13C NMR (CDCL3) () 23.68, 27.43, 28.39, 30.54, 32.07, 41.09, 60.22, 120.26, 121.80, 
129.44, 138.77, 143.28; EI-MS: mlz 260 [M+], HRMS C14H16N203 requires 260.11609, 
found 260.11618. 
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o 
(vi) 4-Methyl-9-Amino-1,2,3,4,4a,5,5, lOb· Trans-Octahydrobenzo[flquinolin-3-one 
(6.11 ) 
To product 6.10 (9.0 mg, 34.6 J.!mol) dissolved in glacial acetic acid (1 mL), 
was added Pt02 (1.0 mg). The mixture was stirred under a H2 balloon, at room 
temperature for 3 days then filtered through celite to remove the catalyst. The 
solvent was removed under reduced pressure and the resulting residue purified by 
pic (30% methanol! ethyl acetate) to give product 6.11 as an oil (3.1 mg, 39%): 1 H 
NMR (CDCI3) 06.93 (d, J = 7.814 Hz, 1 H, H7), 6.62 (s, 1 H, HlO), 6.56 (d, J = 8.302 Hz, 
1 H, H8), 3.64 - 2.42 (m, 11 H, NMe, H4a, H lOb, H2, H6, H5), 1.68 (m, 2H, H 1); 13C NMR 
(CDCb) 0 23.91, 27.55, 28.19, 30.52, 32.48, 41.31, 61.17, 111.57, 114.04, 129.42, 
158.91. 
o 
(vii) 4-Methyl-9·Phenylazo·1,2,3,4,4a,5,6, lOb· Trans-Octahydrobenzo[f]quinolin-3-
one (6.12) 
Nitrosobenzene (1.4 mg, 13.5 J.!mol) dissolved in acetic acid (1 mL) was 
added to product 6.11 (3.1 mg, 13.5 J.!mol) and stirred at room temperature for 20 
hours. The reaction was quenched by addition of water (0.5 mL) and a yellow 
precipitate formed. The mixture was extracted with ethyl acetate, washed with 
saturated bicarbonate and brine then dried over Na2S04. The solvent was 
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removed under reduced pressure and the resulting yellow residue was purified by 
column chromatography (5% methanol/ethyl acetate) to give product 6.12 as a 
yellow oil (3.8 mg, 88%): lH NMR (CDCI3) 5 7.90 (m, 3H, aromatic), 7.77 (m, 1 H, 
aromatic), 7.50 (m, 3H, aromatic), 7.28 (m, 1H, aromatic), 3.31 (m, 1H, H4a), 3.14-
2.50 (m, lOH, NMe, HlOb, H2, H5 & H6), 1.69 (m, 2H, H1); ES-MS m/z 320 [M+ 1 ]+, 
HRMS C2oH22N30 requires 320.1757, found 320.1763. 
CIS: lH NMR (CDCb) d 7.36 (m, 2H, aromatic), 7.16 (m, 1 H, aromatic), 6.99 
(m, 'IH, aromatic), 6.84 (m, 3H, aromatic), 6.69 (m, 1H, aromatic), 3.15(m, 1H, H4a), 
3.05-2.17 (m, lOH, NMe, H2, H5 & H6), 1.68 (m, 2H, H1 j 
(viii) 4-(Aminobenzoccrbcmate)-Phenylacetic Acid (6.13) 
To a mechanically stirred suspension of 4-aminophenylacetic acid (1.0 g, 
6.62 mmol) in water (25 mL) was added NaHC03 (1.39 g, 0.02 mol). 
Benzylchloroformate (3.22 mL, 7.95 mmol, 50% in toluene) was added to the 
solution dropwise and the mixture stirred overnight at room temperature. The 
mixture was extracted twice with ether and acidified with concentrated HCI to 
give a white precipitate, which was extracted with ethyl acetate. The organic 
layers were combined, dried over MgS04 and the solvent removed under vacuum 
to give 6.13 as a white solid (1.69 g, 90%): mp 150-151°C; 1 H NMR (CDCi3) 5 7.37 (m, 
7H, aromatic) 7.22 (m, 2H, aromatic), 6.73 (bs, lH, NH), 5.20 (s, 2H, CH2Ph), 3.61 (s, 
2H, CH2COOH). 
To a stirred solution of Acetonitrile (10 mLj, DMF (0.16 mL, 2.11 mmol) and 
oxalyl chloride (61.0 Ill, 0.70 mmol) cooled to -20°C, was added product 6.13 (0.2 
g, 0.70 mmolj dissolved in acetonitrile (3 mL). The mixture was stirred for 3 hours 
and then the solvent removed by evaporation to give a yellow oil which was not 
purified further. lH NMR (CDCI3) 57.29 - 7.09 (m, 7H, aromatic), 5.08 (s, 2H, CH2Phj, 
3.47 (s, 2H, CH2COCI). 
Attempted synthesis of the cyclic compound 6.15 was carried out as 
described in general procedure D. 
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(ix) 4-(Amino-9 -FI uromethylcarbamate)-Phenylacetic Acid (6.16) 
Dioxane (7 mL) was added to an ice-cooled solution of 4-
aminophenylacetic acid (0.20 g, 1.3 mmol), dissolved in 10% aqueous Na2C03 
(3.5 rnL), and the mixture allowed to equilibrate. To this solution was added 9-
fluoromethylchlorocarbamate (0.34 g, 1.3 mmol) portion-wise over 30 minutes. 
The resulting mixture was stirred in an ice bath for 4 hours then warmed to room 
temperature and stirred overnight. The mixture, which had formed a white 
precipitate, was poured into water .(50 mL) and the precipitate extracted with 
ether. The ether was evaporated under reduced pressure to give product 6.16 as 
a white solid (0.36 g, 73%): mp 210 - 214°C; lH NMR (CDCb) 87.54 - 6.91 (m, 12H, 
aromatic), 4.23 (d, J = 6.84 Hz, 2H, Fmoc CH2), 4.02 (m, 1 H, Fmoc CH), 3.25 (s, 2H, 
CH2COOH), FAB-MS: mlz 374 [M + 1]+, HRMS C23H20N04 requires 374.13923, found 
374.13981. 
To product 6.16 (0.1 g, 0.28 mmol), dissolved in toluene (4 mL), was added 1 
drop of DMF and oxalyl chloride (27 ilL 3.10 mmol). The mixture was stirred at 
room temperature overnight and the solvent evaporated to give a yellow residue 
lH NMR (CDCI3) 8 7.78 7.16 (m, 12H, aromatic), 4.52 (d, J = 6.35 Hz, 1H, Fmoc 
CH2), 4.26 (m, 1 H, Fmoc CH), 3.58 (s, 2H, CH2COCI). 
Attempted synthesis of 'the cyclic compound 6.18 was carried out as 
described in general procedure D. 
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eOOH 
(x) 4-(Phenylazo)·Phenylacetic Acid (0.19) 
Nitrosobenzene (0.15 g, 1.41 mmol), dissolved in acetic acid (5 mL), was 
added to 4-aminophenylacetic acid (0.21 g, 1.41 mmol) and stirred at room 
temperature for 20 hours. The reaction was quenched by addition of water (1 mL) 
and a brown precipitate formed. The mixture was extracted with ethyl acetate, 
the organic solvents combined, washed with saturated bicarbonate solution and 
brine then dried over Na2S04. The solvent was removed under reduced pressure 
and the resulting brown residue was purified by column chromatography (50% 
dichloromethane/petroleum ether) to'give product 0.19 as an orange solid (0.05 
g, 83%): mp 118 - 120°C; lH NMR (COCl3) 0 7.90 (m, 4H, H3 & H3'), 7.39(m, 5H, H2, 
H2' & H1 '), 3.75 (s, 2H, CH2COOH). 
To product 6.19 (0.5 g, 2.1 mmol), suspended in acetonitrile (20 mL), was 
added oxalyl chloride (3 mL 0.03 mol) dropwise until a clear solution was 
obtained. The reaction mixture was stirred for 3 hours then the solvent was 
removed under reduced pressure to give a dark coloured residue that was 
immediately used in the cyclisation reaction described in general procedure O. 
a B 
(xl) 7-Nltrotetralone (0.22) and o·Nltrotetralone (0.23) 
A mixture of products 6.22 and 6.23 was prepared as is described in 
general procedure B. I3-Tetralone {0.90 mL 6.81 mmolJ, concentrated aqueous 
H2S04 (40 mL) and KN03 (0.7 g, 6.9 mmol) were reacted together and worked up 
to give products 0.22 and 0.23 as a red/brown oil which was used in a subsequent 
reaction without further purification (0.83g 63%): 6.22 (53%) lH NMR (COCl3) 0 8.10 
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(m, 1H, H6), 8.03 (s, 1H, H8), 7.42 (d,) = 7.81, 1H, H5), 3.69 (s,2H, H1),3.18 (t,) = 6.84 
Hz, 2H, H3J, 2.60 (m, 2H, H4). 
6.23 (10%) lH NMR (COCl3) [) 8.13 (s, 1 H, H5), 8.10 (m, 1 H, H7), 7.30 (d,) = 8.30 
Hz, 1H, H8), 3.69 (s, 2H, H1J, 3.18 (m, 2H, H3),2.60 (m, 2H, H4) 
(xii) 7-Nitro-2-(1-Pyrrolidinyl)-3,4-Dihydronapthalene (6.24) 
To a stirred solution of product 6.22 (0.3 g, 1.6 mmol) in dry toluene (20 mL) 
was added pyrrolidine (0.26 mL, 3.1 mmol). The mixture was refluxed overnight 
under a Oean-Starkcondenser containing 4A molecular sieves. The solution was 
then cooled to room temperature and the solvent evaporated under vacuum to 
give a red/brown residue that was partially purified by flash chromatography (20% 
ethyl acetate/petroleum ether) to give 6.24; lH I\lMR (COCl3) [) 7.91 (dd,) = 2.44 
Hz, 8.79 Hz, 1H, H6), 7.86 (s, 1H, H8), 6.79 (d, J = 8.79 Hz, lH, H5), 5.20 (s, 1H, H1),3.36 
(m, 4H, H1 '), 2.87 (m, 2H, H4), 2.50 (m, 2H, H3), 1.97 (m, 4H, H2'). 
12 
HOOC 
(xiii) 7-Styryl-9,lO-Dihydrophenanthrene-2-Carboxylic Acid (6.26) 
Product 6.26 was prepared as described in general procedure C. Product 
6.27 (49.2 mg, 0.16 mmol), Pd(OAc)2 (8.0 mg, 3.0 !!mol), (o-tol)3P (2.5 mg, 7.9 Ilmol), 
triethylamine (20 ilL, 0.2 mmol), styrene (22.0 ilL, 0.2 mmol) and acetonitrile (1 mL) 
were reacted together for 24 hours, and worked up to give 6.28 which was 
recrystallised from methanol (25 mg, 68%): mp 132-133°C; lH NMR (COCl3) [) 7.97 
(m, 1 H, H3), 7.92 (d, ) 1.47 Hz, 1 H, H 1), 7.79 (m, 2H, H4 & H5), 7.55 (d, ) = 1.47 Hz, 
1 H, H8), 7.48 (dd, ) = 1.95 Hz, 8.30 Hz, "H, H6), 7.42 - 7.25 (m, 5H, H13 - H17), 7.15 
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(dd, J = 16.60 Hz, 22.46 Hz, 2H, H11 & H12), 3.93 (s, 3H, Me), 2.93 (m, 4H, H8 & H9); 
13C NMR (CDC13) 628.85, 28.91, 52.05, 118.61, 123.50, 124.70, 125.42, 126.23, 126.55, 
127.76,128.12,128.31,128.71, 129.12, 129.32, 137.22, 137.49, 138.24, 167.09; EI-MS: 
m/z 340 [M+], HRMS, C24H2002 requires 340.14633, found 340.14649. 
Product 0.28 (8.6 mg, 0.025 mmol) and K2C03 (6.9 mg, 0.05 mmol) were 
refluxed for 18 hours in methanol/water (3 mL 10: 1 v Iv). The solvent was removed 
under reduced pressure and the residue eXtracted with ethyl acetate and dried 
over Na2S04. The resulting solid was purified by radial chromatography (5% ethyl 
acetatel petroleum ether) to give 6.26 lH NMR (CDCL3) 6 7.74 (m, 2H, H1 & H3), 
7.61 -7.44 (m, 3H, H4, H5 & H6), 7.35 7.07 (m, 6H, H8 & H13 - H17), 6.95 (d, J = 5.37 
Hz, 2H, H11 & H12), 2.73 (m, 4H, H9 & HlO). 
7.2.3.3 BICYCLIC DERIVATIVE S 
Me02C~ 
eN 
(i) MethyI4-Cyono-4-(Phenyl)-Butyrote (0.390)17.18 
To a stirred mixture of benzyl cyanide (0.380) (4.9 mL 0.04 mol) and 
hydroquinone (5.3 mg, 4.8 Jlmol) was added Triton B (0.59 mL 1.29 mmol). The 
mixture was heated to l·moC and methyl acrylate (1.9 mL 0.02 mol) added 
dropwise over 30 minutes. The mixture was further heated to 160°C and stirred for 
1 hour, then cooled to room temperature and neutralised (pH paper) with glacial 
acetic acid (15 drops). The mixture was extracted from ether and water, the 
organic layer dried over MgS04 and the solvent removed by evaporation. The 
resulting dark yellow oil was purified by vacuum distillation (3 mmHg) to give 
product 0.390 (the fraction which distilled between 170 and 180°C; 1.44 g, 17%): 
lH NMR (CDC13) 67.35 (m, 5H, aromatic), 3.97 (m, 1 H, H4), 3.67 (s, 3H, Me), 2.49 (m, 
2H, H3), 2.21 (dd, J = 7.33 Hz, 15.14 Hz, 2H, H2); 13C NMR (CDCI3) 6 30.66, 30.71, 
36.22,51.76,120.13,127.21, 128.25, 129.12, 134.89, 172.38; IR: Umox 1735,2259 cm-1; 
EI-MS: mlz 203 [M+], HRMS, C12H13N02 requires 203.09463, found 203.09476. 
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~ o N 
H 
(ii) 5-Phenyl-Piperidone (6.30)17,18 
To Product 6.390 (1.0 g, 4.9 mmol) dissolved in glacial ace·l"ic acid (10 mL) 
was added Pt02 (0.01 g). The mixture was agitated at room temperature, and 40 
psi of H2 for 3 days. The mixture was then filtered through celite to remove the 
catalyst and the solvent was removed under reduced pressure to give product 
6.400 as an oil which was used without further purification: Product 6.400 (0.90 g 
4.3 mmol) was dissolved in dry toluene (25 mL) and refluxed for 20 hours. The 
solvent was then evaporated under reduced pressure to give a brown oil which 
crystallised to give product 6.30 (0.47 g 61%): mp 125-127°C; lH NMR (CDCb) 07.31 
(m, 5H, aromatic), 6.18 (bs, 1 H; NH), 3.50 (m, 1 H, H4a), 3.38 (m, 1 H, H4b), 3.07 (m, 
·IH, H5), 2.52 (m, 2H, H1J, 2.08 (m, 2H, H6J; 13C NMR (CDCb) 027.66,31.15,39.41, 
48.45,126.89,127.02,128.64,141.70,172.14; IR: Dmax 1659 cm-l; EI-MS: m/z 175 [M+], 
HRMS, CllH13NO requires 175.09971, found 175.09986. 
~ o N 
I 
Me 
(iii) 5-Phenyl-l-Methyl-2-Piperidone (6.29)17,18 
Product 6.29 was prepared as is described in general procedure B. Sodium 
hydride (0.24 g, 4.91 mmol), product 6.30 (0.43 g, 2.46 mmol) and distilled glyme 
(10 mL) were refluxed under nitrogen for 2 hours. lodomethane (0.9 mL, 0.02 mol) 
was added and the mixture stirred at reflux for 3 hours. The mixture was worked up 
to give product 6.29 as an oil (0.4 g, 87%): lH NMR (CDCb) 07.30 (m, 5H, aromatic), 
3.38 (m, 2H, H4J, 3.11 (m, ·1 H,H5), 2.97 (s, 3H, NMe), 2.54 (m, 2H, H 1 J, 2.06 (m, 2H, 
H6). 
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(iv) MethyI4~Cyano-4-(4-Chlorophenyl)-Butyrate (6.39b) 
To a stirred mixture of p-chlorobenzyl cyanide (6.38b) (22.76 g, 0.15 mol) 
and hydroquinone (20.0 mg, 0.18 mmol) was added Triton B (5.5 mL 12.0 mmolJ. 
The mixture was heated to 140°C and methyl acrylate (3.3 g, 38.0 mmol) added 
dropwise over 30 minutes. The mixture was further heated to 160°C and stirred for 
1 hour, then cooled to room temperature and neutralised (pH paper) with glacial 
acetic acid (15 drops). The mixture was then extracted from ether and water, the 
organic layer dried over MgS04 and the solvent removed by evaporation. The 
resulting oil was purified by vacuum distillation (3 mmHg; bp 170 - 173°C) followed 
by flash chromatography (30% ethyl 'acetate/petroleum ether) to give product 
6.39b (2.26 g, 24%): lH NMR (CDCls) 8 7.38 (m, 2H, H9 & HlO), 7.29 (m, 2H, H8 & 
H 11), 3.98 (m, 1 H, H4), 3.70 (s, 3H, Me), 2.51 (m, 2H, H3J, 2.20 (m, 2H, H2); IR: Umox 
1736, 2259 cm-1; EI-MS: m/z 203 [M+], HRMS, C12H12N02CI requires 237.05566, found 
237.05570. 
o N 
H 
(v) 5-(4-Chlorophenyl)-Piperidone (6.41) 
CI 
To product 6.39b (1.94 g, 8.2 mmol) dissolved in glacial acetic acid (10 mL) 
was added Pt02 (0.17g). The mixture was agitated at room temperature, 40psi H2 
for 1 day. The mixture was then filtered through celite to remove the catalyst and 
the solvent was removed under reduced pressure to give product 6.40b as an oil 
that was used without further purification: Product 6.40b (0.90 g 4.3 mmol) was 
dissolved in dry xylene (16.5 mL) and refluxed for 20 hours. The solid that formed 
was collected by filtration and washed with xylene to give 6.41 (0.79 g 46%): mp 
160 -163°C; lH NMR (CDCls) 8 7.32 (m, 2H, H9 & HlO), 7.19 (m, 2H, H8 & H11), 6.09 
(bs, "I H, NH), 3.49 (m, 1 H, H4a), 3.35 (m, "I H, H4b), 3.05 (m, 1 H, H5), 2.51 (m, 2H, H1), 
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2.06 (m, 2H, H6J; 13C NMR (CDCI3) 827.66,31.02,38.87,48.33,128.27,128.82,132.80, 
140.14, 171.92; IR: Umox 1659 cm-1; EI-MS: mlz 209 [M+], HRMS, CllH12NOCI requires 
209.06074, found 209.06066. 
Cl 
(vi) S-(4-Chlorophenyl)-1-Methyl-2-Plperidone (6.31) 
Sodium hydride (0.15 g, 1.6 mmolJ, product 6.41 (0.15 g, 0.7 mmol) and 
toluene (4 mLJ were refluxed under nitrogen for 2 hours. lodomethane (0.68 g, 4.8 
mmolJ was added and the mixture stirred at reflux for 3 hours. The mixture was 
worked up as described and the resulting solid recrystallised from ether I 
petroleum ether to give product 6.31 as needles (95.0 mg, 59%): lH NMR (CDCb) 8 
7.30 (m, 2H, H9 & H 10), 7.18 (m, 2H, H8 & H 11) 3.37 (m, 2H, H4), 3.10 (m, 1 H,H5), 2.98 
(s, 3H, NMe), 2.52 (m, 2H, H1), 2.01 (m, 2H, H6); 13C NMR (CDCb) d 28.01, 31.68, 
34.61, 39.60, 56.07,128.26,128.83,132.83,140.12,169.25; IR: Umox 1631 cm- l ; EI-MS: 
mlz 223 [M+], HRMS, C12H14NOCI requires 223.07639, found 223.0745. 
(vii) Methyl 4-Cyano-4-(4-NitrophenYI)-Butyrate (6.42) 
To a stirred solution of 4-nitrobenzylcyanide (6.35) (6.96 g, 0.04 mol) and 
hydroquinone (5.1 mg, 4.8 mmol) in dioxane (10 mL) was added Triton B (0.59 mL, 
1.30 mmol). The mixture was heated to 120°C and methyl acrylate (3.84 mL 0.043 
mol) added dropwise over 30 minutes. The mixture was then heated to 160°C and 
stirred for 2 hours, then cooled to room temperature and neutralised (pH paper) 
with glacial acetic acid (1O drops). The addition of ice-cold ether caused 
precipitation of unreacted nitro benzyl cyanide, which was separated by filtration. 
The ether-extract was further purified by vacuum distillation (3 mmHg); the 
product distilling at 180 200°C (1.3 g, 13%): lH NMR (CDCl3) 88.26 (m, 2H, H2' & 
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H3'), 7.56 (m, 2H, H1' & H4'J, 4.18 (m, 1H, H4), 3.71 (s, 3H, Me), 2.55 (m, 2H, H3J, 2.24 
(m,2H, H2). 
o 
(viii) 5-(4-aminophenyl)-Piperidone (6.44) 
To Product 6.42 (1.3 g, 5.2 mmolj, dissolved in glacial acetic acid (15 mLj, 
was added Pt02 (O.Olg). The mixture was agitated at room temperature, 40 psi H2 
for 3 days then filtered through celite to remove the catalyst. The solvent was 
removed under reduced pressure to give product 6.43 as an oil which rapidly 
polymerised to an insoluble gel. A sample (-0.1 g) was dissolved in excess toluene 
(500 mL) and refluxed overnight. Evaporation of the solvent gave the crude 6.44 
as an oil. 1 H NMR (CDCI3) d 7.03 (d, J = 8.30 Hz, 2H, aromaticj, 6.66 (d, J = 8.30 Hz, 
2H, aromatic), 3.43 (m, 1 H, H4aj, 3.34 (m, 1 H, H4b), 2.88 (rn, 1 H, H5), 2.48 (m, 2H, 
H1j, 1.96 (m, 2H, H6j. 
(ix) 5-(4-Nitrophenyl)-1-Methyl-2-Piperidone (6.45) 
Product 6.45 was prepared as is described in general procedure B. Product 
6.29 (0.23 g, 1.20 mmolj, concentrated aqueous H2S04 (15 mL) and KN03 (0.12 g, 
1.20 mmolj were reacted and worked up to give a yellow residue. Purification by 
column chromatography (5% methanol/ethyl acetate) gave product 6.45 as a 
yellow oil (0.14 g, 49%): lH NMR [CDCI3) 8 8.21 (d, J :::: 8.30 Hz, 2H, aromatic), 7.43 
(d, J = 8.79 Hz, 2H, aromatic), 3.44 (m, 2H, H4J, 3.26 (m, 1 H, H5), 2.99 (s, 3H, NMe), 
2.54 (m, 2H, H 1), 2.10 (m, 2H, H6); EI-MS: mlz 234 [M+J, HRMS C12H14N03 requires 
234.10044, found 234.10100. 
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o 
(x) 5-(4-Amlnophenyl)-1-Methyl-2-Piperidone (6.34) 
To Product 6.45 (0.14 g, 0.58 mmol), dissolved in glacial acetic acid (15 mL), 
was added Pt02 (O.Olg). The mixture was agitated at room temperature, 40psi H2 
for 3 days then filtered through celite to remove the catalyst. The solvent was 
removed under reduced pressure and the resulting oil was purified by radial 
chromatography (5% methanol/ethyl acetate) to give Product 6.34 (0.061g, 51%): 
lH NMR (CDCb) 8 7.02 (m, 2H, aromatic), 6.66 (m, 2H, aromatic), 3.30 (m, 2H, H4), 
2.95 (m, 4H, NMe & H5), 2.50 (m, 2H, H1), 2,03 (m, 2H, H6); 13C NMR (CDCb) 828.24, 
31.95,34.64,39.40,56.681, 115.27, 127,74. 
rp 
~ N~N)08' 
9' 
o 
(xi) 5-(p-Phenylazobenzyl)-1-Methyl-2-Piperidone (6.32) 
Nitrosobenzene (0.01 g, 98 ""mol), dissolved in acetic acid (1 mL), was 
added to product 6.34 (0.018 g, 98 ""mol) and stirred at room temperature for 20 
hours. The reaction was quenched by addition of water (0.5 mL) and a yellow 
precipitate formed. The mixture was extracted with ethyl acetate, washed with 
saturated bicarbonate and brine, then dried over Na2S04. The solvent was 
removed under reduced pressure and the resulting yellow residue purified by 
column chromatography (100% ethyl acetate) to give product 6.32 as orange 
crystals (0.016 g, 62%): mp 128 - 131°C; lH NMR (CDCb) 8 7.89 (m, 4H, H9, H9', Hll 
& H11 'J, 7.50 (m, 3H, H7', H8 ' , H12'), 7.37 (d, J = 8.302 Hz, 2H, H8 & H12), 3.39 (m, 2H, 
H4J, 3.16 (m, 1 H, H5), 2.97 (s, 3H, NMe), 2.53 (m, 2H, H 1), 2.07 (m, 2H, H6): 13C NMR 
(CDCb) 8 27.97,31.68,34.61, 40.06,55.93, 122.72, 123.10, 127.62, 129.0], 130.98, 
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144.68, 151.65, 152.45, 169.26; IR: \.)max 1637 cm-]; EI-MS: m/z 293 [M+], HRMS 
C18Hl9N30 requires 293.15281, found 293.15287. 
CIS lH NMR (CDCL3) 07.26 (m, 2H, H8 & H12), 7.14 (m, 3H, H7', H8' & H12'), 
6.83 (d, J 8.302 Hz, 4H H9, H9' Hll and H11'), 3.33 (m, 2H, H4), 305 (m, lH, H5), 
2.95 [s, 3H, NMe), 2.48 [m, 2H, H1), 2.00 [m, 2H, H6) 
Br 
(xii) 5-(4-Bromophenyl)-1-Methyl-2-Piperidone (6.36) 
CuBr2 [0.66 g, 0.29 mmol) and t-Butylni"trite (0.044mL, 0.37 mmol) were 
suspended in dry acetonitrile (1.5 mL) ,and cooled in an ice bath. On addition of 
product 6.34 (0.05 g, 0.25 mmol), dissolved in dry acetonitrile (0.5 mL), the stirred 
suspension turned black and a gas was evolved. The mixture was stirred on an ice 
bath for 0.5 hours, warmed to room temperature, then stirred for a further 2 hours. 
The mixture was then poured into 20% HCI (5 mL) and extracted with ether. The 
organics were washed with 20% HCI, dried over MgS04 and the solvent removed 
under reduced pressure to give a yellow residue. Purification by radial 
chromatography (80% ethyl acetate/ petroleum ether) gave product 6.36 as an 
oil (8.3 mg, 13%) :lH NMR (CDCI3) 0 7.46(d, J = 8.30 Hz, 2H, H2' & H4'J, 7.12 (d, J = 
8.79 Hz, 2H, H l' & H5'), 3.36 (m, 2H, H4), 3.04 (m, 1 H, H5J, 2.97 (s, 3H, NMe), 2.51 (m, 
2H, H1), 2.02 (m, 2H, H6); EI-MS: m/z 269 [M+, 81Br], 267 [M+ 79Br], HRMS C12H14NOBr81 
requires 269.02396, found 269.02358, C12H14NOBr79 requires 267.02588, found 
267.02538. 
Experimental 775 
o 
(xiii) S-(4-Stilbenyl)-1-Methyl-2-Piperidone (6.33) 
Product 6.33 was prepared as is described in general procedure C. 
Product 6.36 (8.3 mg, 31 J.lmol), Pd(OAc)2 (7.0 mg, 3.1 J.lmol), {o-tol)3P (4.7 mg, 0.72 
mmol), triethylamine (5.4 J.lL, 38.7 J.lmol) , styrene (4.5 J.lL, 38.7 J.lmol) and acetonitrile 
(0.5mL) were reacted together for 24 hours and worked up to give product 6.33 as 
a white solid (6.1 mg, 68%): lH NMR (CDCb) 87.53 -7.22 (m, 9H, aromatic), 7.09 (s, 
2H, H 11 & H 12), 3.40 (m, 2H, H4), 3.10 (m, 1 H, H5), 2.99 (s, 3H, NMe), 2.54 (m, 2H, 
H1), 2.07 (m, 2H, H6); 13C NMR (CDCL3) 8 28.01, 31.80, 34.73, 39.95, 56.23, 126.45, 
126.79,127.28,127.68,127.96,128.23.128.67, 128.75,136.33,137.13,141.01; EI-MS: 
m/z 291 [M+] HRMS C2oH21NO requires 291.16231, found 291.16293. 
7.2.3.4 THIOLACTAM DERIVAT IVES 
CI 
s 
(I) S-(4-Chlorophenyl)-'-Methyl-2-'rhioplperidone (6.46) 
Product 6.31 (0.06 g, 0.25 mmol), Lawesson's reagent (0.3 g, 0.74 mmol) 
and THF (1.5 mL) were reacted for 15 minutes. The solution was then filtered, '~he 
solvent evaporated and the resulting residue recrystallised from ether/petroleum 
ether to give 6.46 as a pale solid.(0.52 g, 87%): mp143 - 146°C; lH NMR (CDCI3) 8 
7.32 (m, 2H, H9 & HlO), 7.15 (m, 2H, H8 & Hl1), 3.64 (dd, J = 13.67 Hz, 5.37 Hz, 1H, 
H4a), 3.49 (s, 3H NMe), 3.46 - 2.95 (m, 4H, H4b, H5 & H1), 1.96 (m, 2H, H6) 13C NMR 
(CDCl3) 827.43, 39.51,41.42,58.98,128.25,129.00,133.12,139.57, 198.74; IR: Umox 
2937 cm-1; EI-MS: m/z 239 [M+], HRMS C14H17NS requires 239.05355, found 239.05356. 
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R 
s 
(Ii) 4-Mefhyl-3-Thiol-1,2,3AAa,5,o,l Ob· Trans-Odahydrobenzo[f]quinolinone (0.47) 
Product 0.3b (0.02 g, 93 Ilmol) and Lawesson's reagent (0.11 g, 0.28 mmolj, 
dissolved in THF (1 mLj, were stirred together for 30 minutes at room temperature. 
The solution was then filtered, the solvent evaporated and the resulting residue 
purified by radial chromatography (20% ethyl acetate/ petroleum ether) to give 
0.39 as a pale solid (9.8 mg, 45%): lH NMR (COCl3) 07.18 (m, 4H, H7 - HlO), 3.54 (s, 
3H, NMe), 3.38 (m, 2H, H4a & H2a), 3.18 - 2.86 (m, 4H, H2b, H6 & HlOb), 2.59 (m, 1 H, 
H5a), 2.45 (m, 1H, H1a), 1.76 (m, 2H, H1b & H5b); 13C NMR (COCl3) 023.51, 28.00, 
28.24,39.66, 4l.33, 42.28,64.31;124.59,' 126.35,126.93,128.41, 134.89, 137.10; EI-MS: 
m/z 231 [M+], HRMS C14H17NS requires 231.10817, found 231.10865. 
CI 
o N 
I 
Me 
(iii) 1 Ob-Methyl-8-Chloro-4-Methyl-l,2,o-Trihydrobenzo[f]quinolin-3-one (0.51) 
This compound was prepared as described in general procedure A. 
Sodium hydride (0.01 g, 0.45 mmol), distilled glyme (7.5 mL) and lOb-methyl-8-
chloro-l,2,6-trihydrobenzo[f]quinolin-3-one (0.05 g, 0.23 mmol) were stirred at reflux 
under nitrogen for 2 hours. lodomethane (84 ilL 1.4 mmol) was added and the 
mixture refluxed for 3 hours. The mixture was worked up and product 0.51 was 
used without further purification (0.04 g, 82%): 1 H NMR (COCl3) 07.18 (m, 3H, H7, H9 
& HlOj, 5.29 (m, 1 H, H5), 3.48 (m, 2H, H6), 3.19 (s, 3H, NMe), 2.70 (m, 2H, H2), 2.29 
(m, "IH, Hl), 1.94 (m, 1H, H1), l.30 (s,3H, Me). 
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I 
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(iv) 1 Ob-Methyl-8·Chloro-4-Methyl-3-Thiol·l,2,6· Trihydrobenzo[f]quinolinone (6.48) 
Product 6.51 (15.7 mg, 0.06 mmol), and Lawesson's reagent (0.017 g, 0.042 
mmol) dissolved in THF (2 mL), were reacted for 6 hours at reflux. The solution was 
then cooled, filtered, and the solvent removed under reduced pressure to give a 
residue that was purified by radial chromatography (30% ethyl acetatel 
petroleum ether) to give 6.48 as a pale solid (9.7 mg, 58%); lH NMR (CDCl3) 07.25 
{m, 2H, H9 & HlOJ, 7.16 (s, 1 H, H7), 5.70(m, 1 H, H5), 3.81 (s, 3H, NMeJ, 3.57 (m, 2H, 
H6), 3.23 (m, 2H, H2), 2.12 (m, 2H, Hl), 1.34 (s, 3H Me) 
CI 
S 
(v) 1 Ob·Mefhyl-8·Chloro-4-Methyl-3·Thiol-1,2,4o,5,6·Pentobenzo[f]quinolinone 
(6.49) 
6-Chloro-4-methyl-l ,2,4a,5,6-pentabenzo[f]quinolinone (0.015 g, 0.06 mmol) 
and Lawesson's reagent (0.02g, 0.05 mmol) were stirred in THF (1 mL) at 60°C 
overnight. The solution was filtered and the solvent evaporated to give a residue 
that was purified by radial chromatography (30% ethyl acetatel petroleum ether) 
to give 6.49 (8.5 mg, 54%); lH NMR (CDCl3) 0 7.17 (m, 2H, H7 & H9), 7.08 (m, 1 H, 
HlO), 3.72 (m, 1 H, H4a), 3.57 (s, 3H, NMe), 3.35 (m, 1 H, H2), 3.02 (m, 3H, H2 & H6J, 
2.41 (m, lH, H5), 2.18 (m, 1H, H5), 2.15 (m,2H Hl), 1.09 (s,3H, Me) 
Proton-NMR data for the starting material used to prepare compound 6.49 
is as follows lH NMR (CDCl3) 07.16 (m, 3H aromatic), 3.49 (dd, J = 3.42 Hz, 13.19 Hz, 
'I H, H4a), 3.03 (s, 3H, NMe), 2.99 (m, 2H, H2), 2.63 (m, 2H, H6), 2.34 (m, 2H, H5), 1.86 
(m, 2H, H1) 
178 Experimental 
7.2.3.5 PHOTOISOMERISATION EXPERIMENTS 
Photoisomerisation of products 0.19 and 0.32 was carried out using the 
following procedure. 
The sample dissolved in CDCl3 was prepared as for NMR analysis. A proton 
spectrum was taken of the sample, which was then irradiated with light from a 
filtered (330 - 370 nm) mercury lamp for 1 hour. Following initial irradiation, the 
sample was analysed by proton-NMR spectroscopy and then subjected to a 
further hour of irradiation from the mercury lamp at >400 nm wavelength. The 
sample was then again analysed by proton-NMR spectroscopy. 
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A DERIVATION 
EQUATION. 175,48 
A 
MICHAELIS-MENTEN 
The Michaelis-Menten (M-M) model for an enzyme system is shown below. 
E + S ES 
(A 1.1) 
The free enzyme (E) and substrate (S) bind reversibly to form the enzyme-substrate 
complex (ES) which then reacts to release the enzyme and products (P). The total 
enzyme in the system is given by 
Er = [E] + [ES] (Al.2) 
To derive a rate equation for the M-M model, it is assumed that the 
substrate is in excess relative to the concentration of enzyme, so the enzyme is 
working at its highest catalytic rate. This then allows for the application of the 
steady-state approximation (that is, the concentration of the ES complex quickly 
reaches a level at which it remains throughout the reaction). The rate of 
formation of ES is given by 
where 
d~tSJ = kl[E][S] - k.l[ES] - k2[ES] = 0 (A 1.3) 
Solving for [E] gives 
[E] = Km[ES] 
[S] (AlA) 
(Al.5) 
is the Michaelis constant. The equation for the total enzyme may then be 
expressed as 
_ Er[S] 
[ES] - Km + [S] (Al.6) 
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If the rate-determining step of the reaction is the conversion of ES to p, then 
"rhe overall rate (D) is given by 
D b[ES] 
D bET[S] 
Km + [S] (Al.7) 
DERIVATIONS OF MICHAELIS .. MENTEN EQUATION IN 
THE PRESENCE INHIBITORS. 1,2 
COMPETITIVE INHIBITORS 
A model for competitive inhibition is given by the following reaction 
scheme. 
E + S .. ES E + P 
+ 
EI + S --lJllr..... No Reaction 
I is the inhibitor, EI is the enzyme-inhibitor complex and KI is the dissociation 
constant for the EI complex. The EI complex is assumed to be in equilibrium with 
the free reagents so 
rElrp [EI] ==.I..=.tCJ. KI fA 1.8) 
Assuming steady-state conditions for ES, the amount of free enzyme E is given by 
(A 1.4) so (A 1.8) becomes 
[EI] == Km[ESJnJ 
KI[S] 
The total enzyme is now equal to [E] + [ES] + [EI], or: 
E - @ ES Km[ES] [I] 
T - [S] + [ ] + KI[S] 
fA 1.9) 
(Al.lO) 
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Thus, 
[ES] = ill 
Km(l + KI) + [S] 
(Al.ll) 
The rate of the reaction then becomes 
u == k2[ES] 
u= 
aKm + [S] (Al.12) 
where 
Vmox 
(A1.l3) 
UNCOMPETITIVE INHIBITORS 
A model for uncompetitive inhibition is given by the following reaction 
scheme. 
E + S ... ES E + P 
+ 
ESI .. No Reaction 
ESI is the enzyme-substrate-inhibitor complex and KI' is the dissociation 
constant for the ESI complex. The ESI complex is assumed to be in equilibrium with 
the ES complex thus 
,_ I§]ffi 
KI - [ESI] 
The total enzyme ET is now given by 
[E] + [ES] + [ESI] 
Substituting [A 1.4] and [A 1.14] into [A 1.1S] gives 
ES -- ET[S] []- ill 
Km + (KI' + 1 )[S] 
(A1.14) 
(Al.1S) 
(Al.16) 
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so the rate of the reaction is now given by 
_ Vmax[S] 
U - Km + a'[S] 
where 
NONMCOMPETITIVE INHIBITORS 
(A1.16) 
[A 1.17) 
A model for non-competitive inhibition is given by the reaction scheme: 
E + S -- ES E + P 
+ + 
1~ K, 
k1 
l~K' 
EI + S .. ESI jIIo No Reaction 
k-l 
As the inhibitor I does not bind to the active site of the enzyme the 
dissociation constant KI for the inhibitor binding the free enzyme E and the 
enzyme-substrate complex ES is the same thus 
_@JI!l_IEll!l 
KI - [ESI] - [EI] 
The total enzyme concentration is then given by 
Er = [E] + [ES] + [EI] + [ESI] 
Substitution of (A 1.4), fA 1.9) and (A 1.14) into fA 1.19) gives 
_ Er[S] 
[ES] - a(Km + [S]) 
so the rate of the reaction is given by 
Vmax[SJ 
u= 
a(Km + [S]) 
MIXED INHIBITORS 
(A1.18) 
(A 1.19) 
(A 1.20) 
[A 1.21) 
A model for mixed inhibition is similar to that of non-competitive model and 
is given by the following reaction scheme. 
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E + S lr ES E + P 
+ + 
EI ESI ----il]ID~ No Reaction 
For mixed inhibition, the dissociation constant for the EI and ESI complexes are 
different. Therefore, 
[Al.19] 
and 
_ Vmox[S] 
U - Kmd + [S]a' [A 1.20] 
DISCUSSION OF KINETIC PARAMETERS 
Vmox is the maximum rate of the catalysed reaction when the enzyme is 
operating under substrate saturation conditions. 
Km (the Michaelis constant) has units of mollL. Its value is equal to the 
concentration of substrate at which the enzyme achieves half its maximal rate, 
Vmox. Therefore, Km provides a measure of the catalytic efficiency of the enzyme; 
the smaller the value of Km the more efficient the enzyme. Km can also be 
considered in terms of the affinity of the enzyme for its substrate, where a smaller 
value indicates an increased affinity. 
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ApPEN IxB 
TRANSFORMATIONS MICHAELIS .. MENTEN 
RATE-EQUATION 
The following is a discussion of useful linear and direct-linear transformations 
of the M-M rate-equation in the absence and presence of inhibitors. 
LINEAR PLOTS 
LINEWEAVER-BuRK (DOUBLE-RECIPROCAL PLOT) 
1/u 
-l/Km 1/[S] 
1=_1_+ Km ._1 
u Vmax Vmax [S] 
Figure B.l: Double-reciprocal plot of the Michaelis -Men ten rate-equation. Also shown is the trend in 
errors of the plotted data that arises due to a constant absolute-error in the rate measurements. 
The Lineweaver-Burk or double-reciprocal plot (Figure B.1) is generated by 
plotting 1/[S] (on the abscissa) against 1 Iv (on the ordinate). The straight line 
produced has a slope of Km/Vmax, a ordinate-intercept of l/Vmaxl and an abscissa-
intercept of -1 IKm. 
Although the values of Vmax and Km are simply related to the slope and 
ordinate-intercept of this plot, the large errors associated with the inversion of 
small values of [S] and, in particular v (for which the errors are generally larger 
than for [S]J prevent an accurate estimate of the line-of-best-fit for the data 
points, and thus an unreliable measure of Km and Vmax.l 
The Eadie-Hofstee and Hanes plots detailed below, although not entirely 
free from distortion, are less severely affected than the double-reciprocal plot. 
188 
EADIE~HOFSTEE PLOT 
u 
u/[S] Vmax /Km 
Appendix B 
u 
u = Vmax - Km [S]) 
Figure B.2: Eadie-Hofstee plot of the M-M rate-equation. Also shown is the trend in errors of the 
plotted data points resulting from a constant absolute-error in the rate measurements. 
The Eadie-Hofstee plot is generated by plotting o/[S] (on the abscissa) 
against 0 (on the ordinate). The resulting line has a slope of -Km, a ordinate-
intercept of Vmox and an abscissa-intercept of Vmox/Km. As can be seen in Figure 
B.2, o occurs in both of the plotted variables axes, and the error associated with it 
results in an angular distortion to the error bars. 
HANES PLOT 
[S!/\l 
ill= Km +_1_. [S] 
U Vmax Vmax 
Figure B.3: Hanes plot of the Michaelis- Menten rate-equation. Also shown is the trend in errors of the 
plotted data that arises due to a constant absolute-error the rate measurements. 
This representation of the M-M rate-equation demonstrates that a plot of [S] 
(on the abscissa) against [S]/o (on the ordinate) gives a straight line with a slope of 
l/Vmox, a ordinate-intercept of Km/Vmox and an abscissa-intercept of -Km. As can 
be seen from Figure B.3 the error associated with each data point, due to the rate 
measurements, varies less than for the double-reciprocal plot. Kinetic parameters 
generated from this plot are more reliable than those from a Lineweaver-Burk or 
Eadie-Hofstee plots.2 
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DIRECT .. LINEAR PLOTS 
Two forms of direct-linear plot are shown in Figure BA. Each is generated 
by treating the observed values of \) and [S] as constants and Km and Vmax as 
variables. Joining the point at which each \) datum lies on ordinate, with the point 
at which the corresponding [S] datum lies on the abscissa, results in a family of 
lines. The abscissa and ordinate coordinates for the intersections between these 
lines are distributed about the true value of Km and Vmax• The best overall estimate 
of Km and Vmax of the system is given by the median of coordinates of all 
intersections:2 
The plot in Figure BA (8) has an advantage over that in (A) since it provides 
more clearly-defined intersection points, although the latter is an easier plot to 
construct. 
The values of Km and V max estimated by the use of direct-linear plots are 
considered to be statistically similar to values generated by a least-squares fits of 
the observed data to the M-M rate-equations.2 
" 1/" 
(Al (SJ 
o KmIVmox i! ! 
[s],1",i[SI/":! 
[Sl,i"l [sli'" 
[S]/" 
Figure B.4: Direct-linear plots. Lines are constructed by joining the points at which the measured 
data coordinates lie on the abscissa and ordinate. fAJ u data is marked on the ordinate and -[S] on 
the abscissa. (8) l/u is marked on the ordinate and [S]/u on the abscissa . 
• For an even number of intercepts the average of the two middle observations is 
used. 
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OF MICHAELIS-MENTEN RATE .. 
EQUATION IN THE PRESENCE OF INHIBITORS 
Derivation of the M-M rate-equation in the presence of competitive, 
uncompetitive, non-competitive and mixed inhibitors has been shown in appendix 
A. The following linear plots for each of the cases demonstrate the effect of each 
type of inhibitor on the kinetic parameters of Km and Vmax, and allow 
determination of the mode of inhibition and the inhibitor-enzyme dissociation 
constant KI and/or KI'. 
In the following, for the double-reciprocal (Lineweaver-Burk) plots the terms 
a and a' refer to 1 + [IJ/K, and 1 + [I]/K,' respectively, whereas for the Dixon plot, a 
= 1- KI/K,', and for the modified Dixon plot, a = 1 - K,' /KI. 
DOUBLE-RECIPROCAL PLOTS 
fA) (8) 
1/0 1/0 
l/[S] 
(C) (0) 
1/0 1/0 
Figure B.S: Lineweaver-Burk plots in the presence of (A) a competitive inhibitor, (8) an uncompetitive 
inhibitor, (e) a mixed inhibitor, and (D) a non-competitive inhibitor. 
The appearance of the double-reciprocal plots for a series of inhibitor 
concentrations is dependent on the mode of inhibition (Figure B.5). 
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Consider the M-M rate-equation for a competitive inhibitor: 
- ::: vKma . [Sl] + -v1 as the concentration of inhibitor increases, the term a gets 
I..) max max 
larger so that the apparent Km (aKm) also increases. The resulting appearance in a 
double-reciprocal plot, is a line with a steeper gradient than that resulting from a 
system containing less inhibitor. The Vmax for the system is unaffected by a 
competitive so that the intercept of these lines with the 1/1..) axis remains 
unchanged in this case (Figure B.5 (A)). 
In the presence of an uncompetitive inhibitor, the M-M rate-equation is 
given by 
1 Km 1 a 
-:::-- --+--
I..) Vmax' [S] Vmax 
In this system Km is independent of the concentration of inhibitor, and thus so to is 
the slope of the line in the double-reciprocal plot. However, the inhibitor 
concentration does change the ordinate-intercept such that the apparent Vmox 
increases with increasing [I] (Figure B.5 (8)). 
For a mixed or non-competitive inhibitor, the M-M rate-equation may be 
expressed as 
1 Kma 1 a' 
-:::-- -+--
I..) Vmax' [S] Vmox 
In terms of this expression, the only difference between these two models is that 
for the latter a ::: a'. Thus, these two models behave equivalently with respect to a 
double-reciprocal plot; the apparent values for both the Km and Vmax increase 
with increasing concentrations of inhibitor (Figure B.5 (C) and (D)). 
DIXON 
Dixon plots are obtained by plotting 1/1..) (on the ordinate)against [I] (on the 
abscissa). The appearance of these plots for a series of substrate concentrations is 
similar to that of the double reciprocal plots for a series of inhibitor concentrations, 
and as such also provide information regarding the mode of inhibition. In 
addition, for competitive, mixed or non-competitive inhibitors, a Dixon plot can be 
used to obtain a value of K,. As illustrated in Figure B.6, this information is obtained, 
not from the slope or axis-intercepts of the plotted lines as with the double-
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reciprocal plots, but from the coordinates of the points of intersection of the 
plotted lines. 
(A) 
lit) (BJ 1 t) 
[I] 
{CJ (DJ 
lit) lit) 
Figure B.6: Dixon plots in the presence of (A) a competitive inhibitor, (8) an uncompetitive inhibitor, 
(C) a mixed inhibitor, and (D) a non-competitive inhibitor. 
MODIFIED DIXON PLOTS 
Modified Dixon plots are generated by plotting [S]/u (on the ordinate) 
against [I] (on the abscissd). The appearance of these plots for a series of 
substrate concentrations is similar to those of the Dixon plots. However the 
abscissa coordinate of the point at which the lines intercept in this case gives a 
measure of KI' for a uncompe1'itive, non-competitive or mixed inhibitor. For a 
competitive inhibitor, the lines in a modified Dixon plot do not intercept. 
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Figure B.7: Modified Dixon plots in the presence of (A) a competitive inhibitor, (8) an uncompetitive 
inhibitor, (C) a mixed inhibitor, and (D) a non-competitive inhibitor. 
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CRYSTALLOGRAPHIC TABLES 
COMPOUND 3.7 
Table C.l. Crystal data and structure refinement for 3.7. 
Identification code 3.7 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta 25.00° 
Max. and min. transmission 
Refinement method 
Data 1 restraints / parameters 
Goodness-of-fit on F2 
Final R indices [1>2sigma(lJ] 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
ClOH1407 
246.21 
153(2) K 
0.71073 A 
Monoclinic 
. P(2) 1 
a == 5.9860(10) A 
b == 11.425(4) A 
c == 8.618 (2) A 
571.0(3) A3 
2 
1.432 Mg/m3 
0.123 mm-1 
260 
1.00 x 0.60 x 0.30 mm3 
2.44 to 25.00°. 
a=90°. 
)3=104.330(10)°. 
-7<==h<=l, 0<=k<=13, -9<=1<=10 
1180 
1051 [R (int) = 0.0329] 
98.8% 
0.9640 and 0.8869 
Full-matrix least-squares on F2 
1051 11 1157 
1.268 
R1 = 0.0733, wR2 = 0.2073 
R1 = 0.0942, wR2::: 0.2268 
4(4) 
0.543 and -0.478 e.k3 
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Table C.2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 
103) for 3.7. U(eq) is defined as one third of the trace of the orthogonalized uij tensor. 
x y z U(eq) 
0(1) 7526(9) 5770(6) 3675(7) 33(1) 
0(2) 10039(9) 7698(5) 2531 (6) 30(1) 
0(3) 13160(10) 6324(5) 725(7) 33(1 ) 
0(4) 9277(10) 4577(4) 2278(7) 30(1) 
0(5) 13968(9) 4263(5) 3782(6) 26(1) 
0(6) 14632(10) 2024(5) 2541 (7) 35(2) 
0(7) 12725(14) 377(6) 1714(11) 58(2) 
C(1) 8846(13) 5637(6) 2860(9) 23(2) 
e(2) 10256(13) 6514[7) 2283(9) 24(2) 
C(2') 10994(18) 8061 (8) 4161 (11) 43(2) 
C(3) 11536(14) 5964(7) 1469(9) 27(2) 
C(3') 14028(16) 7494(7) 1080(13) 39(2) 
C(4) 11020(13) 4692(7) 1389(9) 22(2) 
C(5) 13108(14) 3936(7) 2162(10) 25(2) 
C(6) 12502(13) 2666(8) 2085(10) 28(2) 
C(7) 14499(16) 855(8) 2302(10) 32(2) 
C(8) 16805(17) 314(8) 2845(10) 36(2) 
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Table C.3. Bond lengths [A] and angles [0] for 3.5. 
0(1 )-C{l) 1.190(10J 
0(2)-C(2) 1.380(10) 
0(2)-C(2') 1.441 (10) 
0(3)-C(3) 1.354(10) 
0(3)-C(3'J 1.439(lOJ 
0(4)-C(1) 1.360(10) 
0(4)-C(4) 1.444(9) 
0(5)-C(5) 1.414(10) 
0(6)-C(7) 1.350(11 ) 
0(6)-C(6) 1.439(10) 
0(7)-C(7) 1.190(12) 
C(l )-C(2) 1.473(10) 
C(2)-C(3) 1.320(11 ) 
C(3)-C[4) 1.484(11 ) 
C(4)-C(5) 1.529(11 ) 
C(5)-C(6) 1.494(11 ) 
C(7)-C(8) 1.478{l3) 
C(2)-0(2)-C(2') 113.8(6) 
C(3)-0(3)-C(3') 116.4(6) 
C(l )-0(4)-C(4) 110.1 (5) 
C(7)-0(6)-C(6) 116.6(7) 
0(1 )-C(1 )-0(4) 123.1 (6) 
0(1 )-C(1 )-C(2) 129.2(7) 
o (4)-C( 1 )-C(2J 107.7(7) 
C(3)-C(2)-0(2) 129.6(7) 
C(3)-C(2)-C(1 ) 108.2(7) 
0(2)-C(2)-C(1 ) 122.0(7) 
C(2)-C(3)-0(3) 133.4(8) 
C(2)-C(3)-C(4) 110.4(7) 
0(3)-C(3)-C(4) 116.2(7) 
0(4)-C(4)-C(3) 103.5(6) 
0(4)-C(4)-C(5) 109.7(6) 
C(3)-C(4)-C(5) 113.2(6) 
0(5)-C(5)-C(6) 109.0(6) 
0(5)-C(5)-C(4) 109.9(6) 
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C(6)-C(5)-C(4) 111.5(6) 
0(6)-C{6)-C(5) 107.1 (6) 
o (7) -C (7) -0 (6) 122.1 (9) 
0(7)-C(7)-C(8) 127.4(9) 
0(6)-C(7)-C(8) 110.5(8) 
Symmetry transformations used to generate equivalent atoms: 
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Table CA. Anisotropic displacement parameters (A2x 103) for 3.5. 
The anisotropic displacement factor exponent takes the form: 
-2rr2[ h2 a*2Ull + ... + 2 h k a* b* U12 ] 
U11 U22 U33 U23 U13 U12 
0(1)24(3) 28(3) 50(3) -3(3) 15(3) -2(3) 
0(2)31 (3) 15(3) 41 (3) -1 (2) 5(3) 4(2) 
0(3)40(3) 21 (3) 38(3) -1 (2) 14(3) -4(3} 
0(4)34(3) 8(3) 51 (3) -1 (2) 13(3) -1 (2) 
0(5)30(3) 18(3) 28(3) -3(2) 5(2) -4(2) 
0(639(3) 12(3) 53(4) -4(3) 7(3) 4(3) 
0(7)50(4) 15(3) 91 (6) -9(3) -17(4) -4(3) 
C(l )21 (4) 5(3) 42(5) 4(3) 5(3) -5(3) 
C(2)32(4) 10(4) 27(4) 2(3) 2(3) -11 (3) 
C(2')55(6) 26(5) 45(5) -10(4) 8(5) 0(4) 
C(3)27(4) 26(5) 27(4) 3(3) 1 (3) 3(3) 
C(3')35(4) 17(4) 70(6) 8(4) 21 (4) -6(4) 
C(4)26(4) 16(4) 23(4) -1 (3) 5(3) -5(3) 
C(5)24(4) 20(4) 33(4) 2(3) 11 (3) -2(3) 
C(6)21 (4) 15(4) 46(5) -6(4) 5(3) 0(3) 
C(7)42(5) 18(4) 36(4) 0(4) 11 (4) 2(4) 
C(8)59(6) 14(4) 36(4) 2(3) 12(4) 10(4) 
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Table C.S. Hydrogen coordinates ( x 104) and isotropic displacement parameters (J\2x 10 3) for 3.5. 
x y z U(eq) 
H(5A) 15183 4654 3878 39 
H(2'A) 11071 8918 4211 64 
H(2'B) 12548 7736 4544 64 
H(2'C) 10012 7777 4838 64 
H(3'A) 15563 7555 877 59 
H(3'B) 14127 7671 2208 59 
H(3'C) 12984 8052 398 59 
H(4A) 10380 4448 252 26 
H(5B) 14339 4066 1580 30 
H(6AJ 11521 2488 2826 34 
H(6B) 11648 2450 986 34 
H(8AJ 16679 -533 2662 54 
H(8B) 17421 468 3990 54 
H(8C) 17842 648 2243 54 
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Table C.6. Torsion angles [0] for 3.5. 
C(4)-0(4]-C(1 )-0(1) -177.7(7) 
C(4J-0(4J-C(1 )-C(2) 2.8(8) 
C(2')-0 (2) -C(2)-C(3) -111.3(9) 
C(2')-0(2)-C(2)-C(1 ) 73.2(9) 
0(1 )-C(1 )-C(2)-C(3) 177.S(8) 
0(4)-C(1 )-C(2)-C(3} -3.0(8) 
0(1 )-C(l )-C(2)-0(2) -6.2 (12) 
0(4]-C(1 )-C(2)-0(2) 173.3(6) 
0(2)-C (2)-C(3)-0(3) 6.1 (14) 
C(1 )-C(2]-C(3)-0(3) -177.9(7) 
o (2)-C (2)-C (3)-C(4) -174.0(7) 
C(l )-C(2)-C(3)-C(4) 2.0(8) 
C (3') -0(3)-C (3}-C(2) 12.9 (12) 
C(3')-0(3)-C (3l-C (4) -167.0[7) 
C(1 )-0 (4)-C(4)-C(3) -1.6(7) 
C(l )-0 (4)-C(4)-C(S) 119.S(7) 
C(2)-C (3)-C (4)-0(4) -0.4(8) 
o (3)-C (3J-C (4) -0(4) 179.6(6) 
C(2)-C(3)-C(4)-C(S) -119.1(7) 
o (3)-C(3)-C(4)-C(S) 60.8(9) 
o (4)-C (4)-C (S) -O(S) -S7.2(8) 
C(3)-C(4)-C(S]-0(S) S8.0(8) 
o (4)-C (4)-C (S]-C (6) 63.7(8) 
C(3)-C (4)-C (S)-C( 6) 178.9(7) 
C(7)-0 (6) -C( 6) -C(S) -169.S(7) 
O(S) -C(S) -C(6)-0( 6) -69.8(8) 
C(4)-C (S)-C( 6 )-O( 6) 168.8(6) 
C(6)-0(6)-C(7)-0(7) 1.S(14) 
C( 6) -0 (6) -C(7) -C(8) -179.2(7) 
Symmetry transformations used to generate equivalent atoms: 
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COMPOUND 3. 1 
Table C.7. Crystal data and structure refinement for 3.13. 
Identification code 3.1 3 
Empirical formula C6 Hl0 06 
Formula weight 178.14 
Temperature 293(2) K 
Wavelength 0.71073 A 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 27.48° 
Absorption correction 
Refinement method 
Data 1 restraints 1 parameters 
Goodness-of-fit on F2 
Final R indices [1>2sigma(l)] 
R indices (all data) 
Absolute structure parameter 
Largest diff. peak and hole 
Orthorombic 
P(2) 1 (2) 1 (2) 1 
a := 6.5460(10) A 
b:= 9.438(2) A 
c = 11.3970(10) A 
704.12(19) A3 
4 
, 1 .680 Mg/m3 
0.154 mm-1 
376 
0.76 x 0.68 x 0.40 mm3 
2.80 to 27.48°. 
-8<=h<=8, -12<=k<=O, -14<=1<=0 
1773 
1610 [R(int) = 0.0164] 
100.0 % 
FUll-matrix least-squares on F2 
1610 10/109 
1.298 
R1 = 0.0437, wR2 = 0.1479 
R1 = 0.0457, wR2 = 0.1492 
-0.3(15) 
0.596 and -0.544 e.k3 
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Table C.S Atomic coordinates (x 104) and equivalent isotropic displacement parameters (ph 
1 03) for 3.13. 
U(eq) is defined as one third of the trace of the orthogonalized uij tensor. 
x y z U(eq) 
0(5) 8505(3) 8632(2) 10080(1 ) 17(1 ) 
0(1) 14036(3J 8685(2) 7125(2) 26(1 ) 
0(2) 12956(3) 11496(2) 6297(2) 21 (1) 
0(4) 11659(2) 9063(2) 8494(1) 16(1 ) 
0(6) 5127(2) 10668(2) 10021 (2) 25(1) 
0(3J 9142[3J 11005(2) 7087(2) 21 (1) 
C(3) 10615(3) 11369(2) 7945(2) 15(1) 
C(lJ 12963(4) 9500(2) 7645(2) 16(1 ) 
C(5) 8377(3J 9794(2) 9275(2J 15(1) 
C(2) 12757(3) 11092(2) 7476(2) 15(1) 
C(6) 7212(4) 10999(3) 9851 (2) 20(1) 
C(4) 10510(3) 10287(2) 8949(2) 14(1) 
204 AppendixC 
Table C.9. Bond lengths [AJ and angles [oJ for 3.13. 
0(5)-C(5) 1.433(3) 
O(l)-C(1 ) 1.198(3) 
0(2)-C(2) 1.403(3) 
0(4)-C(1) 1.354(3) 
0(4)-C(4) 1.474(3) 
0(6)-C(6) 1.413(3) 
o (3)-C(3) 1.415(3) 
C(3)-C(2) 1.523(3) 
C(3)-C(4) 1.536(3) 
C(l )-C(2) 1.522(3) 
C(5)-C(4) 1.518(3) 
C(5)-C(6) 1.519(3) 
C(l )-0(4)-C(4) 109.55(17) 
0(3)-C(3)-C(2) 11O.04(18) 
0(3)-C{3)-C(4) 108.86(18) 
C(2)-C(3)-C(4) 100.88(17) 
0(1 )-C{l )-0(4) 121.8(2) 
O{l )-C{l )-C(2) 128.6(2) 
0(4)-C(1 )-C(2) 109.6(2) 
o (5)-C(5)-C(4) 109.70(17) 
0(5)-C{5)-C{6) 108.97(19) 
C(4)-C(5)-C(6) 109.78(18) 
0(2) (2)-C(1) 112.42(19) 
0(2)-C(2)-C(3) 112.04(19) 
C(1 )-C(2)-C(3) 101.92(19) 
0(6)-C(6)-C(5) 112.3(2) 
0(4)-C(4)-C(5) 108.38(17) 
o (4)-C(4)-C(3) 103.65(17) 
C(5)-C(4)-C(3) 115.26(18) 
Symmetry transformations used to generate equivalent atoms: 
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Table C.l O. Anisotropic displacement parameters (Nx 103) for 3.13. 
The anisotropic displacement factor exponent takes the form: 
-2n2[ h2 a*2Ull + ... + 2 h k a* b* U12] 
U11 U22 U33 U23 U13 U12 
0(5)19(1) 17(1) 16(1 ) 1 (1) 1 (1) -2(1 ) 
O{l )24{l) 21 (1) 31 (1) -4(1 ) 7(1) 7(1 ) 
0(2)23(1) 23(1) 17(1 J 4(1 ) 5(1) 4(1) 
0(4)17(1 ) 12(1 ) 20(1) 2(1 ) 2(1 ) 2(1 ) 
0(6) 14(1) 29(1 ) 30{l ) 9(1 ) 3(1) 2(1) 
0(3)21 (1) 25(1) 18(1 ) 1 (1 ) -5(1 ) 2(1 ) 
C(3)19(1) 12(1 ) 14(1) -1 (1) -1 (1 ) 1 (1) 
C(1)1S(1) 15(1 ) 19(1 ) 0(1 ) -2(1 ) 1 (1 ) 
C(s)ls(l) 16(1 ) 14(1 ) 1 (1 ) -1 (1 ) -1 (1 ) 
C(2) 16(1) 13(1 ) 15(1) 1 (1 ) -1 (1 ) 0(1) 
C(6)16{l) 19(1 ) 24(1) 1 (1 ) 2(1) 1 (1) 
C(4)13(1) 13(1 ) 16(1 ) -1 (1 ) -1 (1) 2(1 ) 
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Table C.ll. Hydrogen coordinates [ x 104) and isotropic displacement parameters (A2x 10 3) for 
3.13. 
x y z U(eq) 
H(5A) 7963 8854 10702 26 
H(2A) 13148 10791 5891 32 
H(6A) 5029 9963 10437 37 
H(3A) 9180 11583 6550 32 
H(3B) 10449 12344 8224 18 
H(5B) 7653 9491 8565 18 
H(2B) 13768 11591 7957 17 
H(6B) 7830 11211 10605 24 
H(6C) 7319 11839 9365 24 
H(4A) 11199 10668 9645 17 
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Table C.12. Torsion angles [0] for 3.13. 
C(4)-0(4)-C(1 )-0(1) -178.5(2) 
C(4)-0(4)-C(1 )-C(2) 0.0(2) 
0(1 )-C(1 )-C[2)-0(2) 35.1 (4) 
0(4)-C(1 )-C(2)-0(2) -143.2(2) 
0(1 )-C(1 )-C(2)-C(3) 155.2(3) 
0(4)-C(1 )-C(2)-C(3) -23.1 (2) 
0(3}-C(3)-C(2)-0(2) 40.6(2) 
C(4)-C(3)-C(2)-0(2) 155.47(18) 
0(3)-C(3)-C(2)-C(1 ) -79.8(2) 
C(4)-C(3)-C(2)-C(1 ) 35.1 (2) 
0(5)-C(5)-C(6)-0(6) -68.3(2) 
C(4)-C(5)-C(6)-0(6) 171.50(19) 
C(1 )-0(4)-C(4)-C(5) 146.04(18) 
C(l )-0(4)-C(4)~C(3) 23.1 (2) 
o (5)-C(5)-C(4)-0(4) 55.1 (2) 
C (6) -C (5) -C (4 )-0 (4) 174.85(17) 
o (5)-C(5)-C(4)-C(3) 170.71 (18) 
C (6)-C(5)-C(4)-C(3) -69.6(3) 
0(3) -C (3)-C(4)-0( 4) 79.8(2) 
C(2)-C(3)-C(4)-0(4) -35.9(2) 
0(3)-C(3)-C(4)-C(5) -38.4(3) 
C (2}-C(3}-C(4}-C(5} -1 54.1 9 ( 18) 
Symmetry transformations used to generate equivalent atoms: 
